# HEALTH TECHNOLOGY ASSESSMENT

VOLUME 19 ISSUE 89 OCTOBER 2015 ISSN 1366-5278

### Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study

Sudhir Venkatesan, Puja R Myles, Gerard McCann, Antonis A Kousoulis, Maimoona Hashmi, Rabah Belatri, Emma Boyle, Alan Barcroft, Tjeerd Pieter van Staa, Jamie J Kirkham, Jonathan S Nguyen Van Tam, Timothy J Williams and Malcolm G Semple



# Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study

Sudhir Venkatesan,<sup>1†</sup> Puja R Myles,<sup>1†</sup> Gerard McCann,<sup>2</sup> Antonis A Kousoulis,<sup>2</sup> Maimoona Hashmi,<sup>2</sup> Rabah Belatri,<sup>2</sup> Emma Boyle,<sup>2</sup> Alan Barcroft,<sup>2</sup> Tjeerd Pieter van Staa,<sup>3</sup> Jamie J Kirkham,<sup>4</sup> Jonathan S Nguyen Van Tam,<sup>1</sup> Timothy J Williams<sup>2</sup> and Malcolm G Semple<sup>4\*</sup>

<sup>1</sup>Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK <sup>2</sup>Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK <sup>3</sup>University of Manchester, Manchester, UK <sup>4</sup>Institute of Translational Medicine, University of Liverpool, Liverpool, UK

\*Corresponding author †Joint first authors

**Declared competing interests of authors:** SV, PRM, GMcC, AAK, MH, RB, EB, AB, TPvS, JJK, JSNVT, JSW and MGS were in receipt of grants from the National Institute for Health Research (NIHR), both for the conduct of this study and others. In addition, PRM reports grants from F. Hoffman La Roche outside the submitted work, and TPvS has participated in expert meetings with GlaxoSmithKline and Boehringer (not related to flu) and has provided methodological advice to Laser (including an observational study on the incidence of flu). The Clinical Practice Research Datalink is a joint venture between the UK Medicines and Healthcare products Regulatory Agency and NIHR.

Published October 2015 DOI: 10.3310/hta19890

This report should be referenced as follows:

Venkatesan S, Myles PR, McCann G, Kousoulis AA, Hashmi M, Belatri R, *et al.* Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study. *Health Technol Assess* 2015;**19**(89).

Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.

### **Health Technology Assessment**

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 5.116

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

#### Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

#### **HTA programme**

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

#### This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/46/22. The contractual start date was in January 2013. The draft report began editorial review in June 2015 and was accepted for publication in August 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Should the study progress further, the full report will be published in the HTA journal.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

# Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

### **NIHR Journals Library Editors**

**Professor Ken Stein** Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Professor Aileen Clarke** Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson Director of NETSCC, HTA, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

**Professor Elaine McColl** Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor John Norrie Health Services Research Unit, University of Aberdeen, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk

## Abstract

Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study

Sudhir Venkatesan,<sup>1†</sup> Puja R Myles,<sup>1†</sup> Gerard McCann,<sup>2</sup> Antonis A Kousoulis,<sup>2</sup> Maimoona Hashmi,<sup>2</sup> Rabah Belatri,<sup>2</sup> Emma Boyle,<sup>2</sup> Alan Barcroft,<sup>2</sup> Tjeerd Pieter van Staa,<sup>3</sup> Jamie J Kirkham,<sup>4</sup> Jonathan S Nguyen Van Tam,<sup>1</sup> Timothy J Williams<sup>2</sup> and Malcolm G Semple<sup>4\*</sup>

<sup>1</sup>Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK <sup>2</sup>Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK <sup>3</sup>University of Manchester, Manchester, UK

<sup>4</sup>Institute of Translational Medicine, University of Liverpool, Liverpool, UK

\*Corresponding author m.g.semple@liverpool.ac.uk †Joint first authors

**Background:** During pandemics of novel influenza and outbreaks of emerging infections, surge in health-care demand can exceed capacity to provide normal standards of care. In such exceptional circumstances, triage tools may aid decisions in identifying people who are most likely to benefit from higher levels of care. Rapid research during the early phase of an outbreak should allow refinement and validation of triage tools so that in the event of surge a valid tool is available. The overarching study aim is to conduct a prospective near real-time analysis of structured clinical assessments of influenza-like illness (ILI) using primary care electronic health records (EHRs) during a pandemic. This abstract summarises the preparatory work, infrastructure development, user testing and proof-of-concept study.

**Objectives:** (1) In preparation for conducting rapid research in the early phase of a future outbreak, to develop processes that allow near real-time analysis of general practitioner (GP) assessments of people presenting with ILI, management decisions and patient outcomes. (2) As proof of concept: conduct a pilot study evaluating the performance of the triage tools 'Community Assessment Tools' and 'Pandemic Medical Early Warning Score' to predict hospital admission and death in patients presenting with ILI to GPs during inter-pandemic winter seasons.

**Design:** Prospective near real-time analysis of structured clinical assessments and anonymised linkage to data from EHRs. User experience was evaluated by semistructured interviews with participating GPs.

Setting: Thirty GPs in England, Wales and Scotland, participating in the Clinical Practice Research Datalink.

Participants: All people presenting with ILI.

Interventions: None.

**Main outcome measures:** Study outcome is proof of concept through demonstration of data capture and near real-time analysis. Primary patient outcomes were hospital admission within 24 hours and death (all causes) within 30 days of GP assessment. Secondary patient outcomes included GP decision to prescribe antibiotics and/or influenza-specific antiviral drugs and/or refer to hospital – if admitted, the need for higher levels of care and length of hospital stay.

**Data sources:** Linked anonymised data from a web-based structured clinical assessment and primary care EHRs.

**Results:** In the 24 months to April 2015, data from 704 adult and 159 child consultations by 30 GPs were captured. GPs referred 11 (1.6%) adults and six (3.8%) children to hospital. There were 13 (1.8%) deaths of adults and two (1.3%) of children. There were too few outcome events to draw any conclusions regarding the performance of the triage tools. GP interviews showed that although there were some difficulties with installation, the web-based data collection tool was quick and easy to use. Some GPs felt that a minimal monetary incentive would promote participation.

**Conclusions:** We have developed processes that allow capture and near real-time automated analysis of GP's clinical assessments and management decisions of people presenting with ILI.

**Future work:** We will develop processes to include other EHR systems, attempt linkage to data on influenza surveillance and maintain processes in readiness for a future outbreak.

**Study registration:** This study is registered as ISRCTN87130712 and UK Clinical Research Network 12827.

**Funding:** The National Institute for Health Research Health Technology Assessment programme. MGS is supported by the UK NIHR Health Protection Research Unit in Emerging and Zoonotic Infections.

# Contents

List of tables	xi
List of figures	xiii
List of abbreviations	xv
Plain English summary	xvii
Scientific summary	xix
Chapter 1 Introduction	1
Triage tools for influenza	1
CURB-65	1
Pandemic Medical Early Warning Score	2
Department of Health Community Assessment Tools	3
Work underpinning this study	6
Justification of this study	7
Chapter 2 Methods	9
Phase 1: set-up of the study, development of the technology and feasibility	10
Developing the real-time surveillance system	10
Eligibility criteria	14
Recruitment of general practitioners	15
Data linkages, validation of primary outcome measures, influenza surveillance data	
and expansion of study to other electronic health record systems	15
Automation of data extraction analysis and reporting	15
Evaluating user experience	15
Phase 2: pilot study, data collection, extraction and statistical analysis	16
Aim	16
Population and recruitment	16
Design	16
Prodictor variables	16
Outcome variables	16
Statistical analysis (alanned and actual)	10
	17
Chapter 3 Ethics and consent	19
Chapter 4 Results	21
Phase 1: set-up of the study, development of the technology and feasibility	21
Development of real-time analysis and reporting	21
Data linkage	22
General practitioner participation and user experience	22
Phase 2: pilot study data collection, extraction and statistical analysis	25
The association between Community Assessment Tools criteria and outcomes of interest	28
Outcome 1: decision to treat with influenza-specific antiviral drugs	31
Outcome 2: decision to treat with antibiotics	32
Outcome 3: referral to hospital	32

Monthly data findings Comparison of Pandemic Medical Early Warning Score with Community Assessment	32
Tools (adults only)	33
Automated weekly and monthly report generation	34
Chapter 5 Discussion	37
Lessons learnt	37
Phase 1	37
Phase 2	37
Chapter 6 Conclusions	41
Acknowledgements	43
References	45
<b>Appendix 1</b> List of Read codes used to identify potential influenza cases in Hospital Episode Statistics data	49
<b>Appendix 2</b> Influenza-related Read codes used by general practitioners for patient assessment prior to an admission to hospital with a discharge diagnosis	54
of influenza and chosen to trigger Local Eligibility Patient Identification Software	51
Appendix 3 Stata algorithms for data management and analysis 'do files'	53
<b>Appendix 4</b> Semistructured interview guide used to evaluate general practitioner user experience of study technological interface	85
Appendix 5 Covariate code lists	87
Appendix 6 FLU-CATs Data Handbook	101
Appendix 7 FLU-CATs protocol	107

# **List of tables**

<b>TABLE 1</b> Pandemic Modified Early Warning Score (reproduced with author'spermission)	2
TABLE 2 General characteristics of GPs (participating in FLU-CATs Study) who           were interviewed	22
TABLE 3 Completeness of data entry and clinical variables by age group	26
TABLE 4 Descriptive analysis of clinical measurements by age group	28
TABLE 5 Descriptive analysis of distribution of CATs criteria by age group	29
TABLE 6 Key themes emerging from free-text comments under 'nature of other clinical concern', where available, presented in order of frequency for adults	29
TABLE 7 Key themes emerging from free-text comments under 'nature of other clinical concern', where available, presented in order of frequency for children	30
TABLE 8 Association between CATs criteria and outcomes of interest in children	30
TABLE 9 Association between CATs criteria and outcomes of interest in adults	31
TABLE 10 Distribution of comorbidities by age group	32
TABLE 11 Distribution of treatments and vaccinations by age group	33
TABLE 12 Distribution of PMEWS and CATs scores in adults, by primary outcomes	33

# **List of figures**

FIGURE 1 Paediatric Community Assessment Tool for children aged < 16 years	4
<b>FIGURE 2</b> Adult Community Assessment Tool for adults aged $\geq$ 16 years	5
FIGURE 3 Architecture of the real-time surveillance system	9
FIGURE 4 Screenshot of LEPIS pop-up window indicating an eligible patient	10
FIGURE 5 Sample data collection form for adult female	11
FIGURE 6 Sample GP summary screen	14
FIGURE 7 Sample screenshots of the weekly automated spreadsheet	34
FIGURE 8 Sample screenshots of the monthly automated report document	35

# List of abbreviations

AUROC	area under receiver operator characteristic	LEPIS	Local Eligibility Patient Identification Software
CAT	Community Assessment Tool	MHRA	Medicines and Healthcare products
CI	confidence interval		Regulatory Agency
CPRD	Clinical Practice Research Datalink	NIHR	National Institute for Health Research
eCRF	electronic case report form	ONS	Office for National Statistics
EHR	electronic health record	OR	odds ratio
FLU-CIN	Pandemic Influenza Clinical Information Network	PCRN	Primary Care Research Network
GP	general practitioner	PDF	portable document format
HES	Hospital Episode Statistics	PHE	Public Health England
HSCIC	Health and Social Care Information Centre	PMEWS	Pandemic Medical Early Warning Score
ILI	influenza-like illness	RCGP	Royal College of General Practitioners
ISAC	Independent Scientific Advisory Committee	RTF	rich text format
IT	information technology		

# **Plain English summary**

Severe pandemics of influenza (flu) and other new infections are rare but inevitable events. When these widespread outbreaks of disease occur, health-care capacity in communities and hospitals can be overwhelmed. Doctors then need to make difficult decisions about who should be admitted to hospital and who can safely be allowed to stay at home.

To do this fairly, most doctors feel that the same type of patient assessment should be used across the wider community. This process is called triage.

The ethical principle of triage is 'to do most for most'. This does not mean treating everybody equally. It means using scarce resources for those people most likely to benefit from treatment.

Triage tools should help doctors identify which people are most likely to benefit from treatment in hospital and which people can safely be managed at home.

The difficulty in designing triage tools for a future pandemic is that the nature of disease caused by a new pathogen (bacteria or virus) is unknown until that pandemic occurs. A further difficulty is that disease often can affect children and adults quite differently. A one-size-fits-all tool is unlikely to work.

This study developed processes that capture information from general practitioner consultations of people with flu-like illness and their electronic health record, and links this information to the hospital record if the patient is admitted to hospital.

This means processes are ready to check that triage tools are 'fit for purpose' at the start of a pandemic, for use should that pandemic become severe.

# **Scientific summary**

#### Background

During pandemics of novel influenza and outbreaks of other emerging infections, surge in health-care demand can exceed capacity to provide normal standards of care. During surge, workload pressures may limit the time available for clinical decision-making and health-care worker absence because of personal sickness, or caring for dependants, may limit the skill mix. Imaging and laboratory services may also be limited. Health-care workers who are unfamiliar with clinical assessment and admission decision-making may be asked to fulfil 'gatekeeper' roles. In such exceptional circumstances, triage tools may aid decisions in identifying people who are most likely to benefit from higher levels of care.

Provisional UK Emergency Planning Guidance published in 2007 suggested the use of the CURB-65 pneumonia score and the Pandemic Medical Early Warning Score (PMEWS) for hospital triage of adults, but did not address the needs of children. Recognising this gap, a 'toolkit' of national guidance was developed in 2008 by the Department of Health for the UK, which included the newly developed Community Assessment Tools (CATs) for both children and adults in primary and secondary care, and matched hospital care pathways. The validity and utility of using triage tools in the community to aid management decisions during a pandemic remains untested. Both PMEWS and CATs were developed specifically with this purpose in mind and so we aimed to capture the criteria that would allow validation of these tools in this study.

The validity and utility of triage tools needs to be assessed in a large community-based prospective study of patients presenting with influenza-like illness (ILI), to give confidence to general practitioners (GPs) who may be asked to use such tools in the event of surge, and policy-makers who may need to recommend their use to GPs. Validation of a triage tool for use in an outbreak of a novel disease requires rapid research during the early phase of that outbreak. Rapid research should allow refinement and validation of triage tools so that in the event of surge a valid tool is available.

#### **Objectives**

- 1. In preparation for conducting rapid research in the early phase of a future outbreak. To develop information technology (IT) infrastructure and processes that allow near real-time analysis of GP assessments of people presenting with ILI, and GP management decisions and patient outcomes.
- As proof of concept and to test processes To conduct a pilot study evaluating the performance of the triage tools 'CATs' and 'PMEWS' in predicting hospital admission and death in patients presenting with ILIs to GPs during inter-pandemic winter seasons.
- 3. To conduct a prospective near real-time analysis of structured clinical assessments for ILI using primary care electronic health records (EHRs) during a pandemic.

This report addresses only the first two objectives, involving preparatory work that would make the third objective feasible in the event of a pandemic.

#### Methods

#### Aim

The overarching study aim is to conduct a prospective near real-time analysis of structured clinical assessments of ILI using primary care EHRs during a pandemic. This report covers the preparatory work, that is, IT infrastructure development, user testing and pilot study as 'proof of concept'.

#### Design

The proof-of-concept study involved setting up and piloting a prospective near real-time analysis of structured clinical assessments and anonymised linkage to data from EHRs. User (GP) experience was evaluated by semistructured interviews. Processes were also developed for retrospective validation of outcome events using Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality data.

#### Setting

Thirty GPs in England, Wales and Scotland participating in the Clinical Practice Research Datalink (CPRD) using the Vision<sup>®</sup> version 3.01 (In Practice Systems Ltd, London, UK) EHR.

#### **Participants**

All people presenting with ILIs to participating GPs.

#### **Interventions**

None.

#### Main outcome measures

Study outcome is proof of concept through demonstration of data capture, appropriateness of data definitions and near real-time analysis. Primary patient outcomes are hospital admission within 24 hours and death (all causes) within 30 days of GP assessment. Secondary patient outcomes included GP decision to prescribe antibiotics and/or influenza-specific antivirals and/or refer to hospital, need for higher levels of care if admitted, and length of hospital stay.

#### Data sources

Linked anonymised data from a study-specific web-based structured clinical assessment and primary care patient EHRs. Retrospective validation of hospital admission was planned using HES, and mortality data validation was planned using ONS data.

#### Results

In the 24 months prior to April 2015, data from 704 adult and 159 child consultations to 30 GPs were captured. Influenza activity during these two winter seasons was low. GPs decided to refer 11 (1.6%) adults and 6 (3.8%) children to hospital. There were 13 (1.8%) deaths among adults and 2 (1.3%) among children. There were too few outcome events from which to draw any conclusions regarding the performance of the triage tools; however, the data captured allowed testing of almost all analytical algorithms and demonstrated proof of concept.

Data relating to each GP consultation were uploaded on to the CPRD database every night. The CPRD team then collated these data and sent weekly data to researchers based at the Universities of Nottingham and Liverpool. Additionally, on a monthly basis, the CPRD team sent background data (comorbidities, prescriptions, death, etc.) sourced from the EHRs for all patients with captured consultations. Each subsequent data instalment comprised the cumulative data acquired since the initiation of the study. Validation of outcome events with HES and ONS data was not possible for inclusion in this interim report because of a moratorium on provision of this data by the Health and Social Care Information Centre.

Six participating GPs agreed to be interviewed about their user experience. The main finding that emerged from these interviews was that the Local Eligibility Patient Identification Software (LEPIS) and web-based electronic Case Report Forms (eCRFs) were easy to use. The simplicity of the eCRFs encouraged GPs to participate in the study despite there not being any financial incentive for participation.

The GPs reported that the triage process of the consultation was quite easy to conduct and did not interfere with the routine GP consultation. Several GPs felt that a monetary incentive, even if small, would be necessary to increase GP participation in the study unless there was a statutory requirement to systematically collect data on all possible influenza cases during a pandemic. All interviewed GPs agreed that the FLU-CATs eCRF, with a few modifications, was ready to be used in a pandemic scenario. However, the setting up of the LEPIS system to enable data collection for the study was fraught with technical difficulties and not compatible with other EHR systems in use in the UK. Both these points are important limitations that would prevent a rapid national level rollout beyond the 650 plus practices currently using the Vision<sup>®</sup> EHR platform. Any decision aid based on the validated criteria could better be delivered separately on an open web-based platform or mobile phone 'app'.

Lessons learnt from the data analysis included that up to 74% of some clinical measurements (blood pressure in adults in this instance) were not recorded as part of GP's routine assessment of an adult person presenting with ILI. We would question the utility and adoption of triage tools that depend upon a clinical measurement that is not used in the routine assessment of ILI for use in a time-pressured pandemic situation.

#### Conclusions

The use of EHRs linked to study-specific data capture forms increased the comprehensiveness, validity and usability of data; pre-prepared analytical processes allowed near real-time analysis of GP assessments, management decisions and patient outcomes on a weekly basis. The processes are dynamic and should allow refinement of triage criteria in the early stages of a future outbreak.

#### Future work

We will test the effect of minimal remuneration on recruitment in future seasons, develop processes to include other EHR systems, attempt linkage to data on influenza surveillance and maintain processes in readiness for a future outbreak.

#### **Study registration**

This study is registered as ISRCTN87130712 and UK Clinical Research Network 12827.

#### Funding

The National Institute for Health Research Health Technology Assessment programme. MGS is supported by the UK NIHR Health Protection Research Unit in Emerging and Zoonotic Infections.

## Chapter 1 Introduction

A surge in health-care demand can exceed capacity to provide normal standards of care during pandemics of severe influenza and other emerging infections. Surge is recognised in historic reports of influenza pandemics and current government guidance.<sup>1,2</sup> In such exceptional circumstances triage tools may aid decisions in identifying people who are most likely to benefit from higher levels of care. Triage tools have value only if they can reliably identify individuals who benefit from higher levels of care, thus maximising outcome for a limited health-care resource and allowing other essential health-care activity to continue. Practitioners and policy-makers require confidence in the evidence behind triage criteria, and reassurance that a triage tool is valid for use in a particular situation. However, it is, by definition, impossible to establish the relationships between the presenting clinical characteristics and outcome for a novel pathogen causing disease in a heterogeneous population of varying age and comorbidities without conducting rapid research during the early phase of that outbreak. Validation of a triage tool for use in a novel disease requires rapid research during the early phase of that outbreak. Rapid research should allow refinement and validation of triage tools so that in the event of surge a valid tool is available.

In 2009, during the early phase of the A/H1N1pdm2009 pandemic, health-seeking behaviour due to perceived risk of influenza increased quite out of proportion to influenza-like illness (ILI) activity in the community.<sup>3</sup> This placed exceptional pressure on primary health-care services and interfered with capacity to deliver both routine and emergency care to previously accepted standards. In England, the National Pandemic Flu Service, which relied upon clinical algorithms, was introduced in mid-July 2009 in order to relieve pressure on primary care services.<sup>4</sup> Later in the same outbreak, ILI in some regions exceeded the capacity of secondary care to continue some routine and specialist services.

In either situation, workload pressures may limit the time available for clinical decision-making, and health-care worker absence due to personal sickness or caring for dependants may limit the skill mix. Access to imaging and laboratory services may also be restricted. Health-care workers who are unfamiliar with clinical assessment and admission decision-making may be asked to fulfil 'gatekeeper' roles.<sup>5</sup> Together, these factors place increased reliance and emphasis on core clinical history-taking and examination skills for triage decisions, which may be devolved to less-experienced staff.

#### **Triage tools for influenza**

Provisional guidance<sup>6</sup> suggested the use of the CURB-65 pneumonia score<sup>7</sup> and the Pandemic Medical Early Warning Score (PMEWS)<sup>8</sup> for hospital triage of adults in the UK. Importantly, neither score was ever intended for use in children. Most children can benefit from access to adult critical care facilities and general intensive care units when there is no paediatric intensive care unit capacity. Recognising this gap, a 'toolkit' of national guidance was developed in 2008 in the UK, which included newly developed Community Assessment Tools (CATs) for both children and adults in primary and secondary care, and matched hospital care pathways.<sup>2</sup> None of the recommended triage tools was validated in the context of a novel influenza outbreak at the onset of the A/H1N1pdm2009 outbreak.

#### CURB-65

'CURB-65' is a validated predictor of mortality from community-acquired pneumonia in adults but it was never intended for use in children.<sup>7,9</sup> CURB-65 was not designed to predict mortality from non-pneumonic presentations.<sup>8-10</sup>

#### Pandemic Medical Early Warning Score

Challen *et al.*<sup>11</sup> proposed the PMEWS as a clinical triage tool to aid hospital admission decisions for adults in a pandemic situation. The PMEWS score attributes an ordinal value to ranges of physiological measurements (respiratory rate, oxygen saturation, heart rate, systolic blood pressure, temperature and neurological assessment) and patient characteristics (age, social factors, chronic disease and performance status) to generate a score of between 0 and 20 (*Table 1*). They validated PMEWS in adults presenting to hospital with community-acquired pneumonia and found that it was better than CURB-65 for predicting the need for admission and higher levels of care, but had limited ability to predict mortality. CURB-65 and PMEWS pose problems for use in primary care: CURB-65 is reliant on a contemporaneous serum urea value, PMEWS could be computationally complicated for some, and both are designed for use only with adults. Many people presenting with ILI are children. Other severity scoring tools exist but these are not suitable for use in primary care because of a greater dependence upon laboratory or radiological investigations.

Ping 1 value for each factor							
King I value for each la							
Physiological	Score						
measurement	3	2	1	0	1	2	3
Respiratory rate (breaths per minute)	≤8			9–18	19–25	26–29	≥30
Oxygen saturation (%)	< 89	90–93	94–96	>96			
Heart rate (beats per minute)	≤40	41–50		51–100	101–110	111–129	≥130
Systolic blood pressure	≤70	71–90	91–100	> 100			
Temperature (°C)		≤35.0	35.1–36	36.1–37.9	38–38.9	≥39	
Neurological assessment				Alert	Confused, agitated	Voice	Pain, unconscious

#### TABLE 1 Pandemic Modified Early Warning Score (reproduced with author's permission)

#### PLUS

#### Score 1 for each factor

- Age > 65 years
- Social isolation or living alone/no fixed abode
- Chronic disease or respiratory, cardiac, renal, immunosuppressed, diabetes mellitus
- Performance status<sup>a</sup> > 2

#### Total P MEWS =

a Assessing performance status: normal activity without restriction, 1; strenuous activity limited, can do light, 2; limited activity but capable of self-care, 3; limited activity, limited self-care, 4; confined to bed/chair, no self-care, 5.

#### Department of Health Community Assessment Tools

In 2009, the Department of Health in England published a package of care that included paediatric and adult CATs and patient pathways for use by the national health services of the UK nations in a severe pandemic event, in primary and secondary care, and matched hospital care pathways.<sup>12</sup> CATs were developed to help non-specialist front-line staff identify, when resources are limited, which sick children and adults are most likely to benefit from interventions and levels of care that are available only in hospitals. CATs were developed by paediatric and adult expert clinical development groups drawing on evidence that supports the recognition of severe influenza and severe pneumonia in the community in adults and children in resource-limited settings, severe chronic obstructive pulmonary disease in adults, potentially serious feverish illness in children and severe bronchiolitis in infants.<sup>5,13-22</sup> Clinicians were warned not to use the CATs and the pathways unless the local situation precluded normal admission and discharge processes.

CATs use six objective criteria and one subjective criterion based on simple (binary) clinical assessment (*Figures 1* and 2). Meeting any CATs criterion warrants referral and admission to hospital. Criteria are (1) severe respiratory distress; (2) increased respiratory rate; (3) oxygen saturation of  $\leq$  92% on pulse oximetry breathing air or oxygen; (4) respiratory exhaustion; (5) severe dehydration or shock; (6) altered consciousness level; and (7) other clinical concern. Although criteria fields are common to paediatric and adult CATs, the abnormal physiological thresholds and clinical signs are age appropriate. Like PMEWS, there is no requirement for laboratory investigation to complete the assessment. However, CATs were intended for use only 'during severe and exceptional circumstances when surge demand for health-care services leads to a need for strict triage'<sup>12</sup> and, as such, were not deployed during the 2009–10 pandemic.

## PAEDIATRIC



### Swine flu paediatric community assessment tool

For use in all children under 16 years old in the community.

This assessment tool should be used during severe and exceptional circumstances when surge demand for healthcare services leads to a need for strict triage. It will assist with deciding whether a sick febrile child with flu-like illness needs referral to the nearest general hospital Emergency Department. Most children are expected to be managed in the community.

Respiratory failure, overwhelming gastroenteritis, shock, heart failure and encephalitis are the most likely modes of critical illness in children suffering from swine flu. Complications such as sepsis and meningitis may co-exist.

Criteria label	REFER CHILDREN TO THE NEAREST GENERAL HOSPITAL EMERGENCY DEPARTMENT IF THEY PRESENT WITH ANY OF THE FOLLOWING:
Α	Severe respiratory distress Lower chest wall indrawing, sternal recession, grunting, or noisy breathing when calm.
В	Increased respiratory rate measured over at least 30 seconds. ≥50 breaths per minute if under 1 year, or ≥40 breaths per minute if ≥1 year.
с	Oxygen saturation ≤92% on pulse oximetry, breathing air or on oxygen Absence of cyanosis is a poor discriminator for severe illness.
D	Respiratory exhaustion or apnoeic episode Apnoea defined as a ≥20 second pause in breathing.
E	Evidence of severe clinical dehydration or clinical shock Sternal capillary refill time >2 seconds, reduced skin turgor, sunken eyes or fontanelle.
F	Altered conscious level Strikingly agitated or irritable, seizures, or floppy infant.
G	Causing other clinical concern to their own GP or clinical team e.g. a rapidly progressive or an unusually prolonged illness.

#### **Further information**

- This tool is designed to support and empower all healthcare professionals working in difficult circumstances with limited resources, but does not supersede a decision by an experienced clinician about whether, when or where to refer a child.
- The assessment applies to all children under 16 years old and is independent of any prior or existing medical condition.
- Infants less than 2 months old with increased respiratory rate and sternal recession should be referred promptly to the nearest hospital because they are at high risk of suffering severe illness or death.
- Fever alone is not used as a criterion for referral to hospital in children over 3 months of age, as it is a
  poor discriminator for severe illness.
- Difficulty in feeding indicates a need for assessment but is not by itself a good measure of severe illness.
- When referral is not indicated, a copy of the home care advice leaflet should be provided, with
  encouragement to call again should the child's condition deteriorate.
- Every assessment should include a record of the time of assessment and time of onset of illness.
   Referrals must include the criteria label(s) to assist with the treatment of children on arrival at hospital.

The Swine Flu Paediatric Community Assessment Tool is endorsed by: The Royal College of General Practitioners, The Royal College of Paediatrics and Child Health, The Royal College of Nursing, The Royal College of Midwives, The College of Emergency Medicine, The Directors of Clinical Care of UK Ambulance Trusts, The British Medical Association and Unite/The Community Practitioners' and Health Visitors' Association.

FIGURE 1 Paediatric Community Assessment Tool for children aged < 16 years. © Crown Copyright, Department of Health, 2009, reproduced under Open Government Licence for public sector information.

ADULT

# Swine flu adult community assessment tool

For use in all adults aged 16 years or older in the community.

This assessment tool should be used during severe and exceptional circumstances when surge demand for healthcare services leads to a need for strict triage. It will assist with deciding whether a sick febrile adult with flu-like illness needs referral to the nearest general hospital Emergency Department. Most adults are expected to be managed in the community.

Respiratory failure, shock, heart failure and encephalopathy are the most likely modes of presentation in adults suffering from severe infection.

Criteria label	REFER ADULTS TO THE NEAREST GENERAL HOSPITAL EMERGENCY DEPARTMENT IF THEY PRESENT WITH ANY OF THE FOLLOWING:
А	Severe respiratory distress Severe breathlessness, e.g. unable to complete sentences in one breath. Use of accessory muscles, supra-clavicular recession, tracheal tug or feeling of suffocation.
В	Increased respiratory rate measured over at least 30 seconds. Over 30 breaths per minute.
с	Oxygen saturation ≤92% on pulse oximetry, breathing air or on oxygen Absence of cyanosis is a poor discriminator for severe illness.
D	Respiratory exhaustion New abnormal breathing pattern, e.g. alternating fast and slow rate or long pauses between breaths.
E	Evidence of severe clinical dehydration or clinical shock Systolic blood pressure <90mmHg and/or diastolic blood pressure <60mmHg. Sternal capillary refill time >2 seconds, reduced skin turgor.
F	Altered conscious level New confusion, striking agitation or seizures.
G	Causing other clinical concern to their own GP or clinical team e.g. a rapidly progressive or an unusually prolonged illness.

#### **Further information**

- The tool is designed to support and empower all healthcare professionals working in difficult circumstances with limited resources but does not supersede a decision by an experienced clinician about whether, when or where to refer an adult.
- The assessment applies to all adults aged 16 years or over and is independent of any prior or existing medical condition.
- Fever alone is not used as a criterion for referral as it is a poor discriminator for severe illness.
- Difficulty in self care indicates a need for assessment but is not by itself a good measure of severe illness
  or need for hospital admission. Referral to a community-based support facility may be suitable.
- When referral is not indicated, a copy of the home care advice leaflet should be provided, with
  encouragement to seek medical advice again should the adult's condition deteriorate.
- Every assessment should include a record of the time of assessment and time of onset of illness.
   Referrals must include the criteria label(s) to assist with the treatment of adults on arrival at hospital.

The Swine Flu Adult Community Assessment Tool is endorsed by: The Royal College of General Practitioners, The Royal College of Physicians, The Royal College of Nursing, The College of Emergency Medicine, The Directors of Clinical Care of UK Ambulance Trusts and The British Medical Association.

**FIGURE 2** Adult Community Assessment Tool for adults aged  $\geq$  16 years. © Crown Copyright, Department of Health, 2009, reproduced under Open Government Licence for public sector information.

#### Work underpinning this study

Goodacre *et al.*<sup>23</sup> conducted an evaluation of the discriminatory value of the CURB-65 score, PMEWS and CATs for predicting severe illness or mortality in 481 patients (346 aged < 16 years) presenting to hospital with suspected pandemic influenza. Initially they were unable to draw any conclusions regarding their clinical utility in a pandemic situation because of insufficient numbers of adults and a low incidence of severe outcome. In a later analysis of the same data, sensitivity, specificity and area under receiver operating characteristic (AUROC) values were reported for adults using these three triage tools with caveats regarding the power of the study.<sup>24</sup>

In another study, PMEWS scores were calculated from a retrospective data enquiry of 300 adult patients with suspected pandemic influenza, who were assessed in the community by Ambulance Service emergency-care practitioners. AUROC curves suggest that PMEWS scores discriminate between decision to 'treat and leave' and 'transfer for hospital assessment'.<sup>25</sup>

The UK Pandemic Influenza Clinical Information Network (FLU-CIN) characterised polymerase chain reaction-confirmed pandemic influenza disease in a cohort of 1520 people [1040 adults, 480 children (aged < 16 years)] admitted to hospital.<sup>26</sup> FLU-CIN compared the clinical validity and utility of CATs, PMEWS and CURB-65 as predictors for interventions that are normally available only in hospital, higher levels of care and death using AUROC curve comparisons with 95% confidence intervals (CIs).<sup>27</sup> CATs showed the best predictive performance for level 2/3 admissions in both adults [AUROC: CATs 0.77 (95% CI 0.73 to 0.80); CURB-65 0.68 (95% CI 0.64 to 0.72); PMEWS 0.68 (95% CI 0.64 to 0.73), comparison of AUROCs; p < 0.001] and children [AUROC: CATs 0.74 (95% CI 0.68 to 0.80); CURB-65 0.52 (95% CI 0.46 to 0.59); PMEWS 0.69 (95% CI 0.62 to 0.75); p < 0.001].

Although the FLU-CIN cohort is limited to patients admitted to hospital with severe influenza and its complications, the data show that these triage tools are capable of predicting higher levels or care and/or death in children and adults. However, the FLU-CIN analysis did not include assessment of triage tools in primary care.

Appropriate use of such triage tools in the community could expedite referral to hospital and, when scores are high, immediate admission to level 2/3 care. Prompt admission and allocation of higher levels of care may be associated with improved patient outcomes. Another study<sup>26</sup> by FLU-CIN found that delayed admission to hospital ( $\geq$  4 days after symptom onset) was significantly associated with increased likelihood of admission to critical care and death.

Morbidity and mortality rates were low during the influenza A/H1N1pdm2009 pandemic compared with some previous influenza epidemics, such as that in 1989–90.<sup>28</sup> The use of antiviral therapy was generally low in the FLU-CIN cohort despite it being widely available at the time. A more severe pandemic may be associated with a greater acceptance of antiviral therapy, and this may impact upon need for higher levels of care and death. Consequently, criteria threshold values may need to be adjusted to optimise the receiver operating characteristic curve for each criterion and the AUROC curve for the various triage tools.

The validity and utility of using triage tools in the community to aid management decisions during a pandemic remains untested. Both PMEWS and CATs were developed with this purpose in mind and so we aimed to capture the criteria that would allow validation of these tools in this study.

#### Justification of this study

The validity and utility of triage tools need to be assessed, in a large community-based prospective study of patients presenting with ILI, to give confidence to general practitioner (GPs), who may be asked to use such tools in the event of surge, and policy-makers who may need to recommend their use to GPs. The routine use of electronic health records (EHRs) by GPs and existing permissions to access anonymous data for research purposes presents an opportunity to study GP assessments, management decisions and patient outcomes. Anonymous linkage of this GP-derived data to Hospital Episode Statistics (HES) data for hospital admissions and Office for National Statistics (ONS) data for causes of death permits a validation of the GP-derived data. Together, these processes should allow for the assessment and comparison of the validity and utility of triage tools in the community in relation to patient relevant outcomes (hospital admission, length of stay, higher levels of care and death).

The Health Protection Agency timeline for the UK 2009 pandemic showed only 12 weeks between identification of person-to-person transmission in the UK (first week of May) and peak influenza activity (last week of July) in the first pandemic wave. Prospective data collection with near real-time iterative and cumulative analysis is the only method for validating triage criteria and tools against a novel pathogen in such a short time.

As pandemics are unpredictable and infrequent, limited but potentially useful information will be gained from prospective feasibility and pilot work conducted in primary care during seasonal influenza while A/H1N1pdm2009 is still circulating. It would not be possible to conduct such a study properly during a pandemic without prior permissions, preparation of processes, feasibility and testing performance with a pilot. The UK National Institute for Health Research (NIHR) recognised the need to fund and support the rapid set-up of relevant research studies and ensure that these studies are successfully conducted so that their findings can inform the ongoing care of patients during an outbreak. This will require some changes to the usual processes undertaken by the Clinical Research Network, as well as the reprioritisation of both national and local resources in what may well be a challenging environment in terms of increased demands for patient care and falling staff numbers because of illness. Consequently, the Clinical Research Network has an urgent public health plan in place to ensure that urgent public health studies can be set up and delivered quickly and effectively. The Clinical Research Network's urgent public health risk process will be activated at the request of the Department of Health. The FLU-CATs Study is one of the portfolio of studies that have been identified and granted the relevant research approvals in advance of an outbreak.<sup>29</sup>

Conducting this study in real-time during the early stages of a pandemic, when the characteristics of the novel virus are not fully understood, is important as it allows refinement and validation of triage tools against the novel pathogen in preparation for possible surge. This cannot be done until a novel virus emerges. Dame Deirdre Hine has recommended that population-based studies be established that, in the early stages of a future pandemic, can measure the severity of the pandemic and support decision-making.<sup>30</sup>

If the behaviour of the virus is markedly different in terms of severity between the first and subsequent waves, or evolves to cause severe disease in a particular organ system (as happened in the 1918–19 pandemic) then triage criteria may need to be adapted to reflect the consequent changes in health-care demand and clinical presentation.

The objective of this study was to establish processes now, in advance of a future pandemic, to validate the community triage tools capable of assisting hospital referral decisions for people of all ages for use if health-care demands exceed health-care capacity (surge).

The development of a triage tool has three distinct phases (set-up, pilot and implementation). It is expected that a triage tool would be implemented only in the exceptional circumstance of surge during an influenza pandemic or substantial outbreak of a novel emerging respiratory pathogen of public health interest. This study reports the set-up and pilot phases of this plan of work.

## Chapter 2 Methods

The study was conducted in primary care settings in the UK. These are community settings in which medical care is provided by GPs. The study was restricted to those GPs whose practices participate in the Clinical Practice Research Datalink (CPRD).

The study is made possible by consistent routine use by GPs of EHRs, an autonomous software agent that sits beside that system, and anonymised patient-specific linkage to external data sources. *Figure 3* outlines the source and flow of information. In principle, any of the electronic patient management systems in use could be used. We chose the Vision® version 3.01 (In Practice Systems Ltd, London, UK) platform because of the established linkage with CPRD. CPRD is the governmental centre, jointly funded by NIHR and the Medicines and Healthcare products Regulatory Agency (MHRA), which aims to provide anonymised health-care records for data services, interventional and observational research.<sup>31</sup> CPRD has ethical and regulatory approval to use anonymised patient data collected in over 650 participating GP practices and for linked–anonymised data access to individual patient data in the NHS England HES and mortality data in the ONS data set for approved purposes.

Eligible patients for the study were identified using Local Eligibility Patient Identification Software (LEPIS). LEPIS was developed for use with the electronic patient records software Vision<sup>®</sup> by researchers at Kings College London. LEPIS is an autonomous software agent that sits in the software background during a GP–patient consultation. It is remotely programmable by secure Ethernet to identify eligible patients using any combination of demographic features, Read codes and medications. LEPIS silently monitors the GP's data entry for all consultations. When an eligible patient is identified, a pop-up window appears on the screen offering the opportunity to recruit that patient into a study. If recruited, LEPIS then 'pipes' the patient data to study specific processes. Further details of LEPIS are provided elsewhere.<sup>32</sup>



FIGURE 3 Architecture of the real-time surveillance system.

#### Phase 1: set-up of the study, development of the technology and feasibility

This phase involved development of systems and feasibility testing. The information technology (IT) solution was deployed over 6 months between March and September 2013: in the UK this is not an endemic influenza season, and it occurred during an inter-pandemic period. Processes included set-up and validation of processes; optimisation of the clinical record entry screen; GP acceptability testing; establishing data-return format; check completeness of data returns; develop data clean-up algorithms; development of definitions, evaluation of completeness and validation of study outcomes using retrospective CPRD, HES and ONS data; and testing of LEPIS.

#### Developing the real-time surveillance system

Eligible patients for the study were identified during GP consultations using LEPIS loaded on participating GPs' computers. LEPIS monitors the consultation record for entry of any eligible diagnostic Read code (see *Appendix 1*). When a participating GP enters a relevant diagnostic Read code, a pop-up window appears prompting them to consider recruiting the patient; not recruiting; or suspending further recruitment prompts for a period of time (*Figure 4*). If recruited, a form appears for structured entry of data related to the consultation (i.e. signs and symptoms, physiological measurements and decisions relating to treatment or hospital referral). The linkage between the LEPIS and Vision® systems enabled automatic triggering of tailor-made data entry forms based on age and sex for men, women and children (age < 16 years), with additional conditional questions relating to pregnancy status if female and age > 12 years. These forms are the electronic case report forms (eCRFs) for the study. The eCRFs were designed to encourage both positive and negative reporting. The eCRFs underwent revision after the first winter season to record if the GP actively decided not to make an assessment because the GP considered the feature to be grossly normal or abnormal. This important feature avoids bias in the analysis of data that might otherwise be considered missing at random, when, in reality, the data are missing because the



FIGURE 4 Screenshot of LEPIS pop-up window indicating an eligible patient.

GP considered the feature to be grossly normal or abnormal. This addresses one challenge of collecting data from routine consultation records, when many clinicians record only a limited number of important negative or positive features based on their personal practice.

Age- and gender-specific eCRFs were developed. Patients aged < 16 years are classified as 'children' and patients aged  $\geq$  16 years are classified as 'adults'. Data collection forms for female patients > 12 years include a query on pregnancy status. A screenshot of a sample female adult LEPIS form is provided (*Figure 5*). The data collection form for children is identical to that for adults, except for three questions that are absent in the children's form – blood pressure measurement, social isolation status and premorbid performance status – as these criteria are used only in the adult PMEWS triage tool.

Sociodemographic and relevant medical history data were extracted by a background process from the routine EHR to minimise GP workload.

The flagging system and web-based data collection form was user-tested by GPs at five practices. Sample web-based forms can be viewed at www.cprd.com/flucats/ (accessed 5 August 2015); these will be maintained for the duration of the study.

Please enter pa	tient reported o	ate of LRTI / flu-like illness onset <required< th=""><th></th></required<>	
Day	Month	Year	
4 🔻	03 •	2015 🔻 📖	
Is the patient pr	egnant <b>REQUIRE</b>	1	
Not Applica	ble		
Not Pregna	nt		
Pregnant			
Possible but	t not confirmed		
Unknown			
Temperature (°C			
Measured			
Not Measur	ed as grossly N	ORMAL	
Not Measur	ed as grossly A	INORMAL	
Any signs of Se	vere Respirato	ry Distress	?
No			
Yes			
Any sign of Res	piratory Exhau	stion REQUIRED	?
Absence of cyan	osis is a poor d	scriminator for severe disease	
No			
Yes			
Respiratory Rat			?
Measured			
Not Measur	ed as grossly N	ORMAL	
Not Measur	ed as grossly A	INORMAL	
Is the patient on	oxygen	ED	
O No			
<u> </u>			

#### FIGURE 5 Sample data collection form for adult female. (continued)

Peripheral Oxygen Saturation	
Absence of cyanosis is a poor discriminator for severe disease	
O Measured	
Not Measured as grossly NORMAL	
Not Measured as grossly ABNORMAL	
Heart Rate RECOURED	
O Measured	
Not Measured as grossly NORMAL	
Not Measured as grossly ABNORMAL	
O Measured	
Not Measured	
Capillary Refill Time  REQUIRED	
Peripheral capillary refill time can be prolonged in normal cool or cold adults; sternal capillary refill is more accura	ite
Measured Normal	
Measured Sternal Capillary Refill Time >2 seconds	
Not measured as Grossly Normal	
Not measured as Grossly Abnormal	
Any sign of Severe Dehydration REQUIRED	?
O No	
O Yes	
New altered conscious level	
Any of: striking agitation, new seizures, new confusion or disorientation in person, place or time; AVPU score <a< td=""><td></td></a<>	
No (patient is alert)	
Confused/Agitated	
<ul> <li>Response to voice only</li> </ul>	
Response to pain only (patient is unconscious)	

FIGURE 5 Sample data collection form for adult female. (continued)
Social isolation	
Any of: lives alone or no fixed abode	
O No	
O Yes	
Unknown	
Premorbid Performance Status REQUIRED	
Patient's usual activity and ability to self-care prior to this acute illness	
Please Choose	
Causing other clinical concern	
No	
Yes	
Decision to Treat with Antivirals	
No	
Yes	
Decision to Treat with Antibiotics REQUIRED	
No	
Yes	
Decision to Refer to Hospital REQUIRED	
O No	
O Yes	
Subm	it 🕨

FIGURE 5 Sample data collection form for adult female.

Data entry checks were incorporated in the eCRF so that measurement values could be entered only if they were within physiologically plausible ranges. To further minimise duplication of tasks, after the completion of each form, GPs are presented with a summary of their assessment along with any decisions made (to treat with antivirals and/or antibiotics, and referral to hospital). This can be cut and pasted, or downloaded in text or portable document format (PDF) for entry into the patient's EHR. A screenshot of a sample GP summary generated following the submission of the data collection form is shown in *Figure 6*.

## Eligibility criteria

All people (any age, any sex) presenting with ILI (regardless of date at onset of disease and prior medical history) to GPs participating in CPRD are eligible for this study. The challenge was to identify a set of Read codes that LEPIS would monitor and pop up to prompt GPs to recruit people with ILI, while not overburdening the GPs with irrelevant prompts.



FIGURE 6 Sample GP summary screen.

Eligible Read codes were identified by systematic analysis of the CPRD database using a 'reverse engineering' process. First, we identified patients of any age admitted to hospital in the winter of 2010–11, who had a diagnosis of 'influenza', 'an influenza-related condition' or 'complication of influenza' in the HES data set, and extracted their CPRD/HES linked data. To identify these patients, we searched for terms such as 'influenza', 'influenza-like illness' and 'acute respiratory infection' (see *Appendix 1* for initial list of eligible Read codes) in the Read-coded clinical terms dictionary. Next, the output was restricted to patients who had visited their GP in the 7 days prior to admission. Then we queried the CPRD data to list all Read codes used by GPs in these consultations that preceded the hospital admission. A total of 831 different Read codes were recorded for these GP consultations. Many of these consultations were unrelated to ILI. These Read codes were reviewed for relevance by PM and MGS, without sight of their frequency, to yield a shortlist of 39 codes. These codes were then listed by frequency and reviewed by the study steering group (see *Appendix 2*). We decided to use all of these codes at least initially as a previous consultation with GPs suggested that GPs prefer syndromic codes for ILI to reflect the diagnostic uncertainty in the absence of laboratory confirmation of influenza. It is our intention to refine the LEPIS trigger list at an interim analysis during the final phase of the study, that is, during a pandemic.<sup>33</sup>

### **Recruitment of general practitioners**

General practitioners from practices that were already contributing to the CPRD were invited to participate in the study by the CPRD team initially by post and followed up electronically. Further recruitment of CPRD GPs was conducted via the NIHR Primary Care Research Networks (PCRNs), and by CPRD and investigator activities at regional and national meetings of GP research groups. GP practices were required to install the LEPIS software on their practice computer system and were given remote IT support. GPs were briefed on the eligible Read codes so that they had the option of proactively triggering the LEPIS pop-up window. No monetary incentives were provided to GPs for participation in the study. Following correspondence with the Royal College of General Practitioners (RCGP), they were sent certificates to include in their continuing professional development portfolios.

## Data linkages, validation of primary outcome measures, influenza surveillance data and expansion of study to other electronic health record systems

The study protocol included plans to validate the primary and secondary outcome events using HES data for 'hospital admission within 24 hours of the consultation' and ONS data for the outcome 'death (all causes) within 30 days of the consultation'. In addition, at the request of NIHR reviewers, the feasibility study scope was expanded to explore linkages with Public Health England (PHE) data sets for data on microbiology and virology. The feasibility study also explored options for expansion of the study-specific technological infrastructure to all CPRD and non-CPRD GP practices in the event of a pandemic.

### Automation of data extraction, analysis and reporting

Algorithms or 'do files' were developed and tested using Stata version 13 (StataCorp LP, College Station, TX, USA) to automate data linkage, extraction, analysis tasks and reporting to facilitate timely production of weekly and monthly reports on the incidence, progression and outcomes of pandemic influenza or a similar pandemic caused by a respiratory virus manifesting as ILI (see *Appendix 3* for 'do files').

### Evaluating user experience

Feedback on the ease of use of the study flagging and data collection system was obtained from participating GPs via e-mail consultation and one-to-one telephone interviews. Interviewees were provided a financial incentive for participation. A semistructured interview guide was used for the telephone interviews (see *Appendix 4*). Interviews were audio-recorded and transcribed verbatim for thematic analysis. Data were analysed using a thematic analysis approach that enables the researcher to identify, analyse and report themes or patterns in the data collected. The analysis followed the steps outlined by Braun and Clarke,<sup>34</sup> beginning with familiarisation of the data through listening to the recording of the interviews, transcribing the data then reading and re-reading each interview, making initial codes in the margins.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Coding was conducted systematically, taking each interview initially in turn and then subsequently moving back and forth across the data set. In order to establish consistency in coding, and thereby enhance dependability and credibility, the transcripts were independently double-coded by two of the authors (SV and PRM). Initial themes were reviewed and refined further, and a revised thematic table of candidate themes was produced.

# Phase 2: pilot study, data collection, extraction and statistical analysis

This phase involved data collection, extraction and statistical analysis from cases of ILI presenting to GPs. This pilot phase has run over two consecutive winter periods: 2013–14 and 2014–15 during an inter-pandemic period. We developed an automated weekly statistical evaluation of performance of triage criteria and tools. This phase is expected to continue to run in subsequent winter periods in a small number of practices as a maintenance process to ensure viability of processes as core systems continue to evolve and as EHR systems change.

### Aim

To investigate the predictive performance of the triage tools CATs and the PMEWS for hospital admission and death in patients presenting with ILI to primary care, using a novel near real-time data collection, collation, linkage and analysis process.

### Population and recruitment

Patients of all ages presenting to study GPs during the reporting period 19 March 2013 to 31 March 2015 (data upload 13 April 2015) with ILI were eligible for inclusion in the study and no exclusion criteria were applied. LEPIS was activated. Patient recruitment was determined by individual GP convenience rather than a specific sampling protocol. We estimated a minimum sample size of 1000 patients, assuming an event rate of 5% (based on the UK mortality and need for interventions in hospitalised influenza patients during the 2009 A/H1N1pdm2009 pandemic<sup>26</sup>) to test the hypothesis that the triage tools being tested would have an AUROC value of > 0.05, demonstrating the ability of the tools to discriminate between patients who experienced an outcome of interest and those who did not.<sup>35,36</sup>

### Design

Open cohort study involving follow-up for 30 days after the initial consultation for ILI.

#### Predictor variables

These include criteria from both the adult and child CATs (see *Figures 1* and *2*) and the adult PMEWS (see *Table 1*). Covariates that were extracted from the routine EHRs included patient sociodemographic characteristics (age, sex), comorbidities associated with an increased influenza risk (cardiovascular disease, chronic liver disease, neurological conditions, chronic renal disease, chronic respiratory disease, diabetes, immunosuppressive conditions), previous prescriptions of statins, antibiotics, influenza-specific antivirals, inhaled and oral corticosteroids, history of seasonal influenza vaccination, pneumococcal vaccination and *Haemophilus influenzae type B* vaccination. The detailed code list for disease covariates is provided in *Appendix 5*.

#### **Outcome variables**

There were two primary outcome variables to be collected from the GP EHR: hospital admission within 24 hours of GP assessment (binary categorical variable, coded as yes/no) and death (from all causes) within 30 days of GP assessment (binary categorical variable, coded as yes/no). Secondary outcome variables included 'any need for augmented level of care (admission to high-dependency units or intensive care units coded as a binary categorical variable)', length of hospital stay [three binary categorical variables were created using different thresholds of stay, < 48 hours (yes/no),  $\geq$  6 days (yes/no),  $\geq$  12 days (yes/no)], GP decision to refer to hospital (binary categorical variable, coded as yes/no), GP decision to prescribe antibiotics (binary categorical variable, coded as yes/no) and GP decision to prescribe influenza-specific antivirals (binary categorical variable, coded as yes/no).

### Statistical analysis (planned and actual)

A descriptive analysis of patient sociodemographic and clinical characteristics was conducted. The planned analyses included an investigation of the association between each CATs criterion and the various outcome measures. Each was investigated, in turn, using univariate logistic regression analysis. In addition, a multivariable model was planned to identify which of the CATs criteria were significant independent predictors of outcome when included in the same model. A separate investigation of the association between other covariates (as listed above) and outcomes using a similar approach was also planned. The analysis plan also considered predictive performance of a combined CATs score (both non-weighted and weighted, which would incorporate all CATs criteria), as well as the effect of varying individual criteria and combined score thresholds (e.g. respiratory rate of > 30, > 35, > 40 breaths per minute or a combined CATs score of > 3, > 4, > 5). Finally, a comparison of predictive performance with the PMEWS score was planned for adults only. Predictive performance would be assessed using measures including sensitivity, specificity, positive predictive value, negative predictive value and AUROC curve values. Separate analyses were run for paediatric and adult patients. All statistical analyses were conducted using Stata.

# Chapter 3 Ethics and consent

The CPRD has been granted generic ethics approval for observational studies that make use of only anonymised data and linked anonymised NHS health-care data (Multiple Research Ethics Committee ref. 05/MRE04/87). All CPRD studies require scientific approval from the MHRA Independent Scientific Advisory Committee (ISAC). The ISAC was established by the Secretary of State for Health in February 2006 to review the scientific merit of proposals for research using data from the CPRD as well as the Yellow Card Scheme database.

The clinical assessment data collection tool (or eCRF) was structured to capture evidence-based criteria recognised in national guidance. The study processes did not require the practitioner to make any change in their normal assessment; only to record the assessment in a structured manner. ISAC deemed that this was a non-interventional study and was exempt from the requirement for patient consent as (1) it involved the development and testing of an IT infrastructure for structured recording of the routine patient consultation rather than any departures from routine patient care and (2) made use of only linked anonymised data for analysis. This study protocol was approved by ISAC on 30 May 2012 (ISAC CPRD Protocol 12\_043).

# **Chapter 4** Results

# Phase 1: set-up of the study, development of the technology and feasibility

The general architecture of the real-time surveillance system is given in *Figure 2*. Data relating to each captured ILI GP consultation were uploaded on the CPRD database every night. The CPRD team then collated these data and sent weekly data to researchers based at the Universities of Nottingham and Liverpool. Additionally, on a monthly basis, the CPRD team sent background data (comorbidities, prescriptions, death, etc.) sourced from the routine electronic primary care record for all patients with captured ILI consultations. Each subsequent data instalment comprised the cumulative data acquired since the initiation of the study. The weekly and monthly data sets are described in detail in the *FLU-CATs Data Handbook* (see *Appendix 6*).

The Health and Social Care Information Centre (HSCIC) has responsibility for processing NHS England HES and linked ONS data since 1 April 2013. The study had permission to obtain 3-monthly HES and ONS linked data (as described in *Data linkage*) through existing agreements with HSCIC. HSCIC announced a delay in issue of HES data on 21 January 2014 for technical reasons and later imposed a moratorium on release of linked–anonymised data. As of 1 August 2015, CPRD has not received linked–anonymised HES data from HSCIC despite CPRD and the study investigators satisfying UK permissions. The retention of HES data by HSCIC has impacted on many research studies including FLU-CATs. It is anticipated that these validation analyses will be carried out as soon as the HES and ONS data are released to the researchers prior to the final phase of the study during a pandemic.

### Development of real-time analysis and reporting

Three distinct stages of work were required:

- Data cleaning and management Some data management of the weekly data as provided by CPRD was necessary to enable analyses. Most of the consultation-specific data collected via the web-based forms were provided as string variables, and data management mainly involved converting them to numeric variables or date variables where appropriate. These tasks have been automated and tested for accuracy in Stata 13 to enable an analyst to complete these usually labour- and time-intensive tasks in < 10 minutes once the data are received.</li>
- 2. Analyses After cleaning, the following analyses were planned: descriptive analysis involving tabulation and summarising of the data; logistic regression analyses (unadjusted and adjusted) to investigate the association between each of the triage criterions and the primary outcomes; and an assessment of the predictive performance of different triage tools using AUROC curve comparisons. All analytical tasks have been automated using Stata 13 and can be completed in < 1 hour by an analyst.</p>
- 3. *Reporting* Automated analyses and reporting mechanisms have been set up within Stata to report key findings from the weekly and monthly data sets. Findings currently being reported include frequency tables and charts, and results of unadjusted and adjusted logistic regression analyses. Weekly data set findings are reported in a Microsoft Excel® version 2010 (Microsoft Corporation, Redmond, WA, USA) spreadsheet and monthly findings in a Microsoft Word® version 2010 (Microsoft Corporation, Redmond, WA, USA) rich text format (RTF) document. This task has been semi-automated in Stata 13 to facilitate the production of weekly and monthly reports in Word and PDF format for policy-makers.

In addition, a Stata 'do file' was developed to extract background data from the CPRD database on comorbidities and select medication for all patients who underwent a FLU-CATs Study consultation. This has been tested by the CPRD team and has now been automated to provide the monthly data extracts. Detailed descriptions of each of the above three steps, along with instructions on how to use the Stata

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

'do files' are contained in the *FLU-CATs Handbook* (see *Appendix 6*). All 'do files' have been tested and validated with each of the weekly and monthly data uploads since the first weekly data tranche was received on 14 July 2014. The April 2015 data set (13 April 2015 tranche of weekly data) was the last tranche of data that was analysed at the time of preparation of this report. All findings presented in this report relate to the FLU-CATs data as of April 2015. Detailed results are provided below (see *Phase 2: pilot study, data collection, extraction and statistical analysis*).

Continuous weekly testing of these three processes has allowed us to reduce data management, analytical and reporting times to 1 day. By adapting the CPRD EHR structure we have also eliminated a separate electronic data entry step and streamlined data collation while maintaining data security.

We currently do not have sufficient data to report results from the AUROC analyses, even although we have recruited 863 eligible patients so far because influenza activity has been low and very few of our patients have progressed to the outcomes of interest.

### Data linkage

A 'do file' was written to extract relevant variables (hospital admission, need for augmented level of care, length of stay and death) from HES and ONS data. This 'do file' has been tested by the CPRD team using historic HES and ONS data sets. CPRD have confirmed that the 'do file' is automated to periodically extract HES data for patients with FLU-CATs GP consultations. However, as of April 2015, no HES or ONS linked data have been received from HSCIC since January 2014. The HES/ONS data received in January 2014 related to the HES period up to the third quarter of 2013 and preceded the first winter influenza season that this study included. Therefore, validation of the few observed outcome events using the FLU-CATs pilot study data has not been possible.

Linkage to PHE data sets was explored and abandoned because of inability to anonymously link patients in CPRD with PHE records with confidence, mostly due to virology requests from primary care not including sufficient unique patient identifiers. As an alternative solution, linkage is being explored at a practice and patient level in collaboration with the RCGP Research and Surveillance Centre.

### General practitioner participation and user experience

As of April 2015, a total of 30 GP practices participated in the FLU-CATs Study, although at any one time only 25 GP practices were actively recruiting. There were a total of 704 adult FLU-CATs consultations (702 single consultations and two repeat consultations) and 159 single consultations for children.

All 30 participating GPs were invited to be interviewed to evaluate the user experience. A total of six GPs agreed to be interviewed (*Table 2*). The interviews are summarised below.

Year qualified	Single-/multi-partner practice	Location group	Location type
1986	Unknown	Urban	Urban – less sparse
1985	Six partners	Urban	Urban – less sparse
1984	Two partners	Urban	Urban – sparse
1979	Two partners	Urban	Urban – less sparse
1986	Senior partner, three other partners	Urban	Urban – less sparse
1982	Nine partners	Rural	Town and fringe – less sparse

#### TABLE 2 General characteristics of GPs (participating in FLU-CATs Study) who were interviewed

The purpose of conducting these interviews was to explore GPs' experiences and views of being involved in a real-time influenza surveillance research project in order to help inform future consultations. GPs who participated in the FLU-CATs Study were sent invitation letters by CPRD: 11 GPs returned expressions of interest, of which six were interviewed over telephone. Each interview lasted between 10 and 20 minutes. A payment of £40 (based on the PCRN recommended rate of £80 per hour) was made to the GPs for their participation in the qualitative interviews.

The main finding that emerged from these interviews was that the LEPIS trigger pop-up and FLU-CATs data collection forms were easy to use. The simplicity of the eCRFs encouraged GPs to participate in the study despite there not being any financial incentive for participation. However, the setting up of the LEPIS system to enable data collection for the study was fraught with technical difficulties. Although the support from CPRD in resolving any technical issues surrounding LEPIS installation was appreciated by the GPs, technical difficulties persisted for some and this reduced patient recruitment. The FLU-CATs process was quite easy to conduct and did not interfere with the routine GP consultation. All interviewed GPs agreed that the FLU-CATs system, with a few modifications, was ready to be used in a pandemic scenario.

### 1. Introduction to, and involvement with, the FLU-CATs Study:

- i. Of the six GPs interviewed, three were introduced to the FLU-CATs Study through the research networks (NIHR PCRN and other local research networks), one through a research coordinator and one directly by CPRD. The remaining GP did not remember exactly how he/she was introduced to the study but thought that it might have been through an e-mail.
- 2. Lack of financial incentive as a barrier to participation:
  - i. One GP said that the lack of financial incentive for the GPs' participation in the FLU-CATs Study was 'inevitably, a barrier', whereas another GP said that it was not. One GP thought it might have been a barrier if the FLU-CATs Study was the first ever CPRD study in which the GP was participating but, as he/she had participated in a few before it was not a barrier for him/her. The consensus among the interviewed GPs, however, appeared to be that as the FLU-CATs Study was relatively straightforward and not 'too onerous', as one GP put it, the lack of a financial incentive was not a barrier to their participation. Interestingly, one GP said 'My partners were a bit reluctant because there was no remuneration at all, but we thought it was relevant because it was relevant to the influenza season and I just thought it would focus our minds on how to manage respiratory tract infections'. One GP said the following about the lack of incentives for participation in the study: 'I think the only difficulty, as I was saying at the beginning, with that is it's a bit difficult to say why would I recommend doing it and my argument is because it makes me feel like a better person because I do, but does that make somebody else feel that it makes them feel like a better person if they do. I think the other thing is if you are thinking about incentives, I don't think in general practice, the incentive needs to be particularly large, it just needs to be an appreciation of the fact that there are costs involved in doing things and the amount of money we got for [another study name] and [another study name], I would say was well in excess of what was necessary to reimburse us for the amount of work that we had done. And, I think if you were pitching something like FLU-CAT, looking for a price, then I think you'd be talking something like a couple of pounds a form not a couple of hundred pounds a form. Again, I think for the future of CPRD, I don't think they would have to have terribly large incentives to make it a reason why people would want to do it. It's perhaps where there has been some difficulty about it, it's just the total lack of an incentive. And, basically, in general practice, if somebody isn't paying you anything it's costing you'.

### 3. LEPIS system installation:

- i. LEPIS pop-up window According to one GP, this issue was serious enough to affect patient recruitment significantly: 'I don't think it pops up with consultations, so I don't think we've hardly recruited anybody. So, it's a real shame because it was easy when it worked, it was dead easy'.
- ii. Two GPs reported issues with the clinical IT system Vision while using the LEPIS system. According to one of them, 'It was very difficult because we are on EMIS-WEB now but we were on Vision and it took a long time to get your software to work. Fortunately, we had a medical student who worked in our office temporarily who was sort of, you know, he was doing a Masters, who was very IT aware and he spent a lot of time talking to Vision and talking to you and trying to get it working and eventually he got it to work, but that was a real pain. And, now we're on EMIS-WEB we can't do it all because apparently it doesn't work with EMIS anyway'. Another issue reported was that the LEPIS system would 'hang' while entering the FLU-CATs form and the GP did not use the system for a while because she did not want the screen to hang during a consultation. (EMIS® is an alternative EHR system.)
- iii. One recommendation to improve the system was to change the point at which LEPIS was triggered: 'The biggest problem though I think with it is the fact that what triggers LEPIS is the receiving of the code not the selecting of the code and I don't know, I mean I have said this before, that we use DXS which is the decisions support system and as soon as you select a code it activates DXS but if you select, let's say flu-like illness, and then you type to the end of your clinical note, you then save it and LEPIS triggers, you're less likely to want to interact with LEPIS than you would be if as soon as you've selected the code flu-like illness, it triggered it. And, that I think is the biggest obstacle to FLU-CAT being done, where it triggers, because you see by the time it triggers you've finished the consultation, you've finished the recording of the consultation and you either decide am I going to bother going back and doing it. . .I think that's an inherent problem of the way that LEPIS works at the moment, that you really want to as soon as you put in that somebody's got I don't know, haematuria, you want it to bring up your haematuria study. You don't want it to let you write the whole of your clinical history down and then trigger it'.
- iv. Another GP had reported technical difficulties with the LEPIS system, and had stopped recruiting for the study and intended to resume once the issue was resolved. The GP remarked that he/she would have found it useful to have received an e-mail or some communication indicating that the issue was resolved, as he/she had realised the system was fixed only on the morning of the telephone interview when checked to see if worked.
- v. Despite having experienced difficulties with the LEPIS system, all interviewed GPs acknowledged the support from the CPRD team in helping resolve their technical glitches.
- vi. According to the CPRD team member responsible for the web development: 'Yes, I mean it's a mixed bag really, because you find some practices that are computer literate and some of them not computer literate and so we try to say this is how it works and some of them don't actually grasp what's required for the study, so they would say well it's not working but they haven't actually done the preliminary installation or for example like, if we take the example of the FLU-CATs, because although there is a wide range of Read-codes, perhaps they put a Read-code which is not in the list, so therefore obviously it would not pop out to say this patient is eligible ... Yes, I mean you would know more than me when you describe the flu, everyone describes it differently, so that's why we have included more and more Read-codes because if you...what we had done for flu example we say, oh this is only the ten Read-codes, but perhaps another doctor will describe it differently and it is another Read-code, although it means the same thing, but it is another Read-code, so we have worked towards including more Read-codes in order to encompass everything, or we try to educate ... a big word educate, you can't educate a doctor...but tell them that basically if they want to recruit for this study, if you want to take part, this is the list of the Read-codes. So, therefore there is that communication when you go'.

- 4. Nature of the FLU-CATs consultations:
  - i. All six GPs agreed that the FLU-CATs consultations were very similar to routine consultations and that the FLU-CATs eCRF was quite easy to complete. One GP said that he/she would fill out the FLU-CATs form after the consultation with the patient and remarked, 'I supposed I had to make note of the blood pressure, which I might not have done had it been a normal viral illness, you know I wouldn't necessarily have done that, yes'. Two GPs said they filled out the FLU-CATs forms during the consultation while the patient was still present. According to one of the GPs, 'One of the main people that did our FLU-CATs study returns has been our nurse practitioner and she quite likes it, it's quite helpful to her and I mean, I find it's not at all unhelpful to me, provided I get it triggered at the right time'.
- 5. Readiness of the current FLU-CATs system for use by all GPs in a potential pandemic situation:
  - i. All six GPs thought that the FLU-CATs system would be ready for use in a pandemic situation with minor modifications. Two GPs expressed the need for the data entry to be better integrated within their clinical system; according to one of them, 'I mean it doesn't take that long. It [FLU-CATs form] was a couple of minutes extra I guess to do it compared to doing the consultation without it. So, in the middle of a pandemic that sort of translates to quite a lot of extra work I suppose. If you could capture straight into the notes without having to sort of...it's a bit faffy at the end, sort of copying and pasting and it wasn't the way the data was dropped into the notes would have been fine but it was pretty much impossible for anyone else to use really. But, otherwise it was okay'.
  - ii. Another GP thought that the lack of pulse oximeters in every consulting room would need to be addressed before the FLU-CATs system is recommended for use in a pandemic situation.
  - iii. All six interviewed GPs said that they would be very interested in reading any outputs that result from the FLU-CATs Study.

# Phase 2: pilot study data collection, extraction and statistical analysis

To test the existing processes, three outcome measures were studied in the pilot: decision to (1) treat with influenza-specific antiviral drugs; (2) treat with antibiotics; and (3) refer to hospital. The relatively small number of deaths reported (which are well captured in primary care data) meant that we did not have sufficient numbers to look at death as an outcome. The non-availability of ONS data meant that we were not able to explore the causes of the few cases of death that may be unrelated to influenza. Likewise we could not assess the secondary outcome measures (such as admission to critical care or length of hospital stay) expected to be derived from HES data owing to the unavailability of HES data during the pilot phase.

There were 863 unique FLU-CATs observations in total: 704 adult consultations (702 single and two repeated) and 159 child consultations. There were 13 (1.8%) deaths in adults and two (1.3%) in children. GPs decided to refer 11 (1.6%) adults and six (3.8%) children to hospital. In the absence of linked HES and ONS data it is not possible to validate these results or explore the causes of death.

An important finding from the pilot study was that clinical measures are not consistently measured in all patients during consultations. In adult patients, temperature was not measured in 32%, respiratory rate was not measured in 60% and blood pressure was not measured in 74%. Children had a lower proportion of unmeasured values for temperature, at 14%, and respiratory rate, at 43%. Non-measurement was not the same as 'non-assessment' by the attending clinician; the 'not measured' category in clinical measurements, such as temperature, respiratory rate and heart rate, were further subdivided into 'not measured as grossly normal', 'not measured as grossly abnormal' and 'not measured at all'.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

In total, five adults, and no children, were prescribed antiviral drugs. A slightly higher proportion of adults (73.0%) were recommended treatment with antibiotics compared with children (69.0%). However, a greater proportion of children (3.8%) were referred to hospital compared with adults (1.6%). Completeness of data entry and a binary description of clinical variables are given in *Table 3*.

Descriptive statistics for children and adults are presented in *Table 4*. As expected, children were observed to have higher mean and median temperature, respiratory rate and heart rate compared with adults.

Data item	Adults ( <i>n</i> = 704), <i>n</i> (%)	Children ( <i>n</i> = 159), <i>n</i> (%)
Temperature		
Measured	479 (68.04)	136 (85.53)
Not measured	225 (31.96)	23 (14.47)
Not measured	133 (18.89)	16 (10.06)
Grossly normal	82 (11.65)	5 (3.14)
Grossly abnormal	10 (1.42)	2 (1.26)
Respiratory rate <sup>a</sup>		
Measured	280 (39.77)	90 (56.60)
Not measured	424 (60.23)	69 (43.40)
Not measured	217 (30.82)	31 (19.50)
Grossly normal	201 (28.55)	38 (23.90)
Grossly abnormal	6 (0.85)	90 (56.60)
Peripheral oxygen saturation <sup>b</sup>		
Measured	417 (59.23)	57 (35.85)
Not measured	287 (40.77)	102 (64.15)
Heart rate		
Measured	478 (67.9)	94 (59.12)
Not measured	226 (32.1)	65 (40.88)
Not measured	138 (19.60)	45 (28.30)
Grossly normal	86 (12.22)	20 (12.58)
Grossly abnormal	2 (0.28)	0 (0)
Blood pressure		
Measured	182 (25.85)	N/A
Not measured	522 (74.15)	
Severe respiratory distress		
Yes	34 (4.83)	11 (6.92)
No	670 (95.17)	148 (93.08)
Respiratory exhaustion		
Yes	10 (1.42)	3 (1.89)
No	694 (98.58)	156 (98.11)
Severe dehydration		
Yes	0	0 (0)
No	704 (100)	100 (100)

### TABLE 3 Completeness of data entry and clinical variables by age group

### TABLE 3 Completeness of data entry and clinical variables by age group (continued)

Data item	Adults ( <i>n</i> = 704), <i>n</i> (%)	Children ( <i>n</i> = 159), <i>n</i> (%)
Sternal capillary refill time		
Normal	443 (62.93)	102 (64.15)
> 2 seconds	261 (37.07)	57 (35.85)
Patient on oxygen		
Yes	1 (0.14)	0 (0)
No	703 (99.86)	159 (100)
Patient on new oxygen		
Yes	0	0
No	1 (0.14)	0
N/A	703 (99.86)	100 (100)
New altered consciousness level		
No, patient alert	702 (99.72)	157 (98.74)
Confused/agitated	1 (0.14)	2 (1.26)
Responsive to pain only/unconscious (voice for children)	1 (0.14)	0 (0)
Social isolation		
Yes	62 (8.81)	N/A
No	609 (86.51)	
Unknown	33 (4.69)	
Activity and ability to self-care		
Normal activity, ability to care for self	531 (75.43)	N/A
Limited activity, can care for self	104 (14.77)	
Housebound, can care for self	11 (1.56)	
Housebound, limited self-care	6 (0.85)	
Confined, no self-care	5 (0.71)	
Not assessed	47 (6.68)	
Decision to treat with antivirals		
Yes	5 (0.71)	0 (0)
No	699 (99.29)	159 (100)
Decision to treat with antibiotics		
Yes	517 (73.44)	110 (69.18)
No	187 (26.56)	49 (30.82)
Decision to refer to hospital		
Yes	11 (1.56)	6 (3.77)
No	693 (98.44)	153 (96.23)
N/A, not applicable.		

a Where this has not been measured, it has not been possible to derive CAT criterion B.

b For the purpose of deriving CAT criterion C, it has been assumed that a non-measurement suggests a clinical judgement of 'grossly normal'.

Clinical measurements	Adults ( <i>n</i> = 704)	Children ( <i>n</i> = 159)
Temperature (°C)		
Mean (SD)	36.82 (0.71)	37.23 (1.03)
Median (IQR)	36.7 (36.3–37.2)	37.05 (36.45–37.85)
Respiratory rate (breaths per minute)		
Mean (SD)	19.69 (5.63)	24.5 (10.52)
Median (IQR)	18 (16–20)	20 (18–28)
Peripheral oxygen value (%)		
Mean (SD)	96.94 (2.10)	N/A
Median (IQR)	98 (96–98)	
Heart rate (beats per minute)		
Mean (SD)	83.20 (13.21)	102.02 (22.73)
Median (IQR)	82 (75–90)	100 (80–120)
Systolic blood pressure (mmHg)		
Mean (SD)	132.83 (19.32)	N/A
Median (IQR)	131.5 (120–143)	
Diastolic blood pressure (mmHg)		
Mean (SD)	77.11 (10.27)	N/A
Median (IQR)	78 (70–84)	
IOR, interguartile range; N/A, not applicable; SD, stan	dard deviation.	

TABLE 4 Descriptive analysis of clinical measurements by age group

The CATs criterion B (increased respiratory rate) could not be determined in 60.2% of adults and 43.4% of children owing to non-measurement of respiratory rate in these patients. The remaining six CATs criteria were estimated in all patients. Of these, CATs criterion G (other clinical concern) had the highest percentage of patients in both adults (21.0%) and in children (22.0%). CATs criterion F (new altered consciousness) was the least commonly seen criteria, observed in only two adult patients (0.3%) and two children (1.3%). Descriptive analyses for each of the CATs criteria are presented in *Table 5*, and key clinical concerns relating to CATs criterion G are presented in *Table 6* (adults) and *Table 7* (children).

# The association between Community Assessment Tools criteria and outcomes of interest

The distribution of events across various criteria and covariates resulted in a low number of events in some categories despite the pilot study reaching nearly 86% of the a priori sample size estimates, and so running a fully adjusted logistic regression model (adjusting for all confounders) was not possible. Therefore, an unadjusted and a multivariable model including all of the seven CATs criteria, adjusted for each other, was run. Generally, because the data were sparse, wide 95% CIs and variable omissions (from the analyses) were seen. Results from the children's analyses are presented in *Table 8* and results from the adults' analyses are presented in *Table 9*.

TABLE 5 Descriptive	e analysis of	f distribution	of CATs	criteria b	by age	group
---------------------	---------------	----------------	---------	------------	--------	-------

Clinical measurements: CATs triage criterion	Adults ( <i>n</i> = 704), <i>n</i> (%)	Children ( <i>n</i> = 159), <i>n</i> (%)
A (severe respiratory distress)		
Yes	34 (4.83)	11 (6.92)
No	670 (95.17)	148 (93.08)
B (increased respiratory rate)		
Yes	4 (0.57)	12 (7.55)
No	276 (39.2)	78 (49.06)
Not measured <sup>a</sup>	424 (60.23)	69 (43.4)
C (oxygen saturation of $\leq$ 92%)		
Yes	15 (2.13)	7 (4.40)
No	689 (97.87)	152 (95.6)
D (respiratory exhaustion)		
Yes	10 (1.42)	3 (1.89)
No	694 (98.58)	156 (98.11)
E (severe clinical dehydration/shock)		
Yes	10 (1.42)	5 (3.14)
No	694 (98.58)	154 (96.86)
F (new altered consciousness)		
Yes	2 (0.28)	2 (1.26)
No	702 (99.72)	157 (98.74)
G (other clinical concern)		
Yes	148 (21.02)	35 (22.01)
No	556 (78.98)	124 (77.99)

a Derived criteria – could not be derived where respiratory rate was not recorded; in children, the respiratory rate threshold for children aged  $\geq$  1 year has been used.

TABLE 6 Key themes emerging from free-text comments under 'nature of other clinical concern', where available, presented in order of frequency for adults

Theme	Frequency (n)
Other (diabetes, heart disease)	44
Clinical signs suggestive of pneumonia (basal crepitations, rhonchi, crackles, decreased air entry and consolidation)	39
Chronic lung disease (particularly asthma and chronic obstructive pulmonary disease)	29
Chest pain (pleuritic chest wall pain)	11
Sputum	7
Wheezing	6
Immunosuppression (long-term oral steroid use, other immunosuppressive treatment and conditions, such as sarcoidosis, which affect the immune system)	6
Prolonged cough (> 4 weeks)	3
Deterioration of symptoms	1
Malignancy	1

**TABLE 7** Key themes emerging from free-text comments under 'nature of other clinical concern', where available, presented in order of frequency for children

Theme	Frequency (n)
Clinical signs suggestive of pneumonia	18
Other	9
Chest related	4
Cough	2
Asthma	1
Immunocompromised	1

### TABLE 8 Association between CATs criteria and outcomes of interest in children

		Unadjusted		Adjusted <sup>a</sup>	
Outcome		OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
1. Decision to treat	with antiv	virals			
CATs criterion	А	n/a	n/a	n/a	n/a
	В	n/a	n/a	n/a	n/a
	С	n/a	n/a	n/a	n/a
	D	n/a	n/a	n/a	n/a
	E	n/a	n/a	n/a	n/a
	F	n/a	n/a	n/a	n/a
	G	n/a	n/a	n/a	n/a
2. Decision to treat	with antil	biotics			
CATs criterion	А	0.51 (0.15 to 1.75)	0.2832	2.96 (0.12 to 70.38)	0.5021
	В	0.30 (0.09 to 1.05)	0.0587	0.14 (0.03 to 0.81)	0.0282
	С	2.77 (0.32 to 23.64)	0.3519	n/a	n/a
	D	0.89 (0.08 to 10.04)	0.9241	0.13 (0.002 to 8.35)	0.3392
	E	n/a	n/a	n/a	n/a
	F	n/a	n/a	n/a	n/a
	G	10.07 (2.31 to 43.92)	0.0021	7.54 (1.12 to 50.92)	0.0382
3. Decision to refer	to hospita	al			
CATs criterion	А	8.00 (1.29 to 49.68)	0.0256	2.89 (0.02 to 397.44)	0.6731
	В	15.40 (1.28 to 185.61)	0.0313	5.19 (0.12 to 234.07)	0.3966
	С	14.80 (2.18 to 100.66)	0.0059	39.12 (0.55 to 2759.05)	0.0913
	D	15.10 (1.67 to 195.43)	0.0377	19.77 (0.07 to 5498.53)	0.2986
	E	7.45 (0.70 to 79.35)	0.0961	n/a	n/a
	F	30.40 (1.65 to 558.88)	0.0215	n/a	n/a
	G	3.78 (0.73 to 19.63)	0.1135	1.36 (0.03 to 72.39)	0.8808

n/a, omitted from logistic regression analysis because of insufficient data; OR, odds ratio. a Adjusted for each of the other CATs criteria.

Statistically significant results are presented in bold text.

		Unadjusted		Adjusted <sup>a</sup>	
Outcome		OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
1. Decision to treat	t with ant	tivirals			
CATs criterion	А	5.05 (0.55 to 46.41)	0.1528	5.64 (0.53 to 59.97)	0.1513
	В	n/a	n/a	0.99 (0.79 to 1.24)	0.915
	С	n/a	n/a	n/a	n/a
	D	n/a	n/a	n/a	n/a
	Е	n/a	n/a	n/a	n/a
	F	174.5 (9.22 to 3303.91)	< 0.001	n/a	n/a
	G	15.42 (1.71 to 139.00)	0.0148	9.88 (0.96 to 101.49)	0.0539
2. Decision to treat	t with ant	tibiotics			
CATs criterion	А	1.73 (0.70 to 4.24)	0.2329	1.19 (0.44 to 3.22)	0.7269
	В	0.89 (0.86 to 0.93)	< 0.001	0.90 (0.87 to 0.94)	< 0.001
	С	1.46 (0.41 to 5.22)	0.5630	0.96 (0.22 to 4.15)	0.9567
	D	n/a	n/a	n/a	n/a
	Е	0.54 (0.15 to 1.92)	0.3310	0.49 (0.12 to 1.99)	0.3178
	F	0.36 (0.02 to 5.79)	0.4714	0.09 (0.004 to 1.87)	0.1201
	G	6.44 (3.31 to 12.55)	< 0.001	6.42 (3.17 to 12.99)	< 0.001
3. Decision to refe	r to hospi	tal			
CATs criterion	А	28.5 (8.20 to 99.04)	< 0.001	26.84 (5.62 to 128.05)	< 0.001
	В	0.90 (0.78 to 1.03)	0.1303	0.98 (0.82 to 1.17)	0.8272
	С	35.43 (9.04 to 138.77)	< 0.001	11.67 (1.68 to 81.16)	0.0130
	D	n/a	n/a	n/a	n/a
	E	36.75 (8.03 to 168.29)	< 0.001	48.99 (6.06 to 396.32)	< 0.001
	F	69.20 (4.04 to 1185.94)	0.0034	5.86 (0.003 to 11240.73)	0.6467
	G	3.21 (0.96 to 10.65)	0.0573	2.51 (0.55 to 11.46)	0.2350

### TABLE 9 Association between CATs criteria and outcomes of interest in adults

n/a, omitted from logistic regression analysis because of insufficient data; OR, odds ratio.

a Adjusted for each of the other CATs criteria.

Statistically significant results are presented in bold text.

### Outcome 1: decision to treat with influenza-specific antiviral drugs

Given that only five adult patients were prescribed influenza-specific antiviral drugs, odds ratios (ORs) and 95% CIs could be obtained for only three criteria in the unadjusted and adjusted analyses. CATs criteria F and G showed strong positive associations (OR 174.5, 95% CI 9.2 to 3303.9 and OR 15.4, 95% CI 1.7 to 139.0, respectively) in the adjusted analyses, but none of the associations was statistically significant in the adjusted analyses.

None of the participating GPs decided to treat any of the recruited children with influenza-specific antiviral drugs, so no further analysis for this outcome was possible for this group.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton So16 7NS, UK.

### **Outcome 2: decision to treat with antibiotics**

In adults, CATs criteria B and G were statistically significantly associated with this outcome in the unadjusted analyses, and remained statistically significant with consistent estimates in adjusted analyses. After adjusting for other CATs criteria, adults presenting with CATs criterion A showed a 10% decreased odds (95% CI 0.9 to 0.9) of being treated with antibiotics and those presenting with CATs criterion G were associated with an increased odds of being treated with antibiotics (OR 6.4, 95% CI 3.2 to 13.0).

In children, although CATs criterion G showed a 10-fold increase in odds of treatment with antibiotics (OR 10.1, 95% CI 2.3 to 43.9) in the unadjusted analyses, this was not seen to be statistically significant after adjustment for other CATs criteria.

### **Outcome 3: referral to hospital**

In adults, CATs criteria A, C, E and F were positively and statistically significantly associated with referral to hospital in the unadjusted analyses. CATs criteria C and E remained statistically significant in the adjusted analyses, with increase in odds of hospital referral by 11.7 times (95% CI 1.7 to 81.2 times) and 49.0 times (95% CI 6.1 to 396.3 times), respectively.

In children, CATs criteria A, D and F were significantly associated with the outcome, although statistical significance was lost after adjustment for other CATs criteria.

## Monthly data findings

Background variables including comorbidities and select treatments/vaccinations were extracted from the CPRD database for patients with FLU-CATs consultations (coded as ever having had a record of the comorbidity/treatment/vaccination before the FLU-CATs consultation date). In the 861 total of FLU-CATs patients, respiratory disease (25.9%) was the most commonly seen comorbidity, followed by diabetes (8.6%), renal disease (6.6%), cardiovascular disease (5.1%), neurological disease (2.2%), liver disease (0.4%) and immunosuppression (0.1%). Distribution of comorbidities in adults and children is presented in *Table 10*.

Overall, 29.9% of all patients had been prescribed antibiotics, whereas only 0.9% had been prescribed influenza-specific antiviral drugs at some point before the FLU-CATs consultation. A total of 15.9% of all patients had past records of seasonal influenza vaccinations. Distribution of treatments and vaccinations in adults and children is presented in *Table 11*.

Comorbidity	Adult ( <i>N</i> = 702ª), <i>n</i> (%)	Children ( <i>N</i> = 159), <i>n</i> (%)
Cardiovascular	41 (4.58)	3 (1.89)
Liver	3 (0.43)	0 (0)
Neurological	17 (2.42)	2 (1.26)
Renal	44 (6.27)	13 (8.18)
Respiratory	209 (29.77)	14 (8.81)
Diabetes	73 (10.40)	1 (0.63)
Immunosuppression	1 (0.14)	0 (0)

### TABLE 10 Distribution of comorbidities by age group

a Two adults had repeat consultations hence 704 observations from 702 cases.

Drug/vaccination	Adult ( <i>N</i> = 702 <sup>a</sup> ), <i>n</i> (%)	Children ( <i>N</i> = 159), <i>n</i> (%)
Statin	198 (28.21)	N/A
Antibiotic	245 (34.90)	12 (7.55)
Antiviral	7 (1.00)	1 (0.63)
Inhaled steroids	146 (79.20)	9 (5.66)
Oral steroids	248 (35.33)	32 (20.13)
Seasonal influenza vaccine	122 (17.38)	15 (9.43)
Hib vaccine	2 (0.28)	0 (0)
Pneumococcal vaccine	6 (0.85)	0 (0)

### TABLE 11 Distribution of treatments and vaccinations by age group

Hib, *H. influenzae* type B; N/A, not applicable.

a Two adults had repeat consultations hence 704 observations from 702 cases.

## **Comparison of Pandemic Medical Early Warning Score with Community Assessment Tools (adults only)**

Given the large number of unmeasured/missing clinical measurements, PMEWS scores could only be calculated for a small proportion of adult patients in whom all necessary measurements were recorded.

*Table 12* shows a comparison of the PMEWS score with the CATs score for the outcomes 'decision to refer to hospital' and 'death'. Data in this pilot study are too sparse for inferential statistics.

	Refer to hospital (N = 1	1), <i>n</i> (%)	Death (N = 13), n (%)		
Scores	Yes	No	Yes	No	
PMEWS					
1	0 (0)	10 (1.44)	0 (0)	10 (1.45)	
2	1 (9.09)	14 (2.02)	0 (0)	15 (2.17)	
3	0 (0)	15 (2.17)	0 (0)	15 (2.17)	
4	0 (0)	7 (1.01)	1 (7.69)	6 (0.87)	
5	0 (0)	8 (1.16)	0 (0)	8 (1.16)	
6	0 (0)	2 (0.29)	1 (7.69)	1 (0.14)	
7	0 (0)	1 (0.14)	0 (0)	1 (0.14)	
9	1 (9.09)	1 (0.14)	0 (0)	2 (0.29)	
14	1 (9.09)	0 (0)	1 (7.69)	0 (0)	
Missing	8 (72.73)	635 (91.63)	10 (76.93)	633 (91.61)	
CATs					
0	2 (18.18)	171 (24.68)	4 (30.78)	169 (24.46)	
1	0 (0)	86 (12.41)	0 (0)	86 (12.45)	
2	3 (27.27)	12 (1.73)	2 (15.38)	13 (1.88)	
3	0 (0)	4 (0.58)	0 (0)	4 (0.58)	
4	2 (18.18)	0 (0)	1 (7.69)	1 (0.14)	
Missing	4 (36.37)	420 (60.60)	6 (46.15)	418 (60.49)	

#### TABLE 12 Distribution of PMEWS and CATs scores in adults, by primary outcomes

## Automated weekly and monthly report generation

Stata 'do files' have been written to automate the logistic regression analyses and reporting of the results. The weekly and monthly 'do files' are described in detail in the *FLU-CATs Handbook* (see *Appendix 6*).

The weekly results are saved into an Excel spreadsheet with three worksheets – CATs criteria, clinical data and regression results. Sample screenshots of the weekly report are provided in *Figure 7*.

	А	В	С	D	E	F	G	Н	1	J	K	L	Μ	N	0	Р	Q
1	NIHR Flu-	CATs Week	ly Report:	dd/mm/YY	YY		Data Sourc	e: Clinica	Practice R	esearch Da	talink- Par	ticipating (	GP Practice	s			
2																	
3	This sprea	adsheet cor	ntains thre	e workshe	ets- 'CATs	criteria' (fr	equencies	of each of	the 7 CAT	s criteria). '	Clinical da	ta' (other c	linical data	a collected t	hrough th	ne LEPIS fo	rm)
4	and 'Analy	vses' (resul	ts of logist	tic regressio	on analyse	5).											
5		,			,	-,.											
6		Freg	Dercent	Cum													
7	No	1/18	93.08	93.08													
-	Voc	110	6.92	100													
-	Tetal	150	100	100													
9	Total	139	100														
10	<b>-</b> -	-	<u> </u>	-													
11	CATS B	Freq.	Percent	Cum.													
12	No	78	49.06	49.06													
13	Yes	12	7.55	56.61													
14	Missing	69	43.4	100.01													
15	Total	159	100														
16																	
17	CATs C	Freq.	Percent	Cum.													
18	No	152	95.6	95.6													
19	Yes	7	4.4	100													
20	Total	159	100														
21																	
22	CATs D	Freq.	Percent	Cum.													
23	No	156	98.11	98.11													
24	Yes	2.50	1.89	100													
25	Total	159	100	100													
2.5	TOtal	133	100														
20	CATE	<b>F</b>	Dement	C													
27		Freq.	Percent oc.oc	Cum.													
20	NO Vez	134	50.00	50.60													
29	Yes	5	3.14	100													
30	Iotal	159	100												_		
	Α	B	С	D	E	F	G	н		J	K	L	M	N	0	P	Q
-										-							
1	Regressio	on Results' o	contains re	esults from	unadjuste	d and adju	sted logisti	c regressi	on analyse	s for outco	mes of int	erest					
1	Regressio	n Results' o	contains re	esults from	unadjuste	d and adju	sted logisti	ic regressi	on analyse	s for outco	mes of int	erest					
1 2 3	Unadjuste	on Results' o ed analyses	contains re	esults from	unadjuste	d and adju	sted logisti	c regressi	on analyse Adjusted	s for outco analyses	mes of int	erest					
1 2 3 4	Unadjuste	on Results' o ed analyses ne: Decision	contains re ; n to treat v	esults from	unadjuste als	d and adju	sted logisti	ic regressi	on analyse Adjusted 1. Outcom	s for outco analyses ne: Decision	mes of int	erest vith antivir	als				
1 2 3 4 5	Unadjuste	on Results' o ed analyses ne: Decision n	contains re , n to treat v OR	esults from with antivin Lower 95%	unadjuste als Upper 95%	d and adju p-value	sted logisti	ic regressi	on analyse Adjusted 1. Outcom	s for outco analyses ne: Decision n	mes of into n to treat v OR	erest vith antivir Lower 95%	als Upper 95%	p-value			
1 2 3 4 5 6	Unadjuste 1. Outcon CATs A	on Results' o ed analyses ne: Decision n 704	ontains re n to treat v OR 5.045455	with antivin Lower 959 0.548503	unadjuste als Upper 95% 46.41103	d and adju p-value 0.152847	sted logisti	ic regressi	on analyse Adjusted 1. Outcom CATs A	s for outco analyses ne: Decision n 670	mes of intention to treat w OR 5.641482	erest vith antivir Lower 95% 0.530679	als Upper 95% 59.97279	p-value 0.151394			
1 2 3 4 5 6 7	Unadjuste 1. Outcon CATs A CATs B	n Results' o ed analyses ne: Decision n 704 704	ontains re n to treat v OR 5.045455 0.998642	with antivir Lower 959 0.548503 0.817824	unadjuste als Upper 95% 46.41103 1.219439	d and adju p-value 0.152847 0.989361	sted logisti	c regressi	Adjusted 1. Outcom CATs A CATs B	analyses ne: Decision n 670 670	mes of int n to treat v OR 5.641482 0.987892	erest vith antivir Lower 95% 0.530679 0.789986	als Upper 95% 59.97279 1.235378	p-value 0.151394 0.915			
1 2 3 4 5 6 7 8	Unadjuste 1. Outcon CATs A CATs B CATs C	n Results' o ed analyses ne: Decision n 704 704 689	contains re n to treat v OR 5.045455 0.998642 1	esults from with antivir. Lower 959 0.548503 0.817824 1	unadjuste als Upper 95% 46.41103 1.219439 1	d and adju p-value 0.152847 0.989361	sted logisti	c regressi	Adjusted 1. Outcom CATs A CATs B CATs C	n for outco ne: Decision n 670 670 670	mes of int n to treat v OR 5.641482 0.987892 1	erest vith antivir Lower 95% 0.530679 0.789986 1	als Upper 95% 59.97279 1.235378 1	p-value 0.151394 0.915			
1 2 3 4 5 6 7 8 9	Unadjuste 1. Outcon CATs A CATs B CATs C CATs D	n Results' o ed analyses ne: Decision n 704 704 689 694	contains re n to treat v OR 5.045455 0.998642 1 1	vith antivir. Lower 95% 0.548503 0.817824 1 1	unadjuste als Upper 95% 46.41103 1.219439 1 1	d and adju p-value 0.152847 0.989361	sted logisti	c regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs D	n for outco ne: Decision n 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1	erest vith antivir Lower 959 0.530679 0.789986 1 1	als Upper 95% 59.97279 1.235378 1 1	p-value 0.151394 0.915			
1 2 3 4 5 6 7 8 9 10	Unadjuste 1. Outcom CATs A CATs B CATs C CATs D CATs E	n Results' o ed analyses ne: Decision n 704 704 689 694 694	contains re n to treat v OR 5.045455 0.998642 1 1 1	with antivir. Lower 959 0.548503 0.817824 1 1 1	unadjuste als Upper 95% 46.41103 1.219439 1 1 1 1	d and adju p-value 0.152847 0.989361	sted logisti	c regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS D CATS E	s for outco analyses ne: Decision n 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1	erest vith antivir Lower 95% 0.530679 0.789986 1 1 1 1	als Upper 95% 59.97279 1.235378 1 1 1	p-value 0.151394 0.915			
1 2 3 4 5 6 7 8 9 10 11	Unadjuste 1. Outcom CATs A CATs B CATs C CATs D CATs E CATs F	n Results' of ed analyses ne: Decision n 704 704 689 694 694 704	contains re n to treat v OR 5.045455 0.998642 1 1 1 1 174.5	with antivir Lower 95% 0.548503 0.817824 1 1 1 9.21644	unadjuste als Upper 95% 46.41103 1.219439 1 1 1 3303.906	d and adju p-value 0.152847 0.989361 0.000581	sted logisti	c regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs D CATs E CATs F	s for outco analyses ne: Decision n 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 1 1	erest vith antivir Lower 95% 0.530679 0.789986 1 1 1 1 1	als Upper 95% 59.97279 1.235378 1 1 1 1 1	p-value 0.151394 0.915			
1 2 3 4 5 6 7 8 9 10 11 11 12	CATS A CATS A CATS B CATS C CATS D CATS E CATS F CATS G	n Results' of ed analyses ne: Decision n 704 704 689 694 694 704 704	contains re n to treat v OR 5.045455 0.998642 1 1 1 174.5 15.41667	with antivir Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965	d and adju p-value 0.152847 0.989361 0.000581 0.014763	sted logisti	c regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs D CATs C CATs D CATs E CATs F CATs G	s for outco analyses ne: Decision n 670 670 670 670 670 670 670 670	mes of int or to treat w OR 5.641482 0.987892 1 1 1 9.882796	erest vith antivir Lower 95% 0.530679 0.789986 1 1 1 1 0.962373	als Upper 95% 59.97279 1.235378 1 1 1 1 1 1 101.4883	p-value 0.151394 0.915 0.053889			
1 2 3 4 5 6 7 8 9 10 11 11 12 13	CATS A CATS A CATS A CATS B CATS C CATS D CATS C CATS C CATS F CATS G	n Results' o ed analyses ne: Decision n 704 689 694 694 704 704	contains re n to treat v OR 5.045455 0.998642 1 1 1 1 174.5 15.41667	with antivir Lower 959 0.548503 0.817824 1 1 9.21644 1.709925	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965	d and adju: p-value 0.152847 0.989361 0.000581 0.014763	sted logisti	ic regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs D CATs C CATs C CATs C CATs C CATs G	s for outco analyses ne: Decision n 670 670 670 670 670 670 670	mes of int n to treat v OR 5.641482 0.987892 1 1 1 1 9.882796	erest vith antivir Lower 95% 0.530679 0.789986 1 1 1 1 0.962373	als Upper 95% 59.97279 1.235378 1 1 1 1 1 101.4883	p-value 0.151394 0.915 0.053889			
1 2 3 4 5 6 7 8 9 10 11 11 12 13 14	Unadjuste 1. Outcon CATs A CATs B CATs C CATs D CATs C CATs C C	n Results' of ed analyses ne: Decision n 704 689 694 694 704 704 704	contains re n to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibic	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vtics	d and adju: p-value 0.152847 0.989361 0.000581 0.014763	sted logisti	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C C	s for outco analyses ne: Decision n 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat w	vith antivir Lower 959 0.530679 0.789986 1 1 1 0.962373 vith antibio	als Upper 95% 59.97279 1.235378 1 1 1 1 101.4883 ptics	p-value 0.151394 0.915 0.053889			
1 2 3 4 5 6 7 8 9 9 10 11 12 13 14 15	Regressio Unadjuste 1. Outcon CATS A CATS A CATS B CATS C CATS C CATS C CATS C CATS G 2. Outcon	n Results' of ad analyses ne: Decision n 704 704 689 694 694 704 704 704 ne: Decision n	contains re n to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v OR	with antivir. Lower 959 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 95%	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitics Upper 95%	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value	sted logisti	ic regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs C CATs C CATs C CATs C CATs C CATs C CATs G 2. Outcom	s for outco analyses ne: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat v OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat v OR	vith antivir Lower 959 0.530679 0.789986 1 1 1 0.962373 vith antibio Lower 959	als Upper 95% 59.97279 1.235378 1 1 1 1 101.4883 otics Upper 95%	p-value 0.151394 0.915 0.053889 p-value			
1 2 3 4 5 6 7 8 9 10 11 11 12 13 14 15 16	Regressio Unadjuste 1. Outcon CATS A CATS A CATS B CATS C CATS C CATS C CATS C CATS F CATS G 2. Outcon CATS A	n Results' of ed analyses ne: Decision n 704 704 689 694 694 694 704 704 704 704 704 704 704 704	contains re n to treat v OR 5.045455 0.998642 11 174.5 15.41667 n to treat v OR 1.727335	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 95% 0.703632	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitics Upper 95% 4.240407	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919	sted logisti	ic regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs A CATS C CATS C CATS A CATS A CATS A CATS A CATS A CATS A CATS A CATS C CATS A CATS A CATS A CATS A CATS A CATS A CATS C CATS A CATS A C	s for outco analyses ne: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat v OR 5.641482 0.98789 1 1 1 9.882796 n to treat v OR 1.19328	vith antivir Lower 95% 0.530679 0.789986 1 1 1 0.962373 vith antibio Lower 95% 0.442619	als Upper 95% 59.97279 1.235378 1 1 1 1 1 1 1.01.4883 vtics Upper 95% 3.217287	p-value 0.151394 0.915 0.053889 p-value 0.726872			
1 2 3 4 5 6 7 8 9 10 11 11 12 13 14 15 16 17	Regressio Unadjuste 1. Outcon CATS A CATS B CATS C CATS D CATS C CATS C CATS C CATS G 2. Outcon CATS A CATS B	n Results' of ad analyses ne: Decision n 704 694 694 704 704 704 ne: Decision n 704 704 704	contains re on to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v OR 1.727335 0.893719	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 95% 0.703632 0.836714	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vtics Upper 95% 4.240407 0.932322	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07	sted logist	ic regressi	Adjusted 1. Outcom CATs A CATs C CATs A CATS A CATS B	s for outco analyses te: Decision n 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat w OR 1.193328 0.903887	vith antivir Lower 95% 0.530679 0.789986 1 1 1 0.962373 vith antibio Lower 95% 0.442619 0.442619	als Upper 959 59.97279 1.235378 1 1 1 101.4883 vtics Upper 959 3.217287 0.944411	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06			
1 2 3 4 5 6 7 8 9 10 11 11 12 13 14 15 16 17 18	Regressio Unadjuste 1. Outcom CATs A CATs B CATs C CATs C CATs C CATs F CATs G 2. Outcom CATs A CATs A CATs A CATs C	n Results' of ed analyses ne: Decision n 704 704 689 694 694 704 704 ne: Decision n 704 704 704 704	contains re on to treat w OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat w OR 1.727335 0.893719 0.893719 1.457426	with antivir. Lower 95% 0.548503 0.817824 1 1 9.2164 1.709925 with antibic Lower 95% 0.703632 0.856714 0.406687	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vtics Upper 95% 4.240407 0.932322 5.222907	d and adju: p-value 0.152847 0.989361 0.014763 p-value 0.232919 1.91E-07 0.562985	sted logisti	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS A CATS C	s for outco analyses te: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 9.882796 n to treat w OR 1.193328 0.903987 0.9003987	erest vith antivir Lower 959 0.530679 0.789986 1 1 1 1 0.962373 vith antibio Lower 959 0.442619 0.865294 0.222383	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 Upper 95% 3.217287 0.944411 4.14667	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CATS A CATS A CATS A CATS C CATS D CATS C CATS C CATS A CATS A CATS A CATS A CATS C CATS C CATS C	n Results' of ed analyses ne: Decision n 704 689 694 704 704 704 ne: Decision n 704 704 704 704	ontains re n to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 NOR 1.727335 0.893719 1.457426 1	with antivir. Lower 959 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 959 0.703632 0.856714 0.406887 1	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitcs Upper 95% 4.240407 0.932322 5.22207 1	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985	sted logisti	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS B CATS C CATS C CATS C CATS C	s for outco analyses ne: Decision 670 670 670 670 670 670 670 670 670 670	n to treat v OR 5.641482 0.987892 1 1 9.882796 n to treat v OR 1.193328 0.903987 0.960287 1	erest vith antivir Lower 959 0.789986 1 1 1 0.962373 vith antibio Lower 959 0.442619 0.865294 0.22283 1	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 vtics Upper 95% 3.217287 0.944411 4.146671	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567			
1 2 3 4 5 6 7 8 9 10 11 11 12 13 14 15 16 17 18 19 20	CATS A CATS A CATS A CATS C CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS A CATS B CATS C CATS D CATS C	n Results' of an analyses ne: Decision n 704 689 694 694 704 704 704 704 704 704 704 704 704	ontains re n to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v OR 1.727335 0.893719 1.457426 1 0.537182	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibio Lower 95% 0.703632 0.856714 0.406687 1 0.149896	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitics Upper 95% 4.240407 0.932322 5.222907 1 1.925092	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964	sted logist	ic regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs C CATs C CATs C CATs G 2. Outcom CATs A CATs A CATs C CATs C	s for outco analyses ne: Decision n 670 670 670 670 670 670 670 670 670 670	mes of int n to treat v OR 5.641482 0.987892 1 1 1 9.882796 n to treat v OR 1.19328 0.903987 0.960287 1 0.488744	erest vith antivir Lower 955 0.530679 0.789986 1 1 1 0.962373 vith antibio Lower 955 0.442619 0.865294 0.222383 1 0.119975	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 0tics Upper 95% 3.217287 0.944411 4.146679 1 1.991011	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567 0.317781			
1 2 3 4 5 6 7 8 9 10 11 11 12 13 14 15 16 17 18 19 20 21	CATS A CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS C CATS C CATS C CATS A CATS A CATS B CATS C CATS C CA	n Results' of ad analyses ne: Decision n 694 694 694 704 704 704 704 704 704 704 704 704 70	ontains re on to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v OR 1.727335 0.893719 1.457426 1 0.537182 0.30065	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibio Lower 95% 0.703632 0.856714 0.406687 1 0.149896 0.022422	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 Hites Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5 722041	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409	sted logist	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS B CATS C CATS D CATS C CATS D CATS C CATS D CATS C CATS D CATS C CATS C	s for outco analyses te: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat w OR 1.193328 0.903887 0.960287 1 0.488744 0.09152	erest vith antivir Lower 959 0.530679 0.789986 1 1 1 1 0.962373 vith antibio Lower 959 0.442619 0.442619 0.422383 1 0.119975 0.004497	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 vtics Upper 95% 3.217287 0.944411 4.146679 1 1.991011 1 986559	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567 0.9567			
1 2 3 4 5 6 7 8 9 10 11 11 12 13 14 15 16 17 18 19 20 21 22	CATS A CATS A CATS A CATS C CATS C CATS C CATS C CATS C CATS C CATS A CATS A CATS A CATS A CATS A CATS C CATS C CATS C CATS C CATS C CATS C CATS C	n Results' of ad analyses ne: Decision n 689 694 704 704 704 704 704 704 704 704 704 70	ontains re on to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v OR 1.727335 0.893719 1.457426 1 0.537182 0.360465 6.4449ec	with antivir. Lower 959 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 959 0.703632 0.856714 0.406687 1 0.149896 0.022432 3.31045	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 tics Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5.792491 1.2 54716	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.47160 4.21E-0°	sted logisti	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS A CATS A CATS C CATS C	s for outco analyses te: Decision 670 670 670 670 670 670 670 670 670 670	mes of int or to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat w OR 1.193328 0.903987 0.960287 1 0.488744 0.9401622 6.421152	erest vith antivir Lower 95% 0.530679 0.789986 1 1 1 1 0.962373 vith antibic Lower 95% 0.442619 0.365224 0.222383 1 0.119975 0.040497 3 174985	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 vtics Upper 95% 3.217287 0.944411 4.146679 1 1.991011 1.86659	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567 0.317781 0.12013 2 985-07			Image: Constraint of the sector of
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CATS A CATS A CATS A CATS CATS C CATS C CATS C CATS C CATS G 2. Outcon CATS A CATS B CATS C CATS B CATS C CATS C CATS F CATS F CATS G	n Results' of ed analyses ne: Decision n 704 689 694 694 694 704 704 704 704 704 704 704 704 704 70	ontains re on to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 0.893719 1.457426 1 0.537182 0.360465 6.444855	with antivir. Lower 959 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 959 0.703632 0.856714 0.40687 1 0.149896 0.022432 3.310405	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitcs Upper 95% 4.240407 0.5322907 1 1.925092 5.792491 1.2.54715	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08	sted logisti	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS D CATS C CATS C CATS C CATS C CATS C CATS C 2. Outcom CATS A CATS A CATS A CATS C CATS C	s for outco analyses te: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat w OR 1.193328 0.903987 0.960287 1 0.488744 0.091622 6.421152	erest vith antivir Lower 959 0.530679 0.789986 1 1 1 1 0.962373 vith antibio Lower 959 0.442619 0.865294 0.222383 1 0.119975 0.004497 3.174885	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 otics Upper 95% 3.217287 0.94411 4.146679 1 1.991011 1.866559 12.98667	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567 0.317781 0.120143 2.28E-07			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Regression Unadjuste 1. Outcom CATS A CATS A CATS C CATS D CATS C CATS D CATS A CATS A CATS A CATS A CATS B CATS C CATS C C	n Results' of an analyses eet analyses eet Decision n 704 689 694 704 704 704 704 704 704 704 704	ontains re on to treat v OR 5.045455 0.998642 1 1 1 174.5 15.41667 0.893719 1.457426 1 0.537182 0.360465 6.444855	with antivir. Lower 959 0.548503 0.817824 1 1 9.21644 1.709925 0.703632 0.856714 0.406887 1 0.149896 0.022432 3.310405	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitos Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5.792491 12.54715	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08	sted logist	ic regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs C CATs C CATs C CATs C CATs C CATs G 2. Outcom CATs A CATs A CATs C CATs C	s for outco analyses he: Decision 670 670 670 670 670 670 670 670 670 670	mes of int to treat v OR 5.641482 0.987892 1 1 1 9.882796 to treat v OR 1.19328 0.903987 0.960287 1 0.488744 0.091622 6.421152	erest vith antivir Lower 955 0.530679 0.789986 1 1 1 0.962373 vith antibio Lower 955 0.442619 0.865294 0.22283 1 0.119975 0.004497 3.174885	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 trics Upper 95% 3.217287 0.944411 4.146679 1 1.991011 1.866559 12.98667	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567 0.317781 0.120143 2.28E-07			
1 2 3 4 5 6 7 8 9 10 11 11 12 13 14 15 16 17 18 19 20 21 22 23 24	CATS A CATS A CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS G 2. Outcon CATS A CATS B CATS C CATS C	n Results' of ad analyses ne: Decision n 704 689 684 694 704 704 704 704 704 704 704 704 704	ontains re on to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v OR 1.727335 0.893719 1.457426 1 0.537182 0.360465 6.444855	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 95% 0.703632 0.856714 0.406687 1 0.149896 0.022432 3.310405 to hospital	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vtics Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5.792491 12.54715	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08	sted logist	ic regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs C CATs C CATs C CATs C CATs G 2. Outcom CATs A CATs B CATs C CATs C CATs D CATs C CATS C	s for outco analyses ne: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat w OR 1.193328 0.903987 0.960287 1 0.488744 0.091622 6.421152 n to refer t	erest vith antivir Lower 959 0.330679 0.789986 1 1 1 1 0.962373 vith antibic Lower 959 0.442619 0.865294 0.222383 1 0.119975 0.004497 3.174885 o hospital	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 otics Upper 95% 3.217287 0.944411 4.146679 1 1.991011 1.866559 12.98667	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567 0.317781 0.120143 2.28E-07			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 5 5 5 5 5 5 5 5 5 5 5 5 5	Regression Unadjuste 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS C CATS C CATS C CATS A CATS A CATS A CATS B CATS C CATS C	n Results' of ad analyses ne: Decision n 704 704 694 704 704 704 704 704 704 704 704 704 70	ontains re on to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v OR 1.727335 0.893719 1.457426 1 0.537182 0.360465 6.444855 n to refer t OR	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibio Lower 95% 0.703632 0.856714 0.406687 1 0.149896 0.022432 3.310405 to hospital Lower 95%	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 tics Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5.792491 12.54715 Upper 95%	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08 p-value	sted logist	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS B CATS C CATS C	s for outco analyses te: Decision n 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat w OR 1.193328 0.903887 0.960287 1 0.488744 0.091622 6.421152 n to refer t OR	erest vith antivir Lower 95% 0.530679 0.789986 1 1 1 1 0.962373 vith antibic Lower 95% 0.442619 0.44261	als Upper 959 59.97279 1.235378 1 1 1 101.4883 vtics Upper 959 3.217287 1.991011 1.866559 12.98667 Upper 959	p-value 0.151394 0.915 0.053889 0.053889 0.726872 6.11E-06 0.9567 0.317781 0.120143 2.28E-07			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	CATS A CATS A CATS A CATS A CATS CATS CATS CATS C CATS CATS CATS C CATS CATS CATS C CATS A CATS A CATS A CATS CATS C CATS CATS C CATS CATS C CATS C CATS CATS C CATS C C CATS C C CATS C C CATS C C C C C C C C C C C C C C C C C C C	n Results' of ed analyses e: Decision n 704 689 694 694 704 704 704 704 704 704 704 704 704 70	ontains re ontains re 0 0 5.045455 0.998642 1 1 174.5 15.41667 1 0.1727335 0.893719 1.457426 0.3307482 0.360465 6.444855 0.444855	with antivir. Lower 959 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 959 0.703632 0.856714 0.406687 1 0.149896 0.022432 3.310405 to hospital Lower 959 8.201248	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitics Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5.792491 12.54715 Upper 95% 99.0398	d and adju: p-value 0.152847 0.989361 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08 p-value 1.36E-07	sted logisti	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS C CATS C	s for outco analyses te: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 9.882796 n to treat w OR 1.193328 0.903987 1 0.488744 0.901622 6.421152 n to refer t OR 26.84171	erest vith antivir 0.530679 0.789986 1 1 1 1 0.962373 vith antibio Lower 95% 0.442619 0.8426294 0.222383 1 0.119975 0.004497 3.174885 o hospital Lower 95% 5.62633	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 0104 0.94441 1.991011 1.866559 12.98667 Upper 95% 128.0546	p-value 0.151394 0.915 0.053889 0.053889 0.053889 0.053889 0.12048 0.317781 0.120143 2.28E-07 p-value 3.88E-05			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 27	Regression Unadjuste 1. Outcom CATS A CATS B CATS C CATS D CATS C CATS A CATS B CATS C CATS B CATS C CATS C	n Results' of an allyses ed analyses et Decision n 704 689 694 704 704 704 704 704 704 704 704 704 70	ontains re on to treat v OR 5.045455 0.998642 1 1 174.5 15.41667 0.893719 1.457426 1.4727335 0.893719 1.457426 1 0.537182 0.360465 6.444855 0.899658	with antivir. Lower 959 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 959 0.703632 0.856714 0.49896 0.022432 3.310405 to hospital Lower 959 8.201248 0.784467	unadjuste lipper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitics Upper 95% 4.240407 0.932322 5.22207 1 1.925092 5.792491 1.2.54715 Upper 95% 99.0398 1.031762	d and adju: p-value 0.152847 0.989361 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08 p-value 1.36E-07 0.130359	sted logist	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS D CATS C CATS C CATS C CATS C CATS C CATS C 2. Outcom CATS A CATS C CATS C	s for outco analyses te: Decision 670 670 670 670 670 670 670 670 670 670	mes of int OR 5.641482 0.987892 1 1 1 1 9.882796 0.98382796 0.98382796 0.903987 0.960287 1 0.488744 0.091622 6.421152 0.902827 0.902827 0.980974	erest vith antivir Lower 95% 0.530679 0.789986 1 1 1 0.962373 vith antibio Lower 95% 0.442619 0.865294 0.22283 1 0.119975 0.004497 3.174885 o hospital Lower 95% 5.62633 0.85534	als Upper 95% 59.97279 1.235378 1 1 1 101.4883 0tics Upper 95% 3.217287 0.944411 4.146679 1 1.991011 1.866559 12.98667 Upper 95% 128.0546 1.165683	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567 0.317781 0.120143 2.28E-07 p-value 3.68E-05 0.827242			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	Regression Unadjuste 1. Outcom CATS A CATS B CATS C CATS D CATS C CATS D CATS A CATS A CATS B CATS C CATS D CATS C CATS C CATS C CATS G 3. Outcom CATS A CATS A CATS A CATS A CATS A CATS B	n Results' of analyses ed analyses ed analyses en e: Decision n 704 689 694 704 704 704 704 704 704 704 704 704 70	ontains re on to treat v OR 5.045455 0.998642 1 1 1 174.5 15.41667 0.893719 1.457426 1 0.537182 0.360465 6.444855 n to refer t OR 28.5 0.899658 35.42857	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 95% 0.703632 0.856714 0.406687 1 0.149896 0.022432 3.310405 to hospital Lower 95% 8.201248 0.784467 9.044975	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitics Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5.792491 12.54715 Upper 95% 99.0398 1.031762 138.7714	d and adju: p-value 0.152847 0.389361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08 p-value 1.36E-07 0.130359 3.03E-07	sted logisti	ic regressi	Adjusted 1. Outcom CATs A CATs B CATs C CATs C CATs C CATs C CATs C CATS C CATS G 2. Outcom CATS A CATS B CATS C CATS C CATS G 3. Outcom CATS A CATS B CATS C	s for outco analyses ne: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 9.882796 n to treat w OR 1.193328 0.903987 0.960287 1 0.488744 0.091622 6.421152 n to refer t OR 1.0380297 1.15328 0.0916287 1.15328 0.90974 1.66676	erest vith antivir Lower 959 0.530679 0.789986 1 1 1 1 0.962373 vith antibic Lower 959 0.442619 0.865294 0.222383 1 0.119975 0.004497 3.174885 o hospital Lower 959 5.62633 0.825534 1.677151	als Upper 95% 59.97279 1.235378 1 1 1 1 101.4883 otics Upper 95% 3.217287 0.944411 4.146679 1.991011 1.991011 1.866559 12.98667 Upper 95% 128.0546 1.165683 8.1.1574	p-value 0.151394 0.915 0.053889 0.053889 0.053889 0.055889 0.726872 0.11E-06 0.9567 0.317781 0.120143 2.28E-07 0.317781 0.120143 2.28E-07 0.837242 0.013046			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29	Regression Unadjuste 1. Outcom CATS A CATS B CATS C CATS D CATS C CATS C CATS C CATS A CATS A CATS C CATS C CATS C CATS G 3. Outcom CATS A CATS A CATS B CATS C CATS A CATS B CATS C	n Results' of analyses ed analyses ed analyses es e: Decision n 704 689 684 694 704 704 704 704 704 704 704 704 704 70	contains re contains re 0 CR 5.045455 0.998642 1 1 174.5 15.41667 n to treat v OR 1.727335 0.893719 1.457426 1 0.537182 0.360465 6.444855 6.444855 n to refer t OR 28.5 0.899658 35.42857 1	sults from with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 95% 0.022432 3.310405 to hospital Lower 95% 8.201248 0.784467 9.044975 1	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vtics Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5.792491 12.54715 Upper 95% 99.0398 1.031762 138.7714 1	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08 p-value 1.36E-07 0.130359 3.03E-07	sted logisti	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS F CATS G 2. Outcom CATS A CATS B CATS C CATS C CATS G 3. Outcom CATS A CATS B CATS G 3. Outcom	s for outco analyses he: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 n to treat w OR 1.193328 0.903987 0.960287 1 0.488744 0.091622 6.421152 n to refer t OR 26.84171 0.980767 11.66676 1	erest vith antivir Lower 959 0.530679 0.789986 1 1 1 1 0.962373 vith antibic Lower 959 0.442619 0.445619 0.44261	als Upper 95% 59.97279 1.235378 1 1 1 1 101.4883 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	p-value 0.151394 0.915 0.053889 p-value 0.726872 6.11E-06 0.9567 0.317781 0.120143 2.28E-07 p-value 3.68E-05 0.827242 0.013046			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	Regression Unadjuste 1. Outcon CATs A CATs A CATs C CATs C	n Results' of analyses ed analyses ed analyses en e: Decision n 704 704 694 694 704 704 704 704 704 704 704 704 704 70	ontains re ontains re onto treat v OR 5.045455 0.998642 1 1 174.5 15.41667 15.41667 1.727335 0.893719 1.457426 1 0.537182 0.360465 6.444855 6.444855 0.899658 35.42857 1 36.75	with antivir. Lower 95% 0.548503 0.817824 1 1 9.21644 1.709925 with antibio Lower 95% 0.703632 0.856714 0.406687 1 0.149896 0.022432 3.310405 to hospital Lower 95% 8.201248 0.784467 9.044975 1 8.8025163	unadjuste als Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 Accelent Upper 95% 4.240407 0.932322 5.222907 1 1.925092 5.792491 12.54715 Upper 95% 99.0398 1.031762 138.7714 1 168.291	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08 p-value 1.36E-07 0.130359 3.03E-07 3.03E-07	sted logisti	ic regressi	Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS A CATS A CATS C CATS C CATS A CATS A CATS C CATS C CATS A CATS C CATS C	s for outco analyses te: Decision 670 670 670 670 670 670 670 670 670 670	mes of int n to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 N of the treat w OR 1.193328 0.903987 0.960287 1 0.488744 0.091622 6.421152 n to refer t OR 26.84171 0.980974 11.66676 1 48.98702	erest vith antivir Lower 95% 0.530679 0.789986 1 1 1 1 1 0.962373 vith antibic Lower 95% 0.442619 0.485294 0.222383 1 0.119975 0.004497 3.174885 o hospital Lower 95% 5.62633 0.82534 1.6775151 1 6.055009	als Upper 959 59.97279 1.235378 1 1 1 1 101.4883 wtics Upper 959 3.217287 1.991011 1.866559 12.98667 Upper 959 128.0546 1.165683 81.1574 1 396.3212	p-value 0.151394 0.915 0.053889 0.053889 0.726872 6.11E-06 0.9567 0.317781 0.120143 2.28E-07 0.317781 0.120143 2.28E-07 0.317781 0.120143			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	CATS A CATS A CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS C CATS A CATS B CATS C CATS C CATS A CATS C CATS A CATS C CATS C CATS C CATS C CATS C	n Results' of analyses and anal	ontains re ontains re OR 5.045455 0.998642 1 1 174.5 15.41667 0.893719 1.457426 0.893719 1.457426 6.444855 6.444855 0.899658 35.42857 1 36.75 69.2	with antivir. Lower 959 0.548503 0.817824 1 1 9.21644 1.709925 with antibic Lower 959 0.703632 0.856714 0.40687 1 0.149896 0.022432 3.310405 to hospital Lower 959 8.201248 0.784467 9.04175 1 8.025163 4.037856	unadjuste Upper 95% 46.41103 1.219439 1 1 3303.906 138.9965 vitcs Upper 95% 4.240407 0.332320 1 1.925092 5.22207 1 1.925092 5.792491 1.2.54715 Upper 95% 99.0398 1.031762 138.7714 168.291 1185.936	d and adju: p-value 0.152847 0.989361 0.000581 0.014763 p-value 0.232919 1.91E-07 0.562985 0.339964 0.471409 4.21E-08 p-value 1.36E-07 0.130359 3.03E-07 3.44E-06 0.003469	sted logisti		Adjusted 1. Outcom CATS A CATS B CATS C CATS C CATS C CATS C CATS C CATS G 2. Outcom CATS A CATS C CATS C CATS C CATS C CATS C CATS G 3. Outcom CATS A CATS B CATS C CATS B CATS C CATS C CAT	s for outco analyses te: Decision 670 670 670 670 670 670 670 670 670 670	mes of int or to treat w OR 5.641482 0.987892 1 1 1 1 9.882796 1 0.882796 1 0.882796 1 0.983827 1 0.903987 1 0.488744 0.901622 6.421152 1 0.488744 0.91622 6.421152 1 0.880974 11.66676 1 48.98702 5.858459	erest vith antivir 0.530679 0.789986 1 1 1 1 0.962373 vith antibic Lower 959 0.442619 0.422283 1 0.119975 0.04497 3.174885 o.hospital Lower 959 5.62633 0.82534 1.677151 1 6.055009 0.003053	als Upper 95% 59.97279 1.235378 1 1 1 1 101.4883 vtics Upper 95% 3.217287 0.944411 1.866559 12.98667 12.98667 12.98667 1.165683 81.1574 1.396.3212 11240.73	p-value 0.151394 0.915 0.915 0.053889 0.053889 0.053889 0.12043 0.317781 0.120143 2.28E-07 0.317781 0.120143 2.28E-07 0.327242 0.032742 0.032742 0.032742			

FIGURE 7 Sample screenshots of the weekly automated spreadsheet.

Monthly reports are saved as a RTF Word document containing plots and tables with frequencies of background CPRD data on comorbidities and treatments. A screenshot of a sample monthly report document in presented in *Figure 8*.



FIGURE 8 Sample screenshots of the monthly automated report document.

# Chapter 5 Discussion

## Lessons learnt

### Phase 1

The CPRD FLU-CATs team identified a number of technical and practical issues during the course of the feasibility study. These were captured via one-to-one interviews with the study team members and are listed below:

- 1. Monetary incentives would be necessary to increase GP participation unless there was a statutory requirement to systematically collect data on all possible influenza cases during a pandemic.
- 2. Funding for system maintenance and updating between study phases was not requested in the original grant. There is a cost associated with keeping the system updated and compliant with the evolving technological infrastructure, and to facilitate rapid re-activation in case of a pandemic.
- 3. External issues: bureaucratic processes, which are expected to be resolved in time, stalled provision by the HSCIC of contemporary HES/ONS linked data. Access to virology data from PHE is unlikely to be resolved because of lack of adherence to data standards by those requesting virology swabs tests in the community. Collaboration with the RCGP Research and Surveillance Centre may provide linked–anonymised virology surveillance data at a practice level and possibly at patient level.
- 4. Briefing of GPs on the study and LEPIS software installation: installing the LEPIS software was generally seen as being quite difficult and time intensive for practice staff. Many practices required regular technical advice from CPRD on this matter. Dedicated IT support is required to aid GPs at set-up.
- 5. LEPIS did not install at some of the practices, so these GPs were not able to participate in the study.
- 6. The reorganisation of primary health care from Primary Health Care Trusts to Clinical Commissioning Groups was associated with preferences for which EHRs are used across Clinical Commissioning Groups. The popularity of Vision appears to be declining in favour of EMIS. It is estimated that 50% of GPs now use EMIS. LEPIS does not work on EMIS and so an alternative solution will need to be developed. Thus, most importantly, to conduct the study in a pandemic situation we would need a flagging system that could work across several clinical IT systems.
- 7. Any decision aid based on the validated criteria would better be delivered separately on an open web-based platform or mobile phone 'app'.

### Phase 2

The two main lessons learnt regarding data analyses relate to missing data, clinical data not being measured and the delays in obtaining HES and ONS linkage data.

1. Missing clinical measurements Up to 74% of some clinical measurements (blood pressure in adults in this instance), were not recorded as part of GPs' routine assessment of an adult person presenting with ILI. We would question the utility and adoption of triage tools that depend upon a clinical measurement that is not used in the routine assessment of ILI for use in a time-pressured pandemic situation. During the early phases of the pilot study, the low recording of clinical measurements prompted the researchers to modify the form to include two further categories: 'not measured – grossly normal' and 'not measured – grossly abnormal'. This was based on informal feedback that the clinical examination did consider factors such as fever, respiratory rate, blood pressure, etc., but that formal measurements were triggered only if they appeared to be grossly abnormal. Our study was not an interventional study and therefore tried to approximate the 'routine' clinical consultation. Although failure of exact measurements resulted in poor recording of PMEWS criteria, we were able to derive the CATs criteria for the majority of patients. Therefore, it is reasonable to assume that CATs offers a more user-friendly and efficient option for GPs over a more data-intensive triage tool such as PMEWS.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

2. Linkage with HES and ONS In the absence of contemporary linked data from HES and ONS, it was not possible to prospectively validate the primary outcomes (hospital admission and death) or study secondary outcomes (e.g. admission to intensive care, length of hospital stay) or examine cause of death. However, it is important to note that the CPRD primary care data routinely records death data and hospital admissions, so while there may be a slight underestimation of these data, it would still be possible to study these outcomes using primary care data alone (although possibly with a 1-month lag without active follow-up of flagged patients).

The LEPIS software and accompanying web-based data collection form have generally been regarded as being quick and easy to use after the initial set-up, taking an experienced user about a minute to complete. However, the research team has identified a number of limitations. One is that the LEPIS software is specific to GP practices that use the Vision system and incompatible with GP practices using EMIS, SystmOne® (Horsforth, Leeds, UK) or other EHR systems. Although the popularity of Vision is reducing, there are still about 650 practices using this system and contributing to CPRD. If all of these GPs could be deployed in the event of a pandemic, there could be a population-based surveillance system providing near real-time reports of the course of the pandemic. There were technical problems with compatibility of the LEPIS software with some configurations of the GP computer systems, which need to be resolved. Moreover, although being very easy to use, LEPIS was seen as being quite difficult to set up, and technical assistance was necessary to help GPs to install the system. Both of these points are important limitations that would prevent a rapid national level rollout using the existing LEPIS software to trigger data collection. A decision aid based on the validated criteria would better be delivered separately on an open web-based platform or mobile phone 'app'.

A lack of any financial incentive was cited by several practices as a reason for not participating. Several GPs felt that even a minimal payment of a few pounds would be sufficient remuneration for the research activity. We will add a small payment for each case submitted in future seasons.

This study is one of the UK NIHR portfolio of pandemic preparedness studies. The investigators are funded to establish capacity and processes during an inter-pandemic period in readiness to run the study during the early stages of a future outbreak of pandemic influenza or other outbreak of severe acute respiratory infection of public health concern. Our results show that a web-based triage tool, which uses simple clinical assessments, can be used with ease during routine consultations, and that linkage to the patient's EHR with automated background processes can be used to define the performance of triage criteria triage tool against outcome events. Using the processes that we have developed, the demonstration of the proof of concept indicates that the study will be of value during the early phases of a novel pandemic and capable of providing a valid triage tool in readiness for surge. If surge occurs, the web-based process could be switched from data collation to provide a decision aid. This would best be provided on common web-based platforms or mobile phone 'apps'.

To scale up the study during a pandemic period will be challenging, as we recognise that about half of willing CPRD practices in the pilot had difficulties installing the LEPIS software, and half of all practices in England and Wales use a different EHR system. That said, the EMIS system also has capability to monitor consultations and trigger to structured data entry forms. The investigators are in negotiation with EMIS to develop a solution for that system.

This study adheres to the five principles of Dynamic Risk Assessment, as applied to the management of emergency situations by UK Government agencies (Evaluate, Select, Assess, Refine, Reassess).<sup>37</sup> That said, the proposed use of triage tools by the NHS in the UK during pandemic surge has been criticised, in particular because of lack of evidence of engagement with the general population and with local ethics committees.<sup>38</sup>

The data collection period of the study to date covers two calendar years, including the set-up and pilot in sequential winter seasons. At most, only 25 GPs were recruiting cases. PHE described influenza activity in the UK as low in 2013–14 and moderate in 2014–15.<sup>39</sup> Perhaps as a result of these factors, and the low-to-moderate influenza activity, only a few of the 863 patients had primary outcomes of interest (death n = 15 and referral to hospital for admission n = 17).

It is possible that GPs chose to ignore the LEPIS prompts when patients with severe illness presented, thus introducing bias to the study. However, the hospital referral rate observed for this study of 19.7 per 1000 consultations is within the ranges quoted for several larger studies that examine variation in GP referral rates in the UK.<sup>40</sup>

A potential limitation of studies such as this relates to possible misclassification of criteria as a result of clinicians' preference to record only certain important negative or positive features. We avoided misclassification of data seen in our previous studies by use of required data entry fields with exclusive options.

This was a non-interventional study. Although the clinical assessment data collection tool (eCRF) was structured to capture evidence-based criteria, recognised in national guidance, it did not require the practitioner to make any change in his/her normal assessment – only to record the assessment. We thought that the presentation of a structured assessment form may result in personal reflection on the nature of the GP's own assessment and so alter the completeness of future assessments. We were therefore surprised to find that some clinical measures are not consistently taken with many patients during consultations. Three-quarters of adults did not have their blood pressure taken, and 60% of adults and 43% of children did not have their respiratory rate measured. Our data collection system did allow GPs to record some clinical assessments, such as respiratory rate, as 'not measured as grossly normal' and 'not measured as grossly abnormal', which reflects pragmatic or usual practice. This finding is important, as it strongly suggests that criteria that rely upon a measurement such as blood pressure, and which is not being used consistently in routine assessment of ILI, should not be included in a triage tool that is designed for use during surge, when time and resources are in even shorter supply.

Denial of access to linked HES and ONS data by the HSCIC has meant that, at the time of writing, it has not been possible to validate the primary outcomes (admission to hospital and death) or secondary outcomes (admission to intensive care and length of hospital stay). A retrospective analysis of the existing data will be possible when the linked data are made available.

# Chapter 6 Conclusions

The use of EHRs linked to background analytical processes allows near real-time analysis of GP assessments, management decisions and patients' outcomes. The processes are dynamic and should allow refinement of triage criteria in the early stages of a future outbreak.

To be prepared, the study is continuing in pilot phase, as it is essential to maintain processes in an environment where EHRs and database processes are continually evolving. Future work will include exploring if minimal remuneration will improve recruitment, development of processes to include other EHR systems; and attempting to link to data on influenza surveillance at a practice and patient level.

# Acknowledgements

We wish to acknowledge the following GPs for their cooperation in the project: Dr Jitendra Patel, Kings Langley Surgery, Kings Langley; Dr Hanif Rahim, St Bartholomew's Medical Centre, Oxford; Dr Iain Jarvis, London Medical Practice, Gloucester; Dr Robert Moore, Greenford Road Medical Centre, Greenford; Dr John Edwards, Wolstanton Medical Centre, Newcastle Staffs; Dr Boghossian Tighe & Dr John Pittard, Staines Thameside Medical, Staines; Dr Peter Martin, Stifford Clays Health Centre, Grays; Dr Michael Heber, Cobtree Medical Practice, Maidstone; Dr Elizabeth Alborough, Barton Surgery, Dawlish; Dr Kevin Douglas, Claremont Medical Practice, Exmouth; Dr Gina Johnson, Kingfisher Practice, Luton; Dr Lindsey Compson, The Mauve Practice, Perth; Dr Tommy Hunter, Barns Medical Practice, Ayr; Dr Robin Fox, The Health Centre, Bicester; Dr James O'Donnell, Park House Surgery, St Helens; Dr Jonathan Unwin, Rosebank Surgery, Gloucester; Dr Andrew Freeman, Dartmouth Medical Practice, Dartmouth; Dr Marc Jacobs, Edzell Health Centre, Edzell; and Dr Monique King, Cherrymead Surgery, Loudwater. We also wish to acknowledge the contribution of 11 other GPs who contributed to the study.

## **Contribution of authors**

Malcolm G Semple, Puja R Myles and Jonathan S Nguyen Van Tam conceived the study.

Jamie J Kirkham advised on the protocol and statistical analysis plan.

Malcolm G Semple with Tjeerd Pieter van Staa, and later Malcolm G Semple with Timothy J Williams, managed the project.

Sudhir Venkatesan and Puja R Myles wrote the automated statistical analysis scripts and conducted data analysis.

Malcolm G Semple, Sudhir Venkatesan and Puja R Myles drafted the report with input from all other authors.

### **Data sharing statement**

Access to the CPRD data is available subject to a licence agreement containing details, terms and conditions of use and charges. Data Governance arrangements around access to data are approved and reviewed annually by the Confidentiality Advisory Group of the Health Research Authority. Among the key principles are that provision of data is for use for public-benefiting medical research only; attempts to identify patients, practices or clinicians is specifically prohibited and an ISAC protocol is required for all research that is, in any way, to be communicated to others. Please contact the CPRD Knowledge Centre for more information (kc@cprd.com).

# References

- Chief Medical Officer Great Britain Ministry of Health. Reports on public health and medical subjects. No 4. *Report on the Pandemic of Influenza, 1918–19*. London: His Majesty's Stationery Office; 1920.
- Department of Health. Pandemic Flu: Management of Demand and Capacity in Healthcare Organisations. London: Her Majesty's Stationery Office; 2009. Archive snapshot 23 January 2013. URL: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/ prod\_consum\_dh/groups/dh\_digitalassets/documents/digitalasset/dh\_098750.pdf (accessed 11 August 2015).
- Keramarou M, Cottrell S, Evans M, Moore C, Stiff R, Elliott C, et al. Two waves of pandemic influenza A (H1N1) 2009 in Wales: the possible impact of media coverage on consultation rates, April–December 2009. Euro Surveill 2011;16:19772.
- Department of Health. Launch of the National Pandemic Flu Service. July, 2009. Archive snapshot 8 April 2010. URL: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publichealth/Flu/ Swineflu/DH\_102909 (accessed 11 August 2015).
- Lim WS. Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. *Thorax* 2007;62:1–46. http://dx.doi.org/10.1136/thx.2006.073080
- Department of Health. NHS Emergency Planning Guidance 2005: Underpinning Materials Critical Care Contingency Planning in the Event of an Emergency where the Numbers of Patients Substantially Exceeds Normal Critical Care Capacity. 14 December 2007. COI for DH Gateway ref. 8443. Archive snapshot 23 January 2013. URL: http://webarchive.nationalarchives.gov.uk/ 20130107105354/; www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH\_081282 (accessed 11 August 2015).
- Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;**58**:377–82. http://dx.doi.org/10.1136/thorax.58.5.377
- Challen K, Bentley A, Bright J, Walter D. Clinical review: mass casualty triage pandemic influenza and critical care. Crit Care 2007;11:212. http://dx.doi.org/10.1186/cc5732
- Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64:iii1–iii55. http://dx.doi.org/10.1136/thx.2009.121434
- Mulrennan S, Tempone SS, Ling ITW, Williams SH, Gan G-C, Murray RJ, et al. Pandemic influenza (H1N1) 2009 pneumonia: CURB-65 score for predicting severity and nasopharyngeal sampling for diagnosis are unreliable. *PLOS ONE* 2010;**5**:e12849. http://dx.doi.org/10.1371/ journal.pone.0012849
- Challen K, Bright J, Bentley A, Walter D. Physiological-social score (PMEWS) vs. CURB-65 to triage pandemic influenza: a comparative validation study using community-acquired pneumonia as a proxy. BMC Health Serv Res 2007;7:33. http://dx.doi.org/10.1186/1472-6963-7-33
- Department of Health and NHS. Swine Flu Clinical Package for Use when there are Exceptional Demands on Healthcare Services. COI for DH Gateway ref. 12368, 2009. Archive snapshot 23 January 2013. URL: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh. gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\_106495 (accessed 11 August 2015).

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

- 13. British Thoracic Society. BTS guidelines for the management of community acquired pneumonia in childhood. *Thorax* 2002;**57**:i1–24. http://dx.doi.org/10.1136/thx.57.suppl\_1.i1
- 14. British Thoracic Society. *BTS Guidelines for the Management of Community Acquired Pneumonia* (*CAP*) in Adults. London: BTS; 2004.
- 15. National Collaborating Centre for Chronic Conditions. *Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care.* NICE Clinical Guideline 12. London: Royal College of Physicians of London; 2004.
- 16. O'Driscoll BR, Howard LS, Davison AG. BTS guideline for emergency oxygen use in adult patients. *Thorax* 2008;**63**:vi1–68. http://dx.doi.org/10.1136/thx.2008.102947
- 17. World Health Organization. *Technical Bases for the Management of Pneumonia in Children at Firstlevel Health Facilities*. WHO/ARI/9120. Geneva: WHO; 1991. URL: www.who.int/maternal\_child\_ adolescent/documents/ari\_91\_20/en/ (accessed 11 August 2015).
- 18. World Health Organization. *Management of the Child with Cough or Difficult Breathing. WHO/ARI/* 9431. Geneva: WHO; 1994.
- 19. World Health Organization. *Child and Adolescent Health and Development: IMCI Technical Seminars. WHO/FCH/CAH/0110.* Geneva: WHO; 2001.
- World Health Organization. Evidence Base for the Community Management of Pneumonia. WHO/ FCH/CAH/0223. Geneva: WHO; 2002. URL: www.who.int/maternal\_child\_adolescent/documents/ fch\_cah\_02\_23/en/ (accessed 11 August 2015).
- Scottish Intercollegiate Guidelines Network. Bronchiolitis in Children. SIGN Guideline 91. Edinburgh: SIGN. 2006. URL: www.sign.ac.uk/guidelines/fulltext/91/ (accessed 11 August 2015).
- National Collaborating Centre for Women's and Children's Health. *Feverish Illness in Children:* Assessment and Initial Management in Children Younger than 5 Years. NICE Clinical Guideline 47. Welsh A, editor. London: RCOG Press; 2007. URL: www.nice.org.uk/guidance/cg47 (accessed 11 August 2015).
- 23. Goodacre S, Challen K, Wilson R, Campbell M. Evaluation of triage methods used to select patients with suspected pandemic influenza for hospital admission: cohort study. *Health Technol Assess* 2010;**14**(46). http://dx.doi.org/10.3310/hta14460-03
- Challen K, Goodacre SW, Wilson R, Bentley A, Campbell M, Fitzsimmons C, et al. Evaluation of triage methods used to select patients with suspected pandemic influenza for hospital admission. Emerg Med J 2012;29:383–8. http://dx.doi.org/10.1136/emj.2010.104380
- Gray JT, Challen K, Oughton L. Does the pandemic medical early warning score system correlate with disposition decisions made at patient contact by emergency care practitioners? *Emerg Med J* 2010;**27**:943–7. http://dx.doi.org/10.1136/emj.2009.072959
- Myles PR, Semple MG, Lim WS, Openshaw PJM, Gadd EM, Read RC, et al. Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009–2010 in the UK. *Thorax* 2012;67:709–17. http://dx.doi.org/10.1136/thoraxjnl-2011-200266
- Myles PR, Nguyen-Van-Tam JS, Lim WS, Nicholson KG, Brett SJ, Enstone JE, *et al.* Comparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective data. *PLOS ONE* 2012;**7**:e34428. http://dx.doi.org/10.1371/ journal.pone.0034428
- 28. Viboud C, Miller M, Olson DR, Osterholm M, Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. *PLOS Curr* 2010;**2**:RRN1153. http://dx.doi.org/10.1371/currents.rrn1153

- 29. National Institute for Health Research. *NIHR Clinical Research Network Urgent Public Health Risk Planning*. London: NIHR; 2014. URL: www.crn.nihr.ac.uk/wp-content/uploads/publichealth/ Urgent%20Public%20Health%20Research%20Process%20Summary.pdf (accessed 20 July 2015).
- Hine D. The 2009 Influenza Pandemic: An Independent Review of the UK Response to the 2009 Influenza Pandemic. London: Cabinet Office, Her Majesty's Government; 2010. URL: www.dhsspsni.gov.uk/the2009influenzapandemic\_acc.pdf (accessed 11 August 2015).
- Kousoulis AA, Rafi I, de Lusignan S. The CPRD and the RCGP: building on research success by enhancing benefits for patients and practices. *Br J Gen Pract* 2015;65:54–5. http://dx.doi.org/ 10.3399/bjgp15X683353
- 32. Van Staa T-P, Dyson L, McCann G, Padmanabhan S, Belatri R, Goldacre B, et al. The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. *Health Technol Assess* 2014;**18**(43). http://dx.doi.org/ 10.3310/hta18430
- Prasad V, Atkinson O, Knox R. Consultation with General Practitioners on Coding Preferences in Electronic Primary Care Patient Records. Myles PR, Nakafero G, editors. Nottingham: University of Nottingham; 2011.
- 34. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in Psychology* 2006;**3**:77–101. http://dx.doi.org/10.1191/1478088706qp063oa
- 35. Obuchowski NA, Lieber ML, Wians FH. ROC curves in clinical chemistry: uses, misuses, and possible solutions. *Clin Chem* 2004;**50**:1118–25. http://dx.doi.org/10.1373/clinchem.2004.031823
- 36. Obuchowski NA. Sample size tables for receiver operating characteristic studies. *Am J Roentgenol* 2000;**175**:603–8. http://dx.doi.org/10.2214/ajr.175.3.1750603
- 37. Department for Communities and Local Government. *Generic Risk Assessments*. London: The Stationery Office; 2009.
- Tillyard ARJ, Slowthe A. Pandemic triage: does the public know what this means? *BMJ* 2009;**339**:b3403. URL: www.bmj.com/rapid-response/2011/11/02/pandemic-triage-does-public-know-what-means (accessed 11 August 2015).
- Public Health England. Surveillance of Influenza and Other Respiratory Viruses in the United Kingdom: Winter 2013/14. London: PHE Publications; 2014. URL: www.gov.uk/government/ uploads/system/uploads/attachment\_data/file/325203/Flu\_annual\_report\_June\_2014.pdf (accessed 11 August 2015).
- 40. O'Donnell CA. Variation in GP referral rates: what can we learn from the literature? *Fam Pract* 2000;**17**:462–71. http://dx.doi.org/ 10.1093/fampra/17.6.462
# **Appendix 1** List of Read codes used to identify potential influenza cases in Hospital Episode Statistics data

H2z..00 Pneumonia or influenza NOS H2..00 Pneumonia and Influenza 16L..00 Influenza-like symptoms H2y..00 Other specified pneumonia or influenza H2A..11 Influenza A(H1N1) swine flu H2A..00 Influenza due to Influenza A virus subtype H1N1 4JU0.00 Influenza H1 virus detected H051. Acute upper respiratory tract infection H05z. Upper respiratory tract infection (URTI) 1W0..00 Possible Influenza A virus H1N1 subtype 1J72.11 Suspected swine influenza 1J72.00 Suspected Influenza A virus subtype H1N1 infection Hyu0700 [X] Influenza + other manifestations, virus not identified Hyu0600 [X] Influenza + other respiratory manifestations, virus not identified 43k2.00 Influenza A antigen level 43dF.00 Influenza A antibody level G520300 Acute myocarditis - influenza 4JU4.00 Influenza A virus, other or untyped strain detected H29..00 Avian influenza Hyu0500 [X] Influenza + other manifestations, influenza virus identified H27.. Influenza H27z.12.Influenza like illness (ILL) H27y100 Influenza with gastrointestinal tract involvement H271z00 Influenza with Respiratory manifestations H270000 Influenza with bronchopneumonia H271000 Influenza with laryngitis H271100 Influenza with pharyngitits H270.00 Influenza with pneumonia H270z00 Influenza with pneumonia NOS H270.11 Chest infection - influenza with pneumonia H271.00 Influenza with other respiratory manifestation H27y.00 Influenza with other manifestations H27yz00 Influenza with other manifestations NOS

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

- H27y000 Influenza with encephalopathy
- 4JU5.00 Influenza B virus detected
- 43k3.00 Influenza B antigen level
- H270100 Influenza with pneumonia, influenza virus identified
- 4JU2.00 Influenza H3 virus detected
- 4JU3.00 Influenza H5 virus detected
- 4J3M.00 Influenza A virus H1N1 subtype not detected

**Appendix 2** Influenza-related Read codes used by general practitioners for patient assessment prior to an admission to hospital with a discharge diagnosis of influenza and chosen to trigger Local Eligibility Patient Identification Software

Rank	Read code	Read code descriptor	Patients, <i>n</i> = 471	Frequency (%)
1	H27z.11	Flu-like illness	72	15.5
2	H2700	Influenza	70	15.0
3	H06z011	Chest infection	60	12.9
4	H2A11	Influenza A (H1N1) swine flu	52	11.2
5	H06z000	Chest infection NOS	41	8.8
6	H2600	Pneumonia due to unspecified organism	27	5.8
7	H061.00	Acute bronchiolitis	19	4.1
8	H06z100	Lower resp tract infection	14	3.0
9	H2y00	Other specified pneumonia or influenza	12	2.6
10	H2z00	Pneumonia or influenza NOS	11	2.4
11	16L00	Influenza-like symptoms	9	1.9
12	H06z111	Respiratory tract infection	8	1.7
13	1J72.11	Suspected swine influenza	7	1.5
14	H200	Pneumonia and influenza	7	1.5
15	H2A00	Influenza due to Influenza A virus subtype H1N1	7	1.5
16	H062.00	Acute lower respiratory tract infection	6	1.3
17	H2100	Lobar (pneumococcal) pneumonia	6	1.3
18	H27z.00	Influenza NOS	5	1.1
19	H2500	Bronchopneumonia due to unspecified organism	4	0.9
20	1W000	Possible influenza A virus H1N1 subtype	3	0.6
21	H000	Acute respiratory infections	3	0.6
22	H060.00	Acute bronchitis	3	0.6
23	H2000	Viral pneumonia	3	0.6
24	H260.00	Lobar pneumonia due to unspecified organism	2	0.4
25	H260000	Lung consolidation	2	0.4
26	H261.00	Basal pneumonia due to unspecified organism	2	0.4
27	H27z.12	Influenza like illness	2	0.4
28	H2800	Atypical pneumonia	2	0.4
29	H5yy.11	Respiratory infection NOS	2	0.4
30	1J72.00	Suspected influenza A virus subtype H1N1 infection	1	0.2

Rank	Read code	Read code descriptor	Patients, <i>n</i> = 471	Frequency (%)
31	H20z.00	Viral pneumonia NOS	1	0.2
32	H2200	Other bacterial pneumonia	1	0.2
33	H22z.00	Bacterial pneumonia NOS	1	0.2
34	H2300	Pneumonia due to other specified organisms	1	0.2
35	H270000	Influenza with bronchopneumonia	1	0.2
36	H270100	Influenza with pneumonia, influenza virus identified	1	0.2
37	H27y.00	Influenza with other manifestations	1	0.2
38	H3000	Bronchitis unspecified	1	0.2
39	H301.00	Laryngotracheobronchitis	1	0.2

# **Appendix 3** Stata algorithms for data management and analysis 'do files'

Copy the following into a Stata do file.

### 1. Data management for adult data

\*\*\*\*NOTE: Replace all file names/pathways with appropriate ones as per your own directories/files\*\*\*\* \*insheet using "R:\HPIRG\Flu-CATs\Weekly data\adults\_20140804.txt", clear

\*\*\*Converting dates from YMD to MDY
tostring submit\_date, gen( submit\_date2)
gen submit\_date3= date( submit\_date2, "YMD")
format submit\_date3 %td
drop submit\_date2 submit\_date
rename submit\_date3 submit\_date

gen frddate2=date(frddate, "DMY") drop frddate rename frddate2 frddate format frddate %td

gen regdate2=date(regdate, "DMY") drop regdate rename regdate2 regdate format regdate %td

gen utsdate2=date(utsdate, "DMY") drop utsdate rename utsdate2 utsdate format utsdate %td

gen lcdate2=date(lcdate, "DMY") drop lcdate rename lcdate2 lcdate format lcdate %td

gen todate2=date(todate, "DMY") drop todate rename todate2 todate format todate %td

gen deathdate2=date(deathdate, "DMY") drop deathdate rename deathdate2 deathdate format deathdate %td

\*\*Keeping only unique consultations (dropping duplicates)
bys patid submit\_date: gen new=\_n
keep if new==1
drop new
count

\*\*data management loops\*\*
\*\*measured/not measured variables\*\*
label define measurements 0 "Not measured" 1 "Measured"
local varlist " temperature respiratoryrate peripheraloxygensaturation heartrate bloodpressure"
foreach varname of local varlist {
 encode `varname', gen(`varname'2)
 drop `varname'
 rename `varname'2 `varname'
 recode `varname' 2=0
 label values `varname' measurements

}

\*\*measurement values\*\* local varlist "temperaturevalue respiratoryratevalue peripheraloxygensaturationvalue heartratevalue bloodpressuresystolic bloodpressurediastolic"

foreach varname of local varlist { replace `varname'=" " if `varname'== "-" destring `varname', replace

}

\*\*binary categorical (yes/no)\*\* label define binary\_categorical 0 "No" 1 "Yes" local varlist "patientonoxygen severerespiratorydistress respiratoryexhaustion severedehydration causingotherclinicalconcern treatwithantivirals treatwithantibiotics refertohospital"

foreach varname of local varlist { encode `varname', gen(`varname'2) drop `varname' rename `varname'2 `varname' recode `varname' 1=0 recode `varname' 2=1 label values `varname' binary\_categorical }

\*\*capillary refill time: code normal as "0" and refill time>2 secs as "1"\*\* encode capillaryrefilltime, gen( capillaryrefilltime2) drop capillaryrefilltime rename capillaryrefilltime2 capillaryrefilltime recode capillaryrefilltime 1=0 recode capillaryrefilltime 2=1 label define capillaryrefilltime 0 "Grossly normal" 1 "sternal capillary refill>2 secs" label values capillaryrefilltime capillaryrefilltime

\*\*patientoxygenvalue: this will show as blank if the previous field 'patientoxygen' was answered as "no"\*\* encode patientonoxygenvalue, gen(patientonoxygenvalue2) drop patientonoxygenvalue rename patientonoxygenvalue2 patientonoxygenvalue \*\*check these recode values carefully in new files as current file does not have any 'yes'\*\* recode patientonoxygenvalue 1=9 recode patientonoxygenvalue 2=0 recode patientonoxygenvalue 3=1 label define patientoxygenvalue 9 "Not applicable" 0 "No" 1 "Yes", replace label values patientonoxygenvalue patientoxygenvalue

\*\*newalteredconsciouslevel \*\* encode newalteredconsciouslevel , gen(newalteredconsciouslevel2) drop newalteredconsciouslevel rename newalteredconsciouslevel2 newalteredconsciouslevel \*\*Check coding before doing below recode newalteredconsciouslevel 2=0 label define newalteredconsciousness 0 "No, patient alert" 1 "Confused/agitated" 2 "Responsive to voice only" 3 "Responsive to pain only/unconscious", replace label values newalteredconsciouslevel newalteredconsciousness

\*\*socialisolation\*\* encode socialisolation, gen(socialisolation2) drop socialisolation rename socialisolation2 socialisolation \*\*check codes in new files\*\* recode socialisolation 1=0 recode socialisolation 3=1 \*\*keep 'unknown' as "2"\*\* label define socialisolation 0 "No" 1 "Yes" 2 "Unknown" label values socialisolation socialisolation \*\*performance status\*\*
encode performancestatus, gen(performancestatus2)
drop performancestatus
rename performancestatus2 performancestatus
\*\*check codes in new file\*\*

\*\*derivation of values based CATs criteria\*\*
gen CAT\_triage\_A= severerespiratorydistress
label variable CAT\_triage\_A `"CAT triage criteria A- severe respiratory distress (yes/no)"'
label values CAT\_triage\_A binary\_categorical

gen CAT\_triage\_B= .
replace CAT\_triage\_B= 1 if respiratoryratevalue>30 & respiratoryratevalue !=.
replace CAT\_triage\_B=0 if respiratoryratevalue<=30
label variable CAT\_triage\_B `"CAT triage criteria B (resp rate>30 breaths/min)- yes/no"'
label values CAT\_triage\_B binary\_categorical

gen CAT\_triage\_C=.

replace CAT\_triage\_C=1 if peripheraloxygensaturationvalue<=92 & peripheraloxygensaturationvalue !=. replace CAT\_triage\_C=0 if peripheraloxygensaturationvalue>92 label variable CAT\_triage\_C `"CAT triage criteria C (peripheral oxygen <=92%)- yes/no"' label values CAT\_triage\_C binary\_categorical

gen CAT\_triage\_D=respiratoryexhaustion label variable CAT\_triage\_D `"CAT triage criteria D- respiratory exhaustion (yes/no)"' label values CAT\_triage\_D binary\_categorical

gen CAT\_triage\_E=.
replace CAT\_triage\_E=1 if capillaryrefilltime==1
replace CAT\_triage\_E=1 if bloodpressuresystolic<90
replace CAT\_triage\_E=1 if bloodpressurediastolic<60
replace CAT\_triage\_E=1 if severedehydration==1
recode CAT\_triage\_E .=0
label variable CAT\_triage\_E `"CAT triage criteria E (severe clinical dehydration)- yes/no""
label values CAT\_triage\_E binary\_categorical</pre>

gen CAT\_triage\_F=. replace CAT\_triage\_F=0 if newalteredconsciouslevel==0 recode CAT\_triage\_F .=1 label variable CAT\_triage\_F `"CAT triage criteria E (new altered conscious level)- yes/no"' label values CAT\_triage\_F binary\_categorical

gen CAT\_triage\_G= causingotherclinicalconcern label variable CAT\_triage\_G `"CAT triage criteria G, causing other clinical concern (yes/no)"' label values CAT\_triage\_G binary\_categorical

\*create variable labels\*\* label variable patid `"unique patient identifier"' label variable pracid `"practice id"" label variable submit\_date `"presentation date"" label variable temperature `"temperature measurement (measured/not measured)"' label variable temperaturevalue `"temperature value in celsius; range allowed (35.0-42.0)" label variable severe respiratory distress `"CAT triage criteria A- severe respiratory distress (yes/no)" label variable respiratoryexhaustion "CAT triage criteria D- respiratory exhaustion (yes/no)" label variable respiratoryrate `"respiratory rate (measured/not measured)' label variable respiratoryratevalue `"respiratory rate- breaths per minute; range allowed (15-120)"' label variable patientonoxygen `"patient on oxygen (yes/no)"" label variable patientonoxygenvalue `"new oxygen need (yes/no)" label variable peripheraloxygensaturation `"peripheral oxygen value (measured/not measured)"' label variable peripheraloxygensaturationvalue `"peripheral oxygen saturation (%); range allowed (70-100)" label variable heartrate `"heart rate (measured/not measured)" label variable heartratevalue `"heart rate value (beats per minute); range allowed (40-200)"' label variable bloodpressure `"blood pressure (measured/not measured)" label variable bloodpressuresystolic `"systolic blood pressure (mmHg); range allowed (70-250)"' label variable bloodpressurediastolic `"diastolic blood pressure (mmHg); range allowed (40-150)" label variable capillaryrefilltime `"sternal capillary refill time: 1 if >2 seconds; 0= grossly normal" label variable severedehydration `"severe dehydration (yes/no)" label variable newalteredconsciouslevel `"new altered consciousness level (alert; confused/agitated; voice; pain/unconscious)" label variable socialisolation `"lives alone or no fixed abode (yes/no/unknown)"" label variable treatwithantivirals "decision to treat with antivirals (yes/no)"

label variable treatwithantibiotics "decision to treat with antibiotics (yes/no)" label variable performancestatus "activity and ability to self care (categorical variable)" label variable causingotherclinicalconcern "CAT triage criteria G, causing other clinical concern (yes/no)" label variable causingotherclinicalconcernvalue "nature of clinical concern, free text" label variable refertohospital "decision to refer to hospital (yes/no)"

order patid pracid formid gender birthyear submit\_date temperature temperaturevalue severerespiratorydistress respiratoryexhaustion respiratoryrate respiratoryratevalue patientonoxygen patientonoxygenvalue peripheraloxygensaturation peripheraloxygensaturationvalue heartrate heartratevalue bloodpressure bloodpressuresystolic bloodpressurediastolic capillaryrefilltime severedehydration newalteredconsciouslevel socialisolation performancestatus causingotherclinicalconcern causingotherclinicalconcernvalue treatwithantibiotics refertohospital CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_G

\*\*\*\*\*\*\*\*

```
**descriptive analysis**
```

local varlist " temperature respiratoryrate peripheraloxygensaturation heartrate bloodpressure" foreach varname of local varlist { tab `varname'

}

local varlist "temperaturevalue respiratoryratevalue peripheraloxygensaturationvalue heartratevalue bloodpressuresystolic bloodpressurediastolic"

foreach varname of local varlist { summ `varname', detail

}

local varlist "patientonoxygen severeespiratorydistress severedehydration causingotherclinicalconcern treatwithantivirals treatwithantibiotics refertohospital"

foreach varname of local varlist { tab `varname' }

tab CAT\_triage\_A, m tab CAT\_triage\_B, m tab CAT\_triage\_C, m tab CAT\_triage\_D, m tab CAT\_triage\_E, m tab CAT\_triage\_F, m tab CAT\_triage\_G, m tab capillaryrefilltime, m tab patientonoxygenvalue tab newalteredconsciouslevel tab socialisolation tab performancestatus

\*\*association between CATs criteria and treatment/referral decisions\*\*

local varlist " CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G"

foreach varname of local varlist { tab`varname' treatwithantivirals, col chi logit treatwithantivirals `varname', or

}

logit treatwithantivirals CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or

local varlist " CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G"
foreach varname of local varlist {
 tab `varname' treatwithantibiotics, col chi

logit treatwithantibiotics `varname', or }
logit treatwithantibiotics CAT_triage_A CAT_triage_B CAT_triage_C CAT_triage_D CAT_triage_E CAT_triage_F CAT_triage_G, or
<pre>local varlist " CAT_triage_A CAT_triage_B CAT_triage_C CAT_triage_D CAT_triage_E CAT_triage_F CAT_triage_G" foreach varname of local varlist {     tab `varname' refertohospital, col chi     logit refertohospital `varname', or }</pre>

logit refertohospital CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or

## 2. Data management for children's data

\*\*\*\*NOTE: Replace all file names/pathways with appropriate ones as per your own directories/files\*\*\*\*
\*insheet using "R:\HPIRG\Flu-CATs\Weekly data\child\_20140804.txt", clear

tostring submit\_date, gen( submit\_date2)
gen submit\_date3= date( submit\_date2, "YMD")
format submit\_date3 %td
drop submit\_date2 submit\_date
rename submit\_date3 submit\_date

gen frddate2=date(frddate, "DMY") drop frddate rename frddate2 frddate format frddate %td

gen regdate2=date(regdate, "DMY") drop regdate rename regdate2 regdate format regdate %td

gen utsdate2=date(utsdate, "DMY") drop utsdate rename utsdate2 utsdate format utsdate %td

gen lcdate2=date(lcdate, "DMY") drop lcdate rename lcdate2 lcdate format lcdate %td

gen todate2=date(todate, "DMY") drop todate rename todate2 todate format todate %td

gen deathdate2=date(deathdate, "DMY") drop deathdate rename deathdate2 deathdate format deathdate %td

set more off

\*\*Keeping only unique consultations (dropping duplicates)
bys patid submit\_date: gen new=\_n
keep if new==1
drop new
count

label values gender gender

\*\*data management loops\*\*

\*\*measured/not measured variables\*\* label define measurements 0 "Not measured" 1 "Measured" local varlist " temperature respiratoryrate peripheraloxygensaturation heartrate" foreach varname of local varlist { encode `varname', gen(`varname'2) drop `varname' rename `varname'2 `varname' recode `varname' 2=0 label values `varname' measurements

}

```
**measurement values**
local varlist "temperaturevalue respiratoryratevalue peripheraloxygensaturationvalue heartratevalue"
```

```
foreach varname of local varlist {
replace `varname'=" " if `varname'== "-"
destring `varname', replace
```

}

```
**binary categorical (yes/no)**
label define binary_categorical 0 "No" 1 "Yes"
local varlist "patientonoxygen severerespiratorydistress respiratoryexhaustion severedehydration causingotherclinicalconcern
treatwithantivirals treatwithantibiotics refertohospital"
```

```
foreach varname of local varlist {
encode `varname', gen( `varname'2)
drop `varname'
rename `varname'2 `varname'
recode `varname' 1=0
recode `varname' 2=1
label values `varname' binary_categorical
}
```

\*\*capillary refill time: code normal as "0" and refill time>2 secs as "1"\*\* encode capillaryrefilltime, gen( capillaryrefilltime2) drop capillaryrefilltime rename capillaryrefilltime2 capillaryrefilltime recode capillaryrefilltime 1=0 recode capillaryrefilltime 2=1 label define capillaryrefilltime 0 "Grossly normal" 1 "sternal capillary refill>2 secs" label values capillaryrefilltime capillaryrefilltime

\*\*patientoxygenvalue: this will show as blank if the previous field 'patientoxygen' was answered as "no"\*\* encode patientonoxygenvalue, gen(patientonoxygenvalue2) drop patientonoxygenvalue rename patientonoxygenvalue2 patientonoxygenvalue \*\*check these recode values carefully in new files as current file does not have any 'yes'\*\* recode patientonoxygenvalue 1=9 recode patientonoxygenvalue 2=0 recode patientonoxygenvalue 3=1 label define patientoxygenvalue 9 "Not applicable" 0 "No" 1 "Yes", replace label values patientonoxygenvalue patientoxygenvalue

\*\*newalteredconsciouslevel \*\*
encode newalteredconsciouslevel , gen(newalteredconsciouslevel2)
drop newalteredconsciouslevel
rename newalteredconsciouslevel2 newalteredconsciouslevel
\*\*check these recode values carefully in new files as current file does not have any values other than 'no'\*\*
recode newalteredconsciouslevel 1=0
label define newalteredconsciousness 0 "No" 1 "Strikingly agitated, irritable, new seizures or floppy infant"
label values newalteredconsciouslevel newalteredconsciousness

\*\*derivation of values based CATs criteria\*\* gen CAT\_triage\_A= severerespiratorydistress label variable CAT\_triage\_A `"CAT triage criteria A- severe respiratory distress (yes/no)"' label values CAT\_triage\_A binary\_categorical gen CAT\_triage\_B= .
replace CAT\_triage\_B= 1 if respiratoryratevalue>=40 & respiratoryratevalue !=.
replace CAT\_triage\_B=0 if respiratoryratevalue<40
label variable CAT\_triage\_B `"CAT triage criteria B (increased resp rate)- yes/no""
label values CAT\_triage\_B binary\_categorical</pre>

\*\*note: need child's age to work out criteria B; the codes above only represent children aged 1 year and above; for children younger than a year, use threshold of >=50 to indicate presence of criteria\*\* \*\*replace CAT\_triage\_B=0 if respiratoryratevalue<=50 & age<1\*\*</pre>

gen CAT\_triage\_C=. replace CAT\_triage\_C=1 if peripheraloxygensaturationvalue<=92 & peripheraloxygensaturationvalue !=. replace CAT\_triage\_C=0 if peripheraloxygensaturationvalue>92 label variable CAT\_triage\_C `"CAT triage criteria C (peripheral oxygen <=92%)- yes/no"' label values CAT\_triage\_C binary\_categorical

gen CAT\_triage\_D=respiratoryexhaustion label variable CAT\_triage\_D `"CAT triage criteria D- respiratory exhaustion (yes/no)"' label values CAT\_triage\_D binary\_categorical

gen CAT\_triage\_E=. replace CAT\_triage\_E=1 if capillaryrefilltime==1 replace CAT\_triage\_E=1 if severedehydration==1 recode CAT\_triage\_E .=0 label variable CAT\_triage\_E `"CAT triage criteria E (severe clinical dehydration)- yes/no" label values CAT\_triage\_E binary\_categorical

gen CAT\_triage\_F=. replace CAT\_triage\_F=1 if newalteredconsciouslevel==1 recode CAT\_triage\_F .=0 label variable CAT\_triage\_F `"CAT triage criteria E (new altered conscious level)- yes/no" label values CAT\_triage\_F binary\_categorical

gen CAT\_triage\_G= causing other clinical concern label variable CAT\_triage\_G `"CAT triage criteria G, causing other clinical concern (yes/no)"' label values CAT\_triage\_G binary\_categorical

\*create variable labels\*\* label variable patid `"unique patient identifier" label variable pracid `"practice id"" label variable submit date `"presentation date"" label variable temperature `"temperature measurement (measured/not measured)"' label variable temperaturevalue `"temperature value in celsius; range allowed (35.0-42.0)"' label variable severerespiratorydistress "CAT triage criteria A- severe respiratory distress (yes/no)" label variable respiratoryexhaustion "CAT triage criteria D- respiratory exhaustion (yes/no)" label variable respiratoryrate `"respiratory rate (measured/not measured)" label variable respiratoryratevalue `"respiratory rate- breaths per minute; range allowed (10-100)"' label variable patientonoxygen `"patient on oxygen (yes/no)" label variable patientonoxygenvalue `"new oxygen need (yes/no)"' label variable peripheraloxygensaturation `"peripheral oxygen value (measured/not measured)" label variable peripheraloxygensaturationvalue `"peripheral oxygen saturation (%); range allowed (70-100)" label variable heartrate `"heart rate (measured/not measured)" label variable heartratevalue `"heart rate value (beats per minute); range allowed (50-200)"' label variable capillaryrefilltime `"sternal capillary refill time: 1 if >2 seconds; 0= grossly normal"' label variable severedehydration `"severe dehydration (yes/no)"' label variable newalteredconsciouslevel "new altered consciousness level (yes/no)" label variable treatwithantivirals `"decision to treat with antivirals (yes/no)" label variable treatwithantibiotics `"decision to treat with antibiotics (yes/no)"' label variable causing other clinical concern `"CAT triage criteria G, causing other clinical concern (yes/no)" label variable causingotherclinicalconcernvalue `"nature of clinical concern, free text" label variable refertohospital `"decision to refer to hospital (yes/no)"

order patid pracid formid gender birthyear submit\_date temperature temperaturevalue severerespiratorydistress respiratoryexhaustion respiratoryrate respiratoryratevalue patientonoxygen patientonoxygenvalue peripheraloxygensaturation peripheraloxygensaturationvalue heartrate heartratevalue capillaryrefilltime severedehydration newalteredconsciouslevel causingotherclinicalconcern causingotherclinicalconcernvalue treatwithantivirals treatwithantibiotics refertohospital CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_E CAT\_triage\_G

\*\*descriptive analysis\*\*

```
local varlist " temperature respiratoryrate peripheraloxygensaturation heartrate"
foreach varname of local varlist {
                     tab `varname
}
local varlist "temperaturevalue respiratoryratevalue peripheraloxygensaturationvalue heartratevalue "
foreach varname of local varlist {
          summ `varname', detail
}
local varlist "patientonoxygen severerespiratorydistress severedehydration causingotherclinical concern treatwithantivirals
treatwithantibiotics refertohospital"
foreach varname of local varlist {
tab `varname'
}
tab CAT_triage_A, m
tab CAT_triage_B, m
tab CAT_triage_C, m
tab CAT_triage_D, m
tab CAT_triage_E, m
tab CAT_triage_F, m
tab CAT triage G, m
tab capillaryrefilltime, m
tab patientonoxygenvalue
tab newalteredconsciouslevel
**association between CATs criteria and treatment/referral decisions**
local varlist " CAT_triage_A CAT_triage_B CAT_triage_C CAT_triage_D CAT_triage_E CAT_triage_F CAT_triage_G"
foreach varname of local varlist {
          tab `varname' treatwithantivirals, col chi
          logit treatwithantivirals `varname', or
}
logit treatwithantivirals CAT_triage_A CAT_triage_B CAT_triage_C CAT_triage_D CAT_triage_E CAT_triage_F CAT_triage_G, or
local varlist " CAT_triage_A CAT_triage_B CAT_triage_C CAT_triage_D CAT_triage_E CAT_triage_F CAT_triage_G"
foreach varname of local varlist {
          tab `varname' treatwithantibiotics, col chi
          logit treatwithantibiotics `varname', or
}
logit treatwithantibiotics CAT_triage_A CAT_triage_B CAT_triage_C CAT_triage_D CAT_triage_E CAT_triage_F CAT_triage_G, or
local varlist " CAT_triage_A CAT_triage_B CAT_triage_C CAT_triage_D CAT_triage_E CAT_triage_F CAT_triage_G"
foreach varname of local varlist {
          tab `varname' refertohospital, col chi
          logit refertohospital `varname', or
```

```
}
```

logit refertohospital CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or

# 3. Weekly reports for adult data

```
clear
*** NOTE: Ensure that the directory mentioned below is the directory containing the CLEANED weekly adult/children data files.
//The results spreadsheet will be saved within this directory.
global path = "R:\HPIRG\Flu-CATs\Last Tranche\Weekly\"
cd "Spath"
use adults 20150413 clean.dta //
//NOTE: The name of the source file may need to be modified. The source file will need to be a cleaned version of the weekly data file.
//This do-file will have to be run separately for adult and for children data.
*******
** EXPORTING FREQUENCIES OF EACH CATs CRITERION INTO EXCEL
**labelling missing values in CAT_triage_B as 9 so that they may be displayed in the spreadsheet
recode CAT_triage_B .=9
label define vesnomissing 0 "No" 1 "Yes" 9 "Missing"
label value CAT_triage_B yesnomissing
putexcel A1=("NIHR Flu-CATs Weekly Report: dd/mm/YYYY") using results, sheet("CATs criteria") replace //Insert the correct date in place
of "dd/mm/YYYY"
putexcel G1=("Data Source: Clinical Practice Research Datalink- Participating GP Practices") using results, sheet("CATs criteria") modify
putexcel A3=("This spreadsheet contains three worksheets- 'CATs criteria' (frequencies of each of the 7 CATs criteria), 'Clinical data' (other
clinical data collected through the LEPIS form)") using results, sheet("CATs criteria") modify
putexcel A4=("and 'Analyses' (results of logistic regression analyses).") using results, sheet("CATs criteria") modify
tabulate CAT_triage_A, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 7
local cum_percent = 0
***CATs criterion A
tabulate CAT_triage_A, m matcell(freq) matrow(names)
putexcel A6=("CATs A") B6=("Freq.") C6=("Percent") D6=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_A) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
        D'row'=('cum_percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify
***CATs criterion B
tabulate CAT_triage_B, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 12
local cum_percent = 0
```

```
tabulate CAT_triage_B, matcell(freq) matrow(names)
putexcel A11=("CATs B") B11=("Freq.") C11=("Percent") D11=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local val_encent : display %9.2f `cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab") B`row'=(`freq_val') C`row'=(`percent_val') ///
        D`row'=(`cum_percent') using results, sheet("CATs criteria") modify
}
```

putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("CATs criteria") modify

\*\*\*CATs criterion C
tabulate CAT\_triage\_C, matcell(freq) matrow(names)
local rows = rowsof(names)

```
local row = 18
local cum percent = 0
tabulate CAT_triage_C, matcell(freq) matrow(names)
putexcel A17=("CATs C") B17=("Freq.") C17=("Percent") D17=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("CATs criteria") modify
***CATs criterion D
tabulate CAT_triage_D, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 23
local cum percent = 0
tabulate CAT_triage_D, matcell(freq) matrow(names)
putexcel A22=("CATs D") B22=("Freq.") C22=("Percent") D22=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent val : display %9.2f `percent val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("CATs criteria") modify
***CATs criterion E
tabulate CAT_triage_E, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 28
local cum percent = 0
tabulate CAT_triage_E, matcell(freq) matrow(names)
putexcel A26=("CATs E") B26=("Freq.") C26=("Percent") D26=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i'.1]
    local val_lab : label (CAT_triage_B) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify
***CATs criterion F
tabulate CAT_triage_F, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 33
local cum percent = 0
tabulate CAT_triage_F, matcell(freq) matrow(names)
putexcel A32=("CATs F") B32=("Freq.") C32=("Percent") D32=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq_val = freq[`i',1]
```

```
local percent_val = `freq_val'/`r(N)'*100
local percent_val : display %9.2f `percent_val'
local cum_percent : display %9.2f (`cum_percent' + `percent_val')
putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
D`row'=(`cum_percent') using results, sheet("CATs criteria") modify
local row = `row' + 1
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify

```
***CATs criterion G
tabulate CAT triage G, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 38
local cum percent = 0
tabulate CAT_triage_G, matcell(freq) matrow(names)
putexcel A37=("CATs G") B37=("Freq.") C37=("Percent") D37=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i'.1]
    local val_lab : label (CAT_triage_B) `val'
    local freq val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("CATs criteria") modify
    local row = row' + 1
```

```
}
```

}

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify

#### \*\*\*\*\*\*\*\*

\*\*EXPORTING "Measure/Not measured" STATUS OF DIFFERENT CLINICAL MEASURES ON THE LEPIS FORM putexcel A1=("'Clinical data' (other clinical data collected through the LEPIS form)") using results, sheet("Clinical data") modify

```
**recoding errors in coding temperature
recode temperature 3=0 4=0
 **Temperature
tabulate temperature, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 5
local cum_percent = 0
tabulate temperature, matcell(freq) matrow(names)
putexcel A4=("Temperature") B4=("Freq.") C4=("Percent") D4=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/'rows' {
    local val = names[`i',1]
    local val lab : label (temperature) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
}
```

putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("Clinical data") modify

\*\*recoding errors in coding respiratoryrate
recode respiratoryrate 3=0 4=0
\*\*\*Respiratory rate
tabulate respiratoryrate, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 10
local cum\_percent = 0
tabulate respiratoryrate, matcell(freq) matrow(names)
putexcel A9=("Respiratory rate") B9=("Freq.") C9=("Percent") D9=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
 local val = names[`i',1]
 local val\_lab : label (respiratoryrate) `val'

```
local freq_val = freq[`i',1]
    local percent val = freg val'/r(N)*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = row' + 1
}
putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("Clinical data") modify
**recoding errors in coding peripheraloxygensaturation
recode peripheraloxygensaturation 3=0 4=0
***Peripheral Oxygen Saturation
tabulate peripheraloxygensaturation, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 15
local cum percent = 0
tabulate peripheraloxygensaturation, matcell(freq) matrow(names)
putexcel A14=("Peripheral Oxygen Saturation") B14=("Freq.") C14=("Percent") D14=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (peripheraloxygensaturation) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum percent : display %9.2f (`cum percent' + `percent val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
        D'row'=('cum percent') using results, sheet("Clinical data") modify
    local row = row' + 1
}
putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("Clinical data") modify
**recoding errors in coding heartrate
recode heartrate 3=0 4=0
***Heart Rate
tabulate heartrate, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 20
local cum percent = 0
tabulate heartrate, matcell(freq) matrow(names)
putexcel A19=("Heart Rate") B19=("Freq.") C19=("Percent") D19=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (heartrate) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
        D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
}
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify
```

\*\*recoding errors in coding bloodpressure
recode bloodpressure 3=0 4=0
\*\*\*Blood Pressure
tabulate bloodpressure, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 25
local cum\_percent = 0
tabulate bloodpressure, matcell(freq) matrow(names)
putexcel A24=("Blood Pressure") B24=("Freq.") C24=("Percent") D24=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
 local val = names[`i',1]
 local val = names[`i',1]
 local freq\_val = freq[`i',1]
 local percent\_val = `freq\_val'/`r(N)'\*100

```
local percent_val : display %9.2f `percent_val'
local cum_percent : display %9.2f (`cum_percent' + `percent_val')
putexcel A`row'=(``val_lab''') B`row'=(`freq_val') C`row'=(`percent_val') ///
D`row'=(`cum_percent') using results, sheet("Clinical data") modify
local row = `row' + 1
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

```
**recoding errors in coding severedehydration
recode severedehydration 3=0 4=0
***Severe Dehydration
tabulate severedehydration, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 30
local cum percent = 0
tabulate severedehydration, matcell(freg) matrow(names)
putexcel A29=("Severe Dehydration") B29=("Freq.") C29=("Percent") D29=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val lab : label (severedehydration) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A'row'=("'val_lab'") B'row'=('freq_val') C'row'=('percent_val') ///
         D'row'=('cum percent') using results, sheet("Clinical data") modify
    local row = row' + 1
```

```
}
```

}

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

```
***New altered conscious level
tabulate newalteredconsciouslevel, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 35
local cum_percent = 0
tabulate newalteredconsciouslevel, matcell(freq) matrow(names)
putexcel A34=("New altered consciousness level") B34=("Freq.") C34=("Percent") D34=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (newalteredconsciouslevel) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
}
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

```
***Social Isolation
tabulate socialisolation, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 40
local cum_percent = 0
tabulate socialisolation, matcell(freq) matrow(names)
putexcel A39=("Social Isolation") B39=("Freq.") C39=("Percent") D39=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (socialisolation) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
}
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

```
***Ability to self-care
tabulate performancestatus, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 46
local cum_percent = 0
tabulate performancestatus, matcell(freq) matrow(names)
putexcel A45=("Ability to self-care") B45=("Freq.") C45=("Percent") D45=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (performancestatus) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
}
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

```
***Treatment with antivirals
tabulate treatwithantivirals, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 55
local cum_percent = 0
tabulate treatwithantivirals, matcell(freq) matrow(names)
putexcel A54=("Treatment with antivirals") B54=("Freq.") C54=("Percent") D54=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (treatwithantivirals) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
```

```
}
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

```
***Treatment with antibiotics
tabulate treatwithantibiotics, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 60
local cum_percent = 0
tabulate treatwithantibiotics, matcell(freq) matrow(names)
putexcel A59=("Treatment with antibiotics") B59=("Freq.") C59=("Percent") D59=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (treatwithantibiotics) `val'
    local freq_val = freq[`i',1]
    local percent val = `freq val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
        D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
```

```
}
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

\*\*\*Refer to hospital
tabulate refertohospital, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 65
local cum\_percent = 0

tabulate refertohospital, matcell(freq) matrow(names) putexcel A64=("Refer to hospital") B64=("Freq.") C64=("Percent") D64=("Cum.") using results, sheet("Clinical data") modify forvalues i = 1/`rows' { local val = names[`i',1] local val\_lab : label (refertohospital) `val' local freq\_val = freq[`i',1] local percent\_val = `freq\_val'/`r(N)'\*100 local percent\_val : display %9.2f `percent\_val' local cum\_percent : display %9.2f (`cum\_percent' + `percent\_val') putexcel A`row'=("`val\_lab'") B`row'=(`freq\_val') C`row'=(`percent\_val') /// D'row'=('cum\_percent') using results, sheet("Clinical data") modify local row = `row' + 1 } putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("Clinical data") modify \*\*\*\*\*\*ANALYSES\*\*\*\*\* \*\*\*Unadjusted\*\*\* \*\*Outcome#1: Decision to treat with antivirals \*CATs A putexcel A1=("Regression Results contains results from unadjusted and adjusted logistic regression results for outcomes of interest") using results, sheet("Regression results") modify logit treatwithantivirals CAT triage A putexcel A3=("Unadjusted analyses") using results, sheet("Regression results") modify putexcel A4=("1. Outcome: Decision to treat with antivirals") using results, sheet("Regression results") modify putexcel B5=("n") C5=("OR") D5=("Lower 95% CI") E5=("Upper 95% CI") F5=("p-value") using results, sheet("Regression results") modify putexcel A6=("CATs A") B6=(e(N)) C6=(exp(\_b[CAT\_triage\_A])) D6=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) E6=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) F6=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify \*CATs B logit treatwithantivirals CAT triage B putexcel A7=("CATs B") B7=(e(N)) C7=(exp(\_b[CAT\_triage\_B])) D7=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) E7=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) F7=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify \*CATs C logit treatwithantivirals CAT\_triage\_C putexcel A8=("CATs C") B8=(e(N)) C8=(exp(\_b[CAT\_triage\_C])) D8=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) E8=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) F8=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify \*CATs D logit treatwithantivirals CAT\_triage\_D putexcel A9=("CATs D") B9=(e(N)) C9=(exp(\_b[CAT\_triage\_D])) D9=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) E9=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) F9=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify \*CATs E logit treatwithantivirals CAT triage E putexcel A10=("CATs E") B10=(e(N)) C10=(exp(\_b[CAT\_triage\_E])) D10=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) E10=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) F10=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify \*CATs F logit treatwithantivirals CAT\_triage\_F putexcel A11=("CATs F") B11=(e(N)) C11=(exp(\_b[CAT\_triage\_F])) D11=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) E11=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) F11=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify \*CATs G logit treatwithantivirals CAT triage G putexcel A12=("CATs G") B12=(e(N)) C12=(exp(\_b[CAT\_triage\_G])) D12=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) E12=(exp( b[CAT triage G]+(1.96\* se[CAT triage G]))) F12=(2\*normal(-abs( b[CAT triage G]/ se[CAT triage G]))) using results, sheet("Regression results") modify \*\*Outcome#2: Decision to treat with antibiotics \*CATs A logit treatwithantibiotics CAT\_triage\_A putexcel A14=("2. Outcome: Decision to treat with antibiotics") using results, sheet("Regression results") modify putexcel B15=("n") C15=("OR") D15=("Lower 95% CI") E15=("Upper 95% CI") F15=("p-value") using results, sheet("Regression results") putexcel A16=("CATs A") B16=(e(N)) C16=(exp(\_b[CAT\_triage\_A])) D16=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) E16=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) F16=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify \*CATs B logit treatwithantibiotics CAT\_triage\_B

putexcel A17=("CATs B") B17=(e(N)) C17=(exp(\_b[CAT\_triage\_B])) D17=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) E17=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) F17=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify \*CATs C logit treatwithantibiotics CAT\_triage\_C putexcel A18=("CATs C") B18=(e(N)) C18=(exp(\_b[CAT\_triage\_C])) D18=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) E18=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) F18=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify \*CATs D logit treatwithantibiotics CAT\_triage\_D putexcel A19=("CATs D") B19=(e(N)) C19=(exp(\_b[CAT\_triage\_D])) D19=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) E19=(exp( b[CAT triage D]+(1.96\* se[CAT triage D]))) F19=(2\*normal(-abs( b[CAT triage D]/ se[CAT triage D]))) using results, sheet("Regression results") modify \*CATs E logit treatwithantibiotics CAT\_triage\_E putexcel A20=("CATs E") B20=(e(N)) C20=(exp(\_b[CAT\_triage\_E])) D20=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) E20=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) F20=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify \*CATs F logit treatwithantibiotics CAT triage F putexcel A21=("CATs F") B21=(e(N)) C21=(exp( b[CAT triage F])) D21=(exp( b[CAT triage F]-(1.96\* se[CAT triage F]))) E21=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) F21=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify \*CATs G logit treatwithantibiotics CAT triage G putexcel A22=("CATs G") B22=(e(N)) C22=(exp(\_b[CAT\_triage\_G])) D22=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) E22=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) F22=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify \*\*Outcome#3: Decision to refer to hospital \*CATs A logit refertohospital CAT\_triage\_A putexcel A24=("3. Outcome: Decision to refer to hospital") using results, sheet("Regression results") modify putexcel B25=("n") C25=("OR") D25=("Lower 95% CI") E25=("Upper 95% CI") F25=("p-value") using results, sheet("Regression results") modify putexcel A26=("CATs A") B26=(e(N)) C26=(exp(\_b[CAT\_triage\_A])) D26=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) E26=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) F26=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify \*CATs B logit refertohospital CAT triage B putexcel A27=("CATs B") B27=(e(N)) C27=(exp(\_b[CAT\_triage\_B])) D27=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) E27=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) F27=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify \*CATs C logit refertohospital CAT\_triage\_C putexcel A28=("CATs C") B28=(e(N)) C28=(exp(\_b[CAT\_triage\_C])) D28=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) E28=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) F28=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify \*CATs D logit refertohospital CAT\_triage\_D putexcel A29=("CATs D") B29=(e(N)) C29=(exp(\_b[CAT\_triage\_D])) D29=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) E29=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) F29=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify \*CATs E logit refertohospital CAT\_triage\_E putexcel A30=("CATs E") B30=(e(N)) C30=(exp( b[CAT triage E])) D30=(exp( b[CAT triage E]-(1.96\* se[CAT triage E]))) E30=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) F30=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify \*CATs F logit refertohospital CAT\_triage\_F putexcel A31=("CATs F") B31=(e(N)) C31=(exp(\_b[CAT\_triage\_F])) D31=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) E31=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) F31=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify \*CATs G logit refertohospital CAT triage G putexcel A32=("CATs G") B32=(e(N)) C32=(exp(\_b[CAT\_triage\_G])) D32=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) E32=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) F32=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify

\*\*Adjusted\*\*

\*\*Outcome#1: Decision to treat with antivirals

#### \*CATs A

logit treatwithantivirals CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or putexcel I3=("Adjusted analyses") using results, sheet("Regression results") modify

putexcel I4=("1. Outcome: Decision to treat with antivirals") using results, sheet("Regression results") modify putexcel J5=("n") K5=("OR") L5=("Lower 95% CI") M5=("Upper 95% CI") N5=("p-value") using results, sheet("Regression results") modify putexcel I6=("CATs A") J6=(e(N)) K6=(exp(\_b[CAT\_triage\_A])) L6=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) M6=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) N6=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify putexcel I7=("CATs B") J7=(e(N)) K7=(exp(\_b[CAT\_triage\_B])) L7=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B])))

M7=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) N7=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify

putexcel I8=("CATs C") J8=(e(N)) K8=(exp(\_b[CAT\_triage\_C])) L8=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) M8=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) N8=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify

putexcel I9=("CATs D") J9=(e(N)) K9=(exp(\_b[CAT\_triage\_D])) L9=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) M9=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) N9=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify

putexcel I10=("CATs E") J10=(e(N)) K10=(exp(\_b[CAT\_triage\_E])) L10=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) M10=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) N10=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify

putexcel l11=("CATs F") J11=(e(N)) K11=(exp(\_b[CAT\_triage\_F])) L11=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) M11=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) N11=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify

putexcel I12=("CATs G") J12=(e(N)) K12=(exp(\_b[CAT\_triage\_G])) L12=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) M12=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) N12=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify

#### \*\*Outcome#2: Decision to treat with antibiotics

logit treatwithantibiotics CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or putexcel I14=("2. Outcome: Decision to treat with antibiotics") using results, sheet("Regression results") modify putexcel J15=("n") K15=("OR") L15=("Lower 95% CI") M15=("Upper 95% CI") N15=("p-value") using results, sheet("Regression results") modify

putexcel I16=("CATs A") J16=(e(N)) K16=(exp(\_b[CAT\_triage\_A])) L16=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) M16=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) N16=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify

putexcel I17=("CATs B") J17=(e(N)) K17=(exp(\_b[CAT\_triage\_B])) L17=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) M17=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) N17=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify

putexcel I18=("CATs C") J18=(e(N)) K18=(exp(\_b[CAT\_triage\_C])) L18=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) M18=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) N18=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify

putexcel I19=("CATs D") J19=(e(N)) K19=(exp(\_b[CAT\_triage\_D])) L19=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) M19=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) N19=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify

putexcel I20=("CATs E") J20=(e(N)) K20=(exp(\_b[CAT\_triage\_E])) L20=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) M20=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) N20=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify

putexcel I21=("CATs F") J21=(e(N)) K21=(exp(\_b[CAT\_triage\_F])) L21=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) M21=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) N21=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify

putexcel I22=("CATs G") J22=(e(N)) K22=(exp(\_b[CAT\_triage\_G])) L22=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) M22=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) N22=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify

#### \*\*Outcome#3: Decision to refer to hospital

logit refertohospital CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or putexcel I24=("3. Outcome: Decision to refer to hospital") using results, sheet("Regression results") modify putexcel J25=("n") K25=("OR") L25=("Lower 95% CI") M25=("Upper 95% CI") N25=("p-value") using results, sheet("Regression results")

modify putexcel I26=("CATs A") J26=(e(N)) K26=(exp(\_b[CAT\_triage\_A])) L26=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A])))

M26=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) N26=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify

putexcel I27=("CATs B") J27=(e(N)) K27=(exp(\_b[CAT\_triage\_B])) L27=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) M27=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) N7=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify

putexcel I28=("CATs C") J28=(e(N)) K28=(exp(\_b[CAT\_triage\_C])) L28=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) M28=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) N28=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify

putexcel I29=("CATs D") J29=(e(N)) K29=(exp(\_b[CAT\_triage\_D])) L29=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) M29=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) N29=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

putexcel I30=("CATs E") J30=(e(N)) K30=(exp(\_b[CAT\_triage\_E])) L30=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) M30=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) N30=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify

putexcel I31=("CATs F") J31=(e(N)) K31=(exp(\_b[CAT\_triage\_F])) L31=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) M31=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) N31=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify

putexcel I32=("CATs G") J32=(e(N)) K32=(exp(\_b[CAT\_triage\_G])) L32=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) M32=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) N32=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify

# 4. Weekly reports for children's data

clear

\*\*\* NOTE: Ensure that the directory mentioned below is the directory containing the CLEANED weekly adult/children data files. //The results spreadsheet will be saved within this directory.

global path = "R:\HPIRG\Flu-CATs\Last Tranche\Weekly\"

cd "\$path"

use child\_20150413\_clean.dta //

//NOTE: The name of the source file may need to be modified. The source file will need to be a cleaned version of the weekly data file. //This do-file will have to be run separately for adult and for children data.

putexcel A1=("NIHR Flu-CATs Weekly Report: dd/mm/YYYY") using results, sheet("CATs criteria") replace //Insert the correct date in place of "dd/mm/YYYY"

putexcel G1=("Data Source: Clinical Practice Research Datalink- Participating GP Practices") using results, sheet("CATs criteria") modify putexcel A3=("This spreadsheet contains three worksheets- 'CATs criteria' (frequencies of each of the 7 CATs criteria), 'Clinical data' (other clinical data collected through the LEPIS form)") using results, sheet("CATs criteria") modify putexcel A4=("and 'Analyses' (results of logistic regression analyses).") using results, sheet("CATs criteria") modify tabulate CAT\_triage\_A, matcell(freq) matrow(names)

```
local rows = rowsof(names)
local row = 7
local cum_percent = 0
***CATs criterion A
tabulate CAT_triage_A, m matcell(freq) matrow(names)
putexcel A6=("CATs A") B6=("Freq.") C6=("Percent") D6=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_A) `val'
    local freq val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
        D'row'=('cum_percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify

```
***CATs criterion B
tabulate CAT_triage_B, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 12
local cum_percent = 0
tabulate CAT_triage_B, matcell(freq) matrow(names)
putexcel A11=("CATs B") B11=("Freq.") C11=("Percent") D11=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
```

```
putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify
***CATs criterion C
tabulate CAT_triage_C, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 18
local cum percent = 0
tabulate CAT_triage_C, matcell(freq) matrow(names)
putexcel A17=("CATs C") B17=("Freq.") C17=("Percent") D17=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq_val = freq[`i',1]
    local percent_val = freq_val'/r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify
***CATs criterion D
tabulate CAT_triage_D, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 23
local cum percent = 0
tabulate CAT_triage_D, matcell(freq) matrow(names)
putexcel A22=("CATs D") B22=("Freq.") C22=("Percent") D22=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
```

```
local val = IndItes[1,1]
local val = label (CAT_triage_B) `val'
local freq_val = freq[`i',1]
local percent_val = 'freq_val'/`r(N)'*100
local percent_val : display %9.2f `percent_val'
local cum_percent : display %9.2f (`cum_percent' + `percent_val')
putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
D`row'=(`cum_percent') using results, sheet("CATs criteria") modify
local row = `row' + 1
}
```

putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("CATs criteria") modify

```
***CATs criterion E
tabulate CAT_triage_E, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 28
local cum percent = 0
tabulate CAT_triage_E, matcell(freq) matrow(names)
putexcel A26=("CATs E") B26=("Freq.") C26=("Percent") D26=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D`row'=(`cum_percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
```

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify

\*\*\*CATs criterion F

```
tabulate CAT_triage_F, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 33
local cum_percent = 0
tabulate CAT_triage_F, matcell(freq) matrow(names)
putexcel A32=("CATs F") B32=("Freq.") C32=("Percent") D32=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent val : display %9.2f `percent val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("CATs criteria") modify
    local row = `row' + 1
}
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("CATs criteria") modify
***CATs criterion G
tabulate CAT_triage_G, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 38
local cum percent = 0
tabulate CAT_triage_G, matcell(freq) matrow(names)
putexcel A37=("CATs G") B37=("Freq.") C37=("Percent") D37=("Cum.") using results, sheet("CATs criteria") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (CAT_triage_B) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
```

```
local percent_val : display %9.2f `percent_val'
local cum_percent : display %9.2f (`cum_percent' + `percent_val')
```

local row = `row' + 1

```
}
```

putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("CATs criteria") modify

putexcel A`row'=(``val\_lab''') B`row'=(`freq\_val') C`row'=(`percent\_val') /// D`row'=(`cum\_percent') using results, sheet("CATs criteria") modify

#### 

\*\*EXPORTING "Measure/Not measured" STATUS OF DIFFERENT CLINICAL MEASURES ON THE LEPIS FORM putexcel A1=("'Clinical data' (other clinical data collected through the LEPIS form)") using results, sheet("Clinical data") modify

```
**recoding errors in coding temperature
recode temperature 3=0 4=0
***Temperature
tabulate temperature, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 5
local cum_percent = 0
tabulate temperature, matcell(freq) matrow(names)
putexcel A4=("Temperature") B4=("Freq.") C4=("Percent") D4=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (temperature) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = row' + 1
}
```

putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("Clinical data") modify

\*\*recoding errors in coding respiratoryrate recode respiratoryrate 3=0 4=0

```
***Respiratory rate
tabulate respiratoryrate, matcell(freg) matrow(names)
local rows = rowsof(names)
local row = 10
local cum_percent = 0
tabulate respiratoryrate, matcell(freq) matrow(names)
putexcel A9=("Respiratory rate") B9=("Freq.") C9=("Percent") D9=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (respiratoryrate) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = row' + 1
}
putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("Clinical data") modify
**recoding errors in coding peripheraloxygensaturation
recode peripheraloxygensaturation 3=0 4=0
***Peripheral Oxygen Saturation
tabulate peripheraloxygensaturation, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 15
local cum_percent = 0
tabulate peripheraloxygensaturation, matcell(freq) matrow(names)
putexcel A14=("Peripheral Oxygen Saturation") B14=("Freq.") C14=("Percent") D14=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (peripheraloxygensaturation) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
}
putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("Clinical data") modify
**recoding errors in coding heartrate
```

```
recode heartrate 3=0 4=0
***Heart Rate
tabulate heartrate, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 20
local cum_percent = 0
tabulate heartrate, matcell(freq) matrow(names)
putexcel A19=("Heart Rate") B19=("Freq.") C19=("Percent") D19=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val lab : label (heartrate) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
        D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = row' + 1
}
```

```
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify
```

\*\*recoding errors in coding severedehydration

recode severedehydration 3=0 4=0

\*\*\*Severe Dehydration

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

```
tabulate severedehydration, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 30
local cum_percent = 0
tabulate severedehydration, matcell(freq) matrow(names)
putexcel A29=("Severe Dehydration") B29=("Freq.") C29=("Percent") D29=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (severedehydration) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent val : display %9.2f `percent val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
}
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify
***New altered conscious level
tabulate newalteredconsciouslevel, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 35
local cum percent = 0
tabulate newalteredconsciouslevel, matcell(freq) matrow(names)
putexcel A34=("New altered consciousness level") B34=("Freq.") C34=("Percent") D34=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (newalteredconsciouslevel) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum_percent : display %9.2f (`cum_percent' + `percent_val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D`row'=(`cum_percent') using results, sheet("Clinical data") modify
    local row = `row' + 1
}
putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify
***Treatment with antivirals
tabulate treatwithantivirals, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 55
local cum_percent = 0
tabulate treatwithantivirals, matcell(freg) matrow(names)
putexcel A54=("Treatment with antivirals") B54=("Freq.") C54=("Percent") D54=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (treatwithantivirals) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum percent : display %9.2f (`cum percent' + `percent val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum_percent') using results, sheet("Clinical data") modify
```

```
local row = `row' + 1
```

}

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

```
***Treatment with antibiotics
tabulate treatwithantibiotics, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 60
local cum_percent = 0
tabulate treatwithantibiotics, matcell(freq) matrow(names)
putexcel A59=("Treatment with antibiotics") B59=("Freq.") C59=("Percent") D59=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
```

\*\*\*\*\*\*ANALYSES\*\*\*\*\*

}

local val = names[`i',1] local val\_lab : label (treatwithantibiotics) `val' local freq\_val = freq[`i',1] local percent\_val = `freq\_val'/`r(N)'\*100 local percent\_val : display %9.2f `percent\_val' local cum\_percent : display %9.2f (`cum\_percent' + `percent\_val') putexcel A`row'=("`val\_lab''') B`row'=(`freq\_val') C`row'=(`percent\_val') /// D`row'=(`cum\_percent') using results, sheet("Clinical data") modify local row = `row' + 1

putexcel A`row'=("Total") B`row'=(r(N)) C`row'=(100.00) using results, sheet("Clinical data") modify

```
***Refer to hospital
tabulate refertohospital, matcell(freq) matrow(names)
local rows = rowsof(names)
local row = 65
local cum percent = 0
tabulate refertohospital, matcell(freg) matrow(names)
putexcel A64=("Refer to hospital") B64=("Freq.") C64=("Percent") D64=("Cum.") using results, sheet("Clinical data") modify
forvalues i = 1/`rows' {
    local val = names[`i',1]
    local val_lab : label (refertohospital) `val'
    local freq_val = freq[`i',1]
    local percent_val = `freq_val'/`r(N)'*100
    local percent_val : display %9.2f `percent_val'
    local cum percent : display %9.2f (`cum percent' + `percent val')
    putexcel A`row'=("`val_lab'") B`row'=(`freq_val') C`row'=(`percent_val') ///
         D'row'=('cum percent') using results, sheet("Clinical data") modify
    local row = row' + 1
}
```

putexcel A'row'=("Total") B'row'=(r(N)) C'row'=(100.00) using results, sheet("Clinical data") modify

```
***Unadjusted***
**Outcome#1: Decision to treat with antivirals
*CATs A
putexcel A1=("Regression Results contains results from unadjusted and adjusted logistic regression results for outcomes of interest") using
results, sheet("Regression results") modify
logit treatwithantivirals CAT triage A
putexcel A3=("Unadjusted analyses") using results, sheet("Regression results") modify
putexcel A4=("1. Outcome: Decision to treat with antivirals") using results, sheet("Regression results") modify
putexcel B5=("n") C5=("OR") D5=("Lower 95% CI") E5=("Upper 95% CI") F5=("p-value") using results, sheet("Regression results") modify
putexcel A6=("CATs A") B6=(e(N)) C6=(exp(_b[CAT_triage_A])) D6=(exp(_b[CAT_triage_A]-(1.96*_se[CAT_triage_A])))
E6=(exp(_b[CAT_triage_A]+(1.96*_se[CAT_triage_A]))) F6=(2*normal(-abs(_b[CAT_triage_A]/_se[CAT_triage_A]))) using results,
sheet("Regression results") modify
*CATs B
logit treatwithantivirals CAT_triage_B
putexcel A7=("CATs B") B7=(e(N)) C7=(exp(_b[CAT_triage_B])) D7=(exp(_b[CAT_triage_B]-(1.96* se[CAT_triage_B])))
E7=(exp(_b[CAT_triage_B]+(1.96*_se[CAT_triage_B]))) F7=(2*normal(-abs(_b[CAT_triage_B]/_se[CAT_triage_B]))) using results,
sheet("Regression results") modify
*CATs C
logit treatwithantivirals CAT triage C
putexcel A8=("CATs C") B8=(e(N)) C8=(exp(_b[CAT_triage_C])) D8=(exp(_b[CAT_triage_C]-(1.96*_se[CAT_triage_C])))
E8=(exp(_b[CAT_triage_C]+(1.96*_se[CAT_triage_C]))) F8=(2*normal(-abs(_b[CAT_triage_C]/_se[CAT_triage_C]))) using results,
sheet("Regression results") modify
*CATs D
logit treatwithantivirals CAT triage D
putexcel A9=("CATs D") B9=(e(N)) C9=(exp(_b[CAT_triage_D])) D9=(exp(_b[CAT_triage_D]-(1.96*_se[CAT_triage_D])))
E9=(exp(_b[CAT_triage_D]+(1.96*_se[CAT_triage_D]))) F9=(2*normal(-abs(_b[CAT_triage_D]/_se[CAT_triage_D]))) using results,
sheet("Regression results") modify
*CATs E
logit treatwithantivirals CAT_triage_E
putexcel A10=("CATs E") B10=(e(N)) C10=(exp(_b[CAT_triage_E])) D10=(exp(_b[CAT_triage_E]-(1.96*_se[CAT_triage_E])))
E10=(exp(_b[CAT_triage_E]+(1.96*_se[CAT_triage_E]))) F10=(2*normal(-abs(_b[CAT_triage_E]/_se[CAT_triage_E]))) using results,
sheet("Regression results") modify
```

\*CATs F

logit treatwithantivirals CAT\_triage\_F

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

putexcel A11=("CATs F") B11=(e(N)) C11=(exp(\_b[CAT\_triage\_F])) D11=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) E11=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) F11=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify \*CATs G logit treatwithantivirals CAT\_triage\_G putexcel A12=("CATs G") B12=(e(N)) C12=(exp(\_b[CAT\_triage\_G])) D12=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) E12=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) F12=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify \*\*Outcome#2: Decision to treat with antibiotics \*CATs A logit treatwithantibiotics CAT\_triage\_A putexcel A14=("2. Outcome: Decision to treat with antibiotics") using results, sheet("Regression results") modify putexcel B15=("n") C15=("OR") D15=("Lower 95% CI") E15=("Upper 95% CI") F15=("p-value") using results, sheet("Regression results") modify putexcel A16=("CATs A") B16=(e(N)) C16=(exp(\_b[CAT\_triage\_A])) D16=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) E16=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) F16=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify \*CATs B logit treatwithantibiotics CAT triage B putexcel A17=("CATs B") B17=(e(N)) C17=(exp( b[CAT triage B])) D17=(exp( b[CAT triage B]-(1.96\* se[CAT triage B]))) E17=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) F17=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify \*CATs C logit treatwithantibiotics CAT triage C putexcel A18=("CATs C") B18=(e(N)) C18=(exp(\_b[CAT\_triage\_C])) D18=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) E18=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) F18=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify \*CATs D logit treatwithantibiotics CAT triage D putexcel A19=("CATs D") B19=(e(N)) C19=(exp( b[CAT triage D])) D19=(exp( b[CAT triage D]-(1.96\* se[CAT triage D]))) E19=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) F19=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify \*CATs F logit treatwithantibiotics CAT\_triage\_E putexcel A20=("CATs E") B20=(e(N)) C20=(exp(\_b[CAT\_triage\_E])) D20=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) E20=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) F20=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify \*CATs F logit treatwithantibiotics CAT triage F putexcel A21=("CATs F") B21=(e(N)) C21=(exp(\_b[CAT\_triage\_F])) D21=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) E21=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) F21=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify \*CATs G logit treatwithantibiotics CAT\_triage\_G putexcel A22=("CATs G") B22=(e(N)) C22=(exp(\_b[CAT\_triage\_G])) D22=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) E22=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) F22=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify \*\*Outcome#3: Decision to refer to hospital \*CATs A logit refertohospital CAT\_triage\_A putexcel A24=("3. Outcome: Decision to refer to hospital") using results, sheet("Regression results") modify putexcel B25=("n") C25=("OR") D25=("Lower 95% CI") E25=("Upper 95% CI") F25=("p-value") using results, sheet("Regression results") modifv putexcel A26=("CATs A") B26=(e(N)) C26=(exp( b[CAT triage A])) D26=(exp( b[CAT triage A]-(1.96\* se[CAT triage A]))) E26=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) F26=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify \*CATs B logit refertohospital CAT\_triage\_B putexcel A27=("CATs B") B27=(e(N)) C27=(exp(\_b[CAT\_triage\_B])) D27=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) E27=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) F27=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify \*CATs C logit refertohospital CAT triage C putexcel A28=("CATs C") B28=(e(N)) C28=(exp(\_b[CAT\_triage\_C])) D28=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) E28=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) F28=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify \*CATs D

logit refertohospital CAT\_triage\_D

putexcel A29=("CATs D") B29=(e(N)) C29=(exp(\_b[CAT\_triage\_D])) D29=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) E29=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) F29=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify \*CATs E

logit refertohospital CAT\_triage\_E

putexcel A30=("CATs E") B30=(e(N)) C30=(exp(\_b[CAT\_triage\_E])) D30=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) E30=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) F30=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify

\*CATs F

logit refertohospital CAT\_triage\_F

putexcel A31=("CATs F") B31=(e(N)) C31=(exp(\_b[CAT\_triage\_F])) D31=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) E31=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) F31=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify

\*CATs G

logit refertohospital CAT\_triage\_G

putexcel A32=("CATs G") B32=(e(N)) C32=(exp(\_b[CAT\_triage\_G])) D32=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) E32=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) F32=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify

\*\*Adjusted\*\*

\*\*Outcome#1: Decision to treat with antivirals

\*CATs A

logit treatwithantivirals CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or putexcel I3=("Adjusted analyses") using results, sheet("Regression results") modify

putexcel I4=("1. Outcome: Decision to treat with antivirals") using results, sheet("Regression results") modify putexcel J5=("n") K5=("OR") L5=("Lower 95% CI") M5=("Upper 95% CI") N5=("p-value") using results, sheet("Regression results") modify putexcel I6=("CATs A") J6=(e(N)) K6=(exp(\_b[CAT\_triage\_A])) L6=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) M6=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) N6=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify

putexcel I7=("CATs B") J7=(e(N)) K7=(exp(\_b[CAT\_triage\_B])) L7=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) M7=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) N7=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify

putexcel I8=("CATs C") J8=(e(N)) K8=(exp(\_b[CAT\_triage\_C])) L8=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) M8=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) N8=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify

putexcel I9=("CATs D") J9=(e(N)) K9=(exp(\_b[CAT\_triage\_D])) L9=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) M9=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) N9=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify

putexcel I10=("CATs E") J10=(e(N)) K10=(exp(\_b[CAT\_triage\_E])) L10=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) M10=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) N10=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify

putexcel I11=("CATs F") J11=(e(N)) K11=(exp(\_b[CAT\_triage\_F])) L11=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) M11=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) N11=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify

putexcel l12=("CATs G") J12=(e(N)) K12=(exp(\_b[CAT\_triage\_G])) L12=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) M12=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) N12=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify

\*\*Outcome#2: Decision to treat with antibiotics

logit treatwithantibiotics CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or putexcel I14=("2. Outcome: Decision to treat with antibiotics") using results, sheet("Regression results") modify putexcel J15=("n") K15=("OR") L15=("Lower 95% CI") M15=("Upper 95% CI") N15=("p-value") using results, sheet("Regression results") modify putexcel I16=("CATs A") J16=(e(N)) K16=(exp(\_b[CAT\_triage\_A])) L16=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) M16=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) N16=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify

putexcel I17=("CATs B") J17=(e(N)) K17=(exp(\_b[CAT\_triage\_B])) L17=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) M17=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) N17=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify

putexcel I18=("CATs C") J18=(e(N)) K18=(exp(\_b[CAT\_triage\_C])) L18=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) M18=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) N18=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify

putexcel I19=("CATs D") J19=(e(N)) K19=(exp(\_b[CAT\_triage\_D])) L19=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) M19=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) N19=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify

putexcel I20=("CATs E") J20=(e(N)) K20=(exp(\_b[CAT\_triage\_E])) L20=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) M20=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) N20=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify

putexcel I21=("CATs F") J21=(e(N)) K21=(exp(\_b[CAT\_triage\_F])) L21=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) M21=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) N21=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify

putexcel I22=("CATs G") J22=(e(N)) K22=(exp(\_b[CAT\_triage\_G])) L22=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) M22=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) N22=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify

\*\*Outcome#3: Decision to refer to hospital

logit refertohospital CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_F CAT\_triage\_G, or putexcel I24=("3. Outcome: Decision to refer to hospital") using results, sheet("Regression results") modify putexcel J25=("n") K25=("OR") L25=("Lower 95% CI") M25=("Upper 95% CI") N25=("p-value") using results, sheet("Regression results") modify

putexcel I26=("CATs A") J26=(e(N)) K26=(exp(\_b[CAT\_triage\_A])) L26=(exp(\_b[CAT\_triage\_A]-(1.96\*\_se[CAT\_triage\_A]))) M26=(exp(\_b[CAT\_triage\_A]+(1.96\*\_se[CAT\_triage\_A]))) N26=(2\*normal(-abs(\_b[CAT\_triage\_A]/\_se[CAT\_triage\_A]))) using results, sheet("Regression results") modify

putexcel l27=("CATs B") J27=(e(N)) K27=(exp(\_b[CAT\_triage\_B])) L27=(exp(\_b[CAT\_triage\_B]-(1.96\*\_se[CAT\_triage\_B]))) M27=(exp(\_b[CAT\_triage\_B]+(1.96\*\_se[CAT\_triage\_B]))) N27=(2\*normal(-abs(\_b[CAT\_triage\_B]/\_se[CAT\_triage\_B]))) using results, sheet("Regression results") modify

putexcel I28=("CATs C") J28=(e(N)) K28=(exp(\_b[CAT\_triage\_C])) L28=(exp(\_b[CAT\_triage\_C]-(1.96\*\_se[CAT\_triage\_C]))) M28=(exp(\_b[CAT\_triage\_C]+(1.96\*\_se[CAT\_triage\_C]))) N28=(2\*normal(-abs(\_b[CAT\_triage\_C]/\_se[CAT\_triage\_C]))) using results, sheet("Regression results") modify

putexcel I29=("CATs D") J29=(e(N)) K29=(exp(\_b[CAT\_triage\_D])) L29=(exp(\_b[CAT\_triage\_D]-(1.96\*\_se[CAT\_triage\_D]))) M29=(exp(\_b[CAT\_triage\_D]+(1.96\*\_se[CAT\_triage\_D]))) N29=(2\*normal(-abs(\_b[CAT\_triage\_D]/\_se[CAT\_triage\_D]))) using results, sheet("Regression results") modify

putexcel I30=("CATs E") J30=(e(N)) K30=(exp(\_b[CAT\_triage\_E])) L30=(exp(\_b[CAT\_triage\_E]-(1.96\*\_se[CAT\_triage\_E]))) M30=(exp(\_b[CAT\_triage\_E]+(1.96\*\_se[CAT\_triage\_E]))) N30=(2\*normal(-abs(\_b[CAT\_triage\_E]/\_se[CAT\_triage\_E]))) using results, sheet("Regression results") modify

putexcel I31=("CATs F") J31=(e(N)) K31=(exp(\_b[CAT\_triage\_F])) L31=(exp(\_b[CAT\_triage\_F]-(1.96\*\_se[CAT\_triage\_F]))) M31=(exp(\_b[CAT\_triage\_F]+(1.96\*\_se[CAT\_triage\_F]))) N31=(2\*normal(-abs(\_b[CAT\_triage\_F]/\_se[CAT\_triage\_F]))) using results, sheet("Regression results") modify

putexcel I32=("CATs G") J32=(e(N)) K32=(exp(\_b[CAT\_triage\_G])) L32=(exp(\_b[CAT\_triage\_G]-(1.96\*\_se[CAT\_triage\_G]))) M32=(exp(\_b[CAT\_triage\_G]+(1.96\*\_se[CAT\_triage\_G]))) N32=(2\*normal(-abs(\_b[CAT\_triage\_G]/\_se[CAT\_triage\_G]))) using results, sheet("Regression results") modify

# 5. Monthly report

clear

\*\*\* NOTE: Ensure that the directory mentioned below is the directory containing the CLEANED weekly adult/children data files. //The results document ("my\_doc1") will be saved within this directory. global path = "R:\HPIRG\Flu-CATs\Last tranche\Monthly\" cd "Spath' use masterfile\_2015\_04.dta merge n:n patid using patient 2015 04.dta // ////NOTE: The names of the master file and the patient file may need to be modified. These files are .dta Stata data files downloaded from Dropbox. //This do-file will have to be run separately for adult and for children data. keep if m==3 drop\_m \*\*Keeping only unique consultations (dropping duplicates) bys patid submit\_date: gen new=\_n keep if new==1 drop new count //\*(note number) gen category=1 if cat=="adult" replace category=2 if cat=="child" label define adultchild 1 "Adults" 2 "Children" label value category adultchild label define gender 1 "Male" 2 "Female" label value gender gender \*\*Adult-Children graph pie, over(category) plabel(\_all percent) graph export "`sf'myplot1.eps", replace \*\*Male-Female graph pie, over(gender) plabel(\_all percent) graph export "`sf'myplot2.eps", replace \*Comorbidities local comorbidities "cardiovascular liver neurological renal respiratory diabetes immune\_supression" foreach comor of local comorbidities { gen \_`comor'=1 if `comor==1'

graph bar (count) \_cardiovascular \_liver \_neurological \_renal \_respiratory \_diabetes \_immune\_supression graph export "`sf'myplot3.eps", replace \*\*Medication local medication "statin antibiotic antiviral flu\_vaccination hib inhaled\_steroids oral\_steroids pneumococcal\_vaccine" foreach med of local medication { gen \_`med'=1 if `med'==1 graph bar (count) \_statin \_antibiotic \_antiviral \_flu\_vaccination \_hib \_inhaled\_steroids \_oral\_steroids \_pneumococcal\_vaccine graph export "`sf'myplot4.eps", replace tempname handle2 //RTFUTIL rtfopen `handle2' using "`sf'mydoc1.rtf", replace file write `handle2' \_n \_tab "{\pard\b Flu-CATs Monthly report: April, 2015 \par}" \_tab \_n //Insert the current month and year file write `handle2' \_n "{\pard\b Data Source: GP practices participating in the CPRD-Flu-CATs Study. \line}" file write `handle2' \_n "{\line}" // Figure1 file write `handle2' "{\pard\b FIGURE 1: Proportion of adults and children\par}" \_n /\* \*/ "{\pard A far greater proportion of patients are adults (81.46%) when compared to children (18.54%). \line}" n rtflink `handle2' using "`sf'myplot1.eps" // Figure2 file write `handle2' \_n "{\page}" \_n file write `handle2' \_n "{\line}" file write `handle2' \_n "{\partial}" \_n /\* file write `handle2' "{\pard\b FIGURE 2: Proportion of males and females\par}" \_n /\* \*/ "{\pard A slightly higher proportion of patients are female (55.37%) when compared to male (44.63). \line}" n rtflink `handle2' using "`sf'myplot2.eps" // Figure3 file write `handle2' \_n "{\page}" \_n file write `handle2' n "{\line}" file write `handle2' "{\pard\b FIGURE 3: Distribution of comorbidities\par}" \_n /\* \*/ "{\pard Respiratory disease is the most commonly observed comorbidity, followed by diabetes mellitus, renal disease, cardiovascular disease, neurological disease and liver disease. \line}"\_n rtflink `handle2' using "`sf'myplot3.eps" // Figure4 file write `handle2' \_n "{\page}" \_n file write `handle2' \_n "{\line}" file write `handle2' "{\pard\b FIGURE 4: Distribution of medications/treatments\par}" \_n /\* \*/ "{\pard The graph below shows the different medications and treatments that patients in the dataset were on. \line}" \_n rtflink `handle2' using "`sf'myplot4.eps' // Table1 gen death\_n=1 if death !=. recode death n (.=0) file write `handle2' \_n "{\page}" \_n /\* \*/ "{\pard A total of 8 deaths were observed. \line}" \_n file write `handle2' \_n "{\line}" file write `handle2' "{\pard\b Table 1\par}" \_n rtfrstyle category gender death\_n death, cwidths(1500 1440 1440 1440) local(b d e) listtex category gender death n death if death n=1,/\*\*/ handle(`handle2') begin("`b'") delim("`d'") end("`e'") /\* \*/ head("`b'\ql{\i Category}`d'\ql{\i Gender}`d'\ql{\i Death }`d'\ql{\i Date of death }`e'") file write `handle2' \_n "{\line}" file write `handle2' \_n \_tab(2) /\* \*/ "{\pard\b [Any additional notes]\par}" \_n \_n //Insert any additional notes.

rtfclose `handle2'

\*-----END CODE

# 6. PMEWS & CATs data analysis for comparisons

\*\*Calculating the PMEWS score- use for adults only (we don't have BP measurements for children) once initial data management has been carried out\*\*

\*\*While the physiological data (MEWS) component can be carried out using the weekly data downloads corresponding to the FLUCATs web-based data collection form//

//to score the patient data, merging with the monthly data downloads from CPRD will be required as comorbidity data are needed\*\*\*

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

//As monthly data will be used for the PMEWS, the monthly form data (containing clinical measurements) will have to be combined with the monthly//

// masterfile (containing comorbidity data) and the monthly patient file (containing patient age)

\*\*Cleaning the monthly adult form data// //Note: the directory below (and all subsequent file directories) will need to be modified as approriate by the user. use "R:\HPIRG\Flu-CATs\Last tranche\Monthly\form\_adults\_2015\_04.dta"

\*\*\*Converting dates from YMD to MDY
tostring submit\_date, gen( submit\_date2)
gen submit\_date3= date( submit\_date2, "YMD")
format submit\_date3 %td
drop submit\_date2 submit\_date
rename submit\_date3 submit\_date

\*\*Keeping only unique consultations (dropping duplicates)
bys patid submit\_date: gen new=\_n
keep if new==1
drop new
count

\*\*data management loops\*\*

\*\*measured/not measured variables\*\*

label define measurements 0 "Not measured" 1 "Measured"

local varlist " temperature respiratoryrate peripheraloxygensaturation heartrate bloodpressure"

foreach varname of local varlist {

encode `varname', gen(`varname'2) drop `varname' rename `varname'2 `varname' recode `varname' 2=0 label values `varname' measurements

}

\*\*measurement values\*\* local varlist "temperaturevalue respiratoryratevalue peripheraloxygensaturationvalue heartratevalue bloodpressuresystolic bloodpressurediastolic"

```
foreach varname of local varlist {
replace `varname'=" " if `varname'== "-"
destring `varname', replace
```

}

\*\*binary categorical (yes/no)\*\* label define binary\_categorical 0 "No" 1 "Yes" local varlist "patientonoxygen severerespiratorydistress respiratoryexhaustion severedehydration causingotherclinicalconcern treatwithantivirals treatwithantibiotics refertohospital"

foreach varname of local varlist {
 encode `varname', gen( `varname'2)
 drop `varname'
 rename `varname'2 `varname'
 recode `varname' 1=0
 recode `varname' 2=1
 label values `varname' binary\_categorical
}

\*\*capillary refill time: code normal as "0" and refill time>2 secs as "1"\*\* encode capillaryrefilltime, gen( capillaryrefilltime2) drop capillaryrefilltime rename capillaryrefilltime2 capillaryrefilltime recode capillaryrefilltime 1=0 recode capillaryrefilltime 2=1 label define capillaryrefilltime 0 "Grossly normal" 1 "sternal capillary refill>2 secs" label values capillaryrefilltime capillaryrefilltime \*\*patientoxygenvalue: this will show as blank if the previous field 'patientoxygen' was answered as "no"\*\*
encode patientonoxygenvalue, gen(patientonoxygenvalue2)
drop patientonoxygenvalue
rename patientonoxygenvalue2 patientonoxygenvalue
\*\*check these recode values carefully in new files as current file does not have any 'yes'\*\*
recode patientonoxygenvalue 1=9
recode patientonoxygenvalue 2=0
recode patientonoxygenvalue 3=1
label define patientoxygenvalue 9 "Not applicable" 0 "No" 1 "Yes", replace

label values patientonoxygenvalue patientoxygenvalue

\*\*newalteredconsciouslevel \*\*
encode newalteredconsciouslevel , gen(newalteredconsciouslevel2)
drop newalteredconsciouslevel
rename newalteredconsciouslevel2 newalteredconsciouslevel
\*\*Check coding before doing below
recode newalteredconsciouslevel 2=0
label define newalteredconsciousness 0 "No, patient alert" 1 "Confused/agitated" 2 "Responsive to voice only" 3 "Responsive to pain
only/unconscious", replace
label values newalteredconsciouslevel newalteredconsciousness

\*\*socialisolation\*\*
encode socialisolation, gen(socialisolation2)
drop socialisolation
rename socialisolation2 socialisolation
\*\*check codes in new files\*\*
recode socialisolation 1=0
recode socialisolation 3=1
\*\*keep 'unknown' as "2"\*\*
label define socialisolation 0 "No" 1 "Yes" 2 "Unknown"
label values socialisolation socialisolation

\*\*performance status\*\*
encode performancestatus, gen(performancestatus2)
drop performancestatus
rename performancestatus2 performancestatus
\*\*check codes in new file\*\*

\*\*derivation of values based CATs criteria\*\*
gen CAT\_triage\_A= severerespiratorydistress
label variable CAT\_triage\_A `"CAT triage criteria A- severe respiratory distress (yes/no)""
label values CAT\_triage\_A binary\_categorical

gen CAT\_triage\_B= . replace CAT\_triage\_B= 1 if respiratoryratevalue>30 & respiratoryratevalue !=. replace CAT\_triage\_B=0 if respiratoryratevalue<=30 label variable CAT\_triage\_B `"CAT triage criteria B (resp rate>30 breaths/min)- yes/no" label values CAT\_triage\_B binary\_categorical

gen CAT\_triage\_C=. replace CAT\_triage\_C=1 if peripheraloxygensaturationvalue<=92 & peripheraloxygensaturationvalue !=. replace CAT\_triage\_C=0 if peripheraloxygensaturationvalue>92 label variable CAT\_triage\_C `"CAT triage criteria C (peripheral oxygen <=92%)- yes/no"' label values CAT\_triage\_C binary\_categorical

gen CAT\_triage\_D=respiratoryexhaustion label variable CAT\_triage\_D `"CAT triage criteria D- respiratory exhaustion (yes/no)"' label values CAT\_triage\_D binary\_categorical

gen CAT\_triage\_E=.
replace CAT\_triage\_E=1 if capillaryrefilltime==1
replace CAT\_triage\_E=1 if bloodpressuresystolic<90
replace CAT\_triage\_E=1 if bloodpressurediastolic<60
replace CAT\_triage\_E=1 if severedehydration==1
recode CAT\_triage\_E .=0
label variable CAT\_triage\_E `"CAT triage criteria E (severe clinical dehydration)- yes/no"'
label values CAT\_triage\_E binary\_categorical</pre>

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton So16 7NS, UK.

#### **APPENDIX 3**

gen CAT\_triage\_F=. replace CAT\_triage\_F=0 if newalteredconsciouslevel==0 recode CAT\_triage\_F .=1 label variable CAT\_triage\_F `"CAT triage criteria E (new altered conscious level)- yes/no"' label values CAT\_triage\_F binary\_categorical

gen CAT\_triage\_G= causingotherclinicalconcern label variable CAT\_triage\_G `"CAT triage criteria G, causing other clinical concern (yes/no)"' label values CAT\_triage\_G binary\_categorical

\*create variable labels\*\* label variable patid `"unique patient identifier"' label variable pracid `"practice id"' label variable submit\_date `"presentation date"" label variable temperature `"temperature measurement (measured/not measured)"' label variable temperaturevalue `"temperature value in celsius; range allowed (35.0-42.0)" label variable severerespiratory distress "CAT triage criteria A- severe respiratory distress (yes/no)" label variable respiratoryexhaustion "CAT triage criteria D- respiratory exhaustion (yes/no)" label variable respiratoryrate `"respiratory rate (measured/not measured)" label variable respiratoryratevalue "respiratory rate- breaths per minute; range allowed (15-120)" label variable patientonoxygen `"patient on oxygen (yes/no)" label variable patientonoxygenvalue `"new oxygen need (yes/no)"' label variable peripheraloxygensaturation `"peripheral oxygen value (measured/not measured)" label variable peripheraloxygensaturationvalue `"peripheral oxygen saturation (%); range allowed (70-100)"' label variable heartrate `"heart rate (measured/not measured)" label variable heartratevalue `"heart rate value (beats per minute); range allowed (40-200)"' label variable bloodpressure `"blood pressure (measured/not measured)" label variable bloodpressuresystolic `"systolic blood pressure (mmHg); range allowed (70-250)"' label variable bloodpressurediastolic "diastolic blood pressure (mmHg); range allowed (40-150)" label variable capillaryrefilltime `"sternal capillary refill time: 1 if >2 seconds; 0= grossly normal"' label variable severedehydration `"severe dehydration (yes/no)" label variable newalteredconsciouslevel `"new altered consciousness level (alert; confused/agitated; voice; pain/unconscious)" label variable socialisolation `"lives alone or no fixed abode (yes/no/unknown)" label variable treatwithantivirals `"decision to treat with antivirals (yes/no)" label variable treatwithantibiotics `"decision to treat with antibiotics (yes/no)" label variable performancestatus `"activity and ability to self care (categorical variable)" label variable causingotherclinicalconcern "CAT triage criteria G, causing other clinical concern (yes/no)" label variable causingotherclinicalconcernvalue `"nature of clinical concern, free text" label variable refertohospital `"decision to refer to hospital (yes/no)"' order patid pracid formid submit date temperature temperaturevalue severerespiratorydistress respiratoryexhaustion respiratoryrate respiratoryratevalue patientonoxygen patientonoxygenvalue peripheraloxygensaturation peripheraloxygensaturationvalue heartrate

respiratoryratevalue patientonoxygen patientonoxygenvalue peripheraloxygensaturation peripheraloxygensaturation value heartratevalue bloodpressure bloodpressuresystolic bloodpressurediastolic capillaryrefilltime severedehydration newalteredconsciouslevel socialisolation performancestatus causingotherclinicalconcern causingotherclinicalconcernvalue treatwithantivirals treatwithantibiotics refertohospital CAT\_triage\_A CAT\_triage\_B CAT\_triage\_C CAT\_triage\_D CAT\_triage\_E CAT\_triage\_G

\*\*\*Merging clean monthly adult form file with masterfile to obtain comorbidity data
merge n:n patid using "R:\HPIRG\Flu-CATs\Last tranche\Monthly\masterfile\_2015\_04.dta"
\*\*Dropping children data
drop if cat=="child"
tab \_m
//the number of observations with \_m==3 must match the total number of adults in the masterfile
drop \_m

\*\*\*Merging with monthly patient file to obtain age data
merge n:n patid using "R:\HPIRG\Flu-CATs\Last tranche\Monthly\patient\_2015\_04.dta"
drop if cat=="child"
\*\*Keeping only unique consultations (dropping duplicates)
bys patid submit\_date: gen new=\_n
tab new
keep if new==1
count // this must equal the total number of adults in the clean monthly form file
drop \_m
\*\*\*Calculating the PMEWS

gen pmews\_rr =. order pmews\_rr, after(respiratoryratevalue) replace pmews\_rr=3 if (respiratoryratevalue <=8 | respiratoryratevalue >=30) & (respiratoryratevalue != .) replace pmews\_rr=0 if (respiratoryratevalue >8 & respiratoryratevalue <19) &(respiratoryratevalue != .) replace pmews\_rr=1 if (respiratoryratevalue >18 & respiratoryratevalue <26) & (respiratoryratevalue != .) replace pmews rr=2 if (respiratoryratevalue >25 & respiratoryratevalue <30) & (respiratoryratevalue != .)

gen pmews o2=. order pmews\_o2 pmews\_rr, after(peripheraloxygensaturationvalue) replace pmews\_o2=3 if (peripheraloxygensaturationvalue <89) & (peripheraloxygensaturationvalue !=.) replace pmews\_o2=2 if (peripheraloxygensaturationvalue >88 & peripheraloxygensaturationvalue <94) & (peripheraloxygensaturationvalue !=.) replace pmews\_o2=1 if (peripheraloxygensaturationvalue >93 & peripheraloxygensaturationvalue <97) & (peripheraloxygensaturationvalue !=.) replace pmews\_o2=0 if (peripheraloxygensaturationvalue >96) & (peripheraloxygensaturationvalue !=.) gen pmews\_hr=. order pmews\_hr, after(heartratevalue) replace pmews\_hr=3 if (heartratevalue <=40 | heartratevalue >= 130) & (heartratevalue !=.) replace pmews\_hr=2 if (heartratevalue >40 & heartratevalue <51) & (heartratevalue !=.) replace pmews hr=2 if (heartratevalue >110 & heartratevalue <130) & (heartratevalue !=.) replace pmews\_hr=1 if (heartratevalue >100 & heartratevalue <111) & (heartratevalue !=.) replace pmews\_hr=0 if (heartratevalue >50 & heartratevalue <101) & (heartratevalue !=.) gen pmews sysbp=. order pmews\_sysbp, after(bloodpressuresystolic) replace pmews sysbp=3 if (bloodpressuresystolic <=70) & (bloodpressuresystolic !=.) replace pmews\_sysbp=2 if (bloodpressuresystolic >70 & bloodpressuresystolic <91) & (bloodpressuresystolic !=.) replace pmews\_sysbp=1 if (bloodpressuresystolic >90 & bloodpressuresystolic <101) & (bloodpressuresystolic !=.) replace pmews\_sysbp=0 if (bloodpressuresystolic >100) & (bloodpressuresystolic !=.) gen pmews\_temp=. order pmews temp, after(temperaturevalue) replace pmews\_temp=2 if (temperaturevalue <=35 | temperaturevalue >=39) & (temperaturevalue !=.) replace pmews temp=1 if (temperaturevalue >35 & temperaturevalue <36.1) & (temperaturevalue !=.) replace pmews\_temp=1 if (temperaturevalue >=38 & temperaturevalue <39) & (temperaturevalue !=.) replace pmews\_temp=0 if (temperaturevalue >36 & temperaturevalue <38) & (temperaturevalue !=.) gen pmews\_neuro=. order pmews\_neuro, after(newalteredconsciouslevel) replace pmews\_neuro=0 if newalteredconsciouslevel== 0 replace pmews neuro=1 if newalteredconsciouslevel== 1 replace pmews\_neuro=2 if newalteredconsciouslevel== 2 replace pmews neuro=3 if newalteredconsciouslevel== 3 gen year of consultation=year(submit date) gen age\_at\_consultation=year\_of\_consultation-year gen pmews\_age65=1 if age\_at\_consultation>=65 & age\_at\_consultation !=. replace pmews\_age65=0 if age\_at\_consultation<65 & age\_at\_consultation !=. gen pmews\_living=1 if socialisolation==1 replace pmews\_living=0 if socialisolation==0 gen pmews\_chronic=1 if cardiovascular==1 | liver==1 | neurological==1 | renal==1 | respiratory==1 | diabetes==1 | immune\_supression==1

replace pmews\_chronic=0 if cardiovascular==0| liver==0| neurological==0| renal==0| respiratory==0| diabetes==0| immune supression==0

gen pmews performance=1 if performancestatus==5 replace pmews\_performance=2 if performancestatus==4 replace pmews performance=3 if performancestatus==3 replace pmews\_performance=4 if performancestatus==2 replace pmews\_performance=5 if performancestatus==1

gen

total\_pmews=pmews\_rr+pmews\_o2+pmews\_hr+pmews\_sysbp+pmews\_temp+pmews\_neuro+pmews\_age65+pmews\_living+pmews\_chr onic+pmews\_performance gen pmews2=1 if total pmews>=2 & total pmews !=. replace pmews2=0 if total\_pmews<2 & total\_pmews !=.

gen total\_cats=CAT\_triage\_A+CAT\_triage\_B+CAT\_triage\_C+CAT\_triage\_D+CAT\_triage\_E+CAT\_triage\_F+CAT\_triage\_G gen cats3=1 if total cats>=3 & total cats !=. replace cats3=0 if total cats<3 & total cats !=.

//The CATs and the PMEWS score can now be compared.
## **Appendix 4** Semistructured interview guide used to evaluate general practitioner user experience of study technological interface

Introduction	<ul> <li>Introduce interviewer and state the aim of the study</li> <li>Aim: To explore GPs' perspectives on participation in real-time surveillance study in collaboration with CPRD</li> <li>Mention that the call will be recorded</li> <li>Obtain consent</li> </ul>
Decision to participate in the Flu-CATs	<ul> <li>Who were you approached by to participate in the Flu-CATs?</li> <li>Motivation to participate in the FLU-CATs project?</li> <li>Any personal benefit?</li> <li>Any barriers to participation?</li> </ul>
Setting up the LEPIS system	• The general experience of having the LEPIS system set-up:
	<ul><li>How long did it take?</li><li>Were there any problems setting it up? Prompt to obtain more detail</li></ul>
The Flu-CATs consultation	<ul> <li>Roughly how long did each FLU-CATs consultation last?</li> <li>Was it different when compared to a 'routine' GP consultation? If so, how?</li> <li>Were there any challenges in recording FLU-CATs-related clinical measurements?</li> </ul>
	• Was any particular CATs criterion more difficult to record than others?
	<ul> <li>How was your experience of using the LEPIS system?</li> <li>Is there any other clinical parameter that you think might shed insight into influenza-related severe outcomes?</li> </ul>
Thoughts/reflections	Implementing this in a real pandemic scenario:
	<ul> <li>How feasible do you think it is?</li> <li>Do you think FLU-CATs consultations would be different in a pandemic scenario when compared to now (seasonal flu)?</li> </ul>
	<ul> <li>Is there anything you would like see improved?</li> <li>Would you be willing to participate in the FLU-CATs again (Winter of 2014–15)?</li> <li>Would you be interested in the reading the outputs from the FLU-CATs project?</li> <li>Is there anything else that you would like to add?</li> </ul>

# **Appendix 5** Covariate code lists

Read code	Read term
History of cardiovascular disease at any point	nt previous to the study consultation
G300	lschaemic heart disease
G580.00	Congestive heart failure
G313	IHD - Ischaemic heart disease
G5800	Heart failure
G3z00	lschaemic heart disease
G58z.00	Heart failure NOS
P6z00	Congenital heart anomaly NOS
G580100	Chronic congestive heart failure
G580.12	Right heart failure
G3y00	Other specified ischaemic heart disease
G3400	Other chronic ischaemic heart disease
P600	Other congenital heart anomalies
G34z.00	Other chronic ischaemic heart disease NOS
P6z3.00	Cyanotic congenital heart disease NOS
G342.00	Atherosclerotic cardiovascular disease
Рбу5.00	Congenital heart block
P512	Congenital heart disease, septal and bulbar anomalies
P6zz.00	Congenital heart anomaly NOS
P6800	Congenital heart disease
G34y.00	Other specified chronic ischaemic heart disease
G583.00	Heart failure with normal ejection fraction
G34yz00	Other specified chronic ischaemic heart disease NOS
P6z2.00	Acyanotic congenital heart disease NOS
G580400	Congestive heart failure due to valvular disease
G583.11	HFNEF - heart failure with normal ejection fraction
Gyu3300	[X]Other forms of chronic ischaemic heart disease
Рбу5000	Congenital heart block, unspecified
P6y5z00	Congenital heart block NOS
Gyu5g00	[X]Cardiovascular disease, unspecified
History of chronic liver disease at any point	previous to the study consultation
J6100	Cirrhosis and chronic liver disease
J614.00	Chronic hepatitis
J61z.00	Chronic liver disease NOS
J614z00	Chronic hepatitis NOS
J6200	Liver abscess and sequelae of chronic liver disease
PB61.00	Biliary atresia

Read code	Read term
J61y.00	Other non-alcoholic chronic liver disease
J62y.00	Other sequelae of chronic liver disease
J61yz00	Other non-alcoholic chronic liver disease NOS
J614y00	Chronic hepatitis unspecified
PB61z00	Biliary atresia NOS
History of chronic neurological disease at an	ny point previous to the study consultation
G6600	Stroke and cerebrovascular accident unspecified
G6512	Transient ischaemic attack
F2000	Multiple sclerosis
F2300	Congenital cerebral palsy
G6612	Stroke unspecified
G6413	Stroke due to cerebral arterial occlusion
G6112	Stroke due to intracerebral haemorrhage
G664.00	Cerebellar stroke syndrome
G663.00	Brain stem stroke syndrome
F230100	Cerebral palsy with spastic diplegia
F2311	Congenital spastic cerebral palsy
F137000	Athetoid cerebral palsy
F23z.00	Congenital cerebral palsy NOS
F2312	Infantile cerebral palsy
G669.00	Cerebral palsy, not congenital or infantile, acute
F207.00	Relapsing and remitting multiple sclerosis
F23y200	Spastic cerebral palsy
F208.00	Secondary progressive multiple sclerosis
F23y400	Ataxic diplegic cerebral palsy
F23y000	Ataxic infantile cerebral palsy
F23yz00	Other infantile cerebral palsy NOS
F202.00	Generalised multiple sclerosis
F206.00	Primary progressive multiple sclerosis
F23y300	Dyskinetic cerebral palsy
F23y.00	Other congenital cerebral palsy
F200.00	Multiple sclerosis of the brain stem
Fyu9.00	[X]Cerebral palsy and other paralytic syndromes
F201.00	Multiple sclerosis of the spinal cord
Fyu9000	[X]Other infantile cerebral palsy
F137.11	Athetoid cerebral palsy
F29y100	Postpolio syndrome
F23y100	Flaccid infantile cerebral palsy

Read code	Read term
History of chronic renal disease at any point	t previous to the study consultation
1Z12.00	Chronic kidney disease stage 3
K0500	Chronic renal failure
1Z13.00	Chronic kidney disease stage 4
K0100	Nephrotic syndrome
1Z15.00	Chronic kidney disease stage 3A
1Z1C.00	Chronic kidney disease stage 3 without proteinuria
1Z1E.00	Chronic kidney disease stage 3A without proteinuria
1Z14.00	Chronic kidney disease stage 5
1Z16.00	Chronic kidney disease stage 3B
K0Z00	Nephritis, nephrosis and nephrotic syndrome NOS
1Z1G.00	Chronic kidney disease stage 3B without proteinuria
1Z1B.00	Chronic kidney disease stage 3 with proteinuria
ZV42000	[V]Kidney transplanted
К000	Nephritis, nephrosis and nephrotic syndrome
1Z1J.00	Chronic kidney disease stage 4 without proteinuria
1Z1D.00	Chronic kidney disease stage 3A with proteinuria
1Z1H.00	Chronic kidney disease stage 4 with proteinuria
1Z1F.00	Chronic kidney disease stage 3B with proteinuria
K011.00	Nephrotic syndrome with membranous glomerulonephritis
K01z.00	Nephrotic syndrome NOS
1Z1K.00	Chronic kidney disease stage 5 with proteinuria
K01x100	Nephrotic syndrome in diabetes mellitus
TB00111	Renal transplant with complication, without blame
K013.00	Nephrotic syndrome with minimal change glomerulonephritis
K015.00	Nephrotic syndrome, focal and segmental glomerular lesions
K016.00	Nephrotic syndrome, diffuse membranous glomerulonephritis
1Z1L.00	Chronic kidney disease stage 5 without proteinuria
K01x000	Nephrotic syndrome in amyloidosis
K014.00	Nephrotic syndrome, minor glomerular abnormality
K013.12	Steroid sensitive nephrotic syndrome
K01x400	Nephrotic syndrome in systemic lupus erythematosus
K01B.00	Nephrotic syndrome, diffuse crescentic glomerulonephritis
TB00100	Kidney transplant with complication, without blame
К0у00	Other specified nephritis, nephrosis or nephrotic syndrome
K01w.00	Congenital nephrotic syndrome
K010.00	Nephrotic syndrome with proliferative glomerulonephritis
K01A.00	Nephrotic syndrome, dense deposit disease
Kyu2100	[X]Other chronic renal failure

Read code	Read term
K01x300	Nephrotic syndrome in polyarteritis nodosa
K01y.00	Nephrotic syndrome with other pathological kidney lesions
K012.00	Nephrotic syndrome+membranoproliferative glomerulonephritis
History of chronic respiratory disease at any	point previous to the study consultation
H3300	Asthma
H300	Chronic obstructive pulmonary disease
H333.00	Acute exacerbation of asthma
H33zz00	Asthma NOS
H33z100	Asthma attack
H3400	Bronchiectasis
H3600	Mild chronic obstructive pulmonary disease
H3311	Bronchial asthma
H3200	Emphysema
H33z011	Severe asthma attack
H3100	Chronic bronchitis
H3800	Severe chronic obstructive pulmonary disease
H330.00	Extrinsic (atopic) asthma
H330.12	Childhood asthma
663V100	Mild asthma
C370.00	Cystic fibrosis
H330.11	Allergic asthma
663V200	Moderate asthma
H331.00	Intrinsic asthma
10200	Asthma confirmed
H330011	Hay fever with asthma
H330.13	Hay fever with asthma
H331.11	Late onset asthma
H31z.00	Chronic bronchitis NOS
H33z000	Status asthmaticus NOS
H58y300	Interstitial lung disease NEC
H330.14	Pollen asthma
H330111	Extrinsic asthma with asthma attack
H330000	Extrinsic asthma without status asthmaticus
H33z200	Late-onset asthma
663V300	Severe asthma
H33z111	Asthma attack NOS
H310000	Chronic catarrhal bronchitis
H312000	Chronic asthmatic bronchitis
H34z.00	Bronchiectasis NOS

Read code	Read term
H312100	Emphysematous bronchitis
H3900	Very severe chronic obstructive pulmonary disease
H4500	Pneumoconiosis NOS
H32z.00	Emphysema NOS
H330z00	Extrinsic asthma NOS
H3z11	Chronic obstructive pulmonary disease NOS
Q317000	Perinatal bronchopulmonary dysplasia
H334.00	Brittle asthma
H312011	Chronic wheezy bronchitis
H43z.00	Pneumoconiosis due to inorganic dust NOS
H320.00	Chronic bullous emphysema
H331000	Intrinsic asthma without status asthmaticus
H331z00	Intrinsic asthma NOS
H340.00	Recurrent bronchiectasis
H311.00	Mucopurulent chronic bronchitis
C370z00	Cystic fibrosis NOS
66Yi.00	Multiple COPD emergency hospital admissions
H330100	Extrinsic asthma with status asthmaticus
A115.00	Tuberculous bronchiectasis
H4000	Coal workers' pneumoconiosis
C370200	Cystic fibrosis with pulmonary manifestations
H322.00	Centrilobular emphysema
SK07.00	Subcutaneous emphysema
H581.00	Interstitial emphysema
H331111	Intrinsic asthma with asthma attack
H33zz12	Allergic asthma NEC
Q317.00	Perinatal chronic respiratory disease
H591.00	Chronic respiratory failure
H320z00	Chronic bullous emphysema NOS
H341.00	Post-infective bronchiectasis
H331100	Intrinsic asthma with status asthmaticus
H42z.00	Silica pneumoconiosis NOS
H31y100	Chronic tracheobronchitis
H32yz00	Other emphysema NOS
Hyu3100	[X]Other specified chronic obstructive pulmonary disease
H311000	Purulent chronic bronchitis
H4200	Silica and silicate pneumoconiosis
H32y.00	Other emphysema
H310z00	Simple chronic bronchitis NOS

Read code	Read term
H313.00	Mixed simple and mucopurulent chronic bronchitis
H32y200	MacLeod's unilateral emphysema
H464.00	Chronic respiratory conditions due to chemical fumes
Q317z00	Perinatal chronic respiratory disease NOS
P861.00	Congenital bronchiectasis
H321.00	Panlobular emphysema
H320200	Giant bullous emphysema
H31y.00	Other chronic bronchitis
H31yz00	Other chronic bronchitis NOS
H4300	Pneumoconiosis due to other inorganic dust
Q312.00	Perinatal interstitial emphysema and related conditions
H320000	Segmental bullous emphysema
H320100	Zonal bullous emphysema
C370100	Cystic fibrosis with meconium ileus
H582.00	Compensatory emphysema
C370y00	Cystic fibrosis with other manifestations
C370300	Cystic fibrosis with intestinal manifestations
Hyu3000	[X]Other emphysema
H320300	Bullous emphysema with collapse
H4y2100	Chronic drug-induced interstitial lung disorders
Q317y00	Other specified perinatal chronic respiratory disease
Q312111	Perinatal mediastinal emphysema
H464000	Chronic emphysema due to chemical fumes
H3y11	Other specified chronic obstructive pulmonary disease
C370500	Cystic fibrosis with distal intestinal obstruction syndrome
H450.00	Pneumoconiosis associated with tuberculosis
H311100	Fetid chronic bronchitis
H420.00	Talc pneumoconiosis
H32y100	Atrophic (senile) emphysema
C370400	Arthropathy in cystic fibrosis
H32y111	Acute interstitial emphysema
C370000	Cystic fibrosis with no meconium ileus
H464z00	Chronic respiratory conditions due to chemical fumes NOS
H32y000	Acute vesicular emphysema
C370800	Cystic fibrosis related cirrhosis
History of diabetes at any point previous to	the study consultation
C1000	Diabetes mellitus
C10F.00	Type 2 diabetes mellitus
C100112	Non-insulin dependent diabetes mellitus

Read code	Read term
C109.00	Non-insulin dependent diabetes mellitus
C10E.00	Type 1 diabetes mellitus
C109.12	Type 2 diabetes mellitus
C100011	Insulin dependent diabetes mellitus
C100111	Maturity onset diabetes
C100100	Diabetes mellitus, adult onset, no mention of complication
C101.00	Diabetes mellitus with ketoacidosis
C10FJ00	Insulin treated Type 2 diabetes mellitus
C106.00	Diabetes mellitus with neurological manifestation
C106.12	Diabetes mellitus with neuropathy
C108.11	IDDM-Insulin dependent diabetes mellitus
C10FM00	Type 2 diabetes mellitus with persistent microalbuminuria
C108.12	Type 1 diabetes mellitus
C109.11	NIDDM - Non-insulin dependent diabetes mellitus
C109.13	Type II diabetes mellitus
C10EM00	Type 1 diabetes mellitus with ketoacidosis
C109J00	Insulin treated Type 2 diabetes mellitus
C10FL00	Type 2 diabetes mellitus with persistent proteinuria
C10F.11	Type II diabetes mellitus
C10FC00	Type 2 diabetes mellitus with nephropathy
C10F600	Type 2 diabetes mellitus with retinopathy
C107.00	Diabetes mellitus with peripheral circulatory disorder
C105.00	Diabetes mellitus with ophthalmic manifestation
C104.00	Diabetes mellitus with renal manifestation
66AJ.11	Unstable diabetes
C108.13	Type I diabetes mellitus
C10F900	Type 2 diabetes mellitus without complication
C10E.12	Insulin dependent diabetes mellitus
C10FN00	Type 2 diabetes mellitus with ketoacidosis
C100z00	Diabetes mellitus NOS with no mention of complication
C108900	Insulin dependent diabetes maturity onset
C10EK00	Type 1 diabetes mellitus with persistent proteinuria
C10ED00	Type 1 diabetes mellitus with nephropathy
C10E700	Type 1 diabetes mellitus with retinopathy
C10EL00	Type 1 diabetes mellitus with persistent microalbuminuria
C10FK00	Hyperosmolar non-ketotic state in type 2 diabetes mellitus
C101z00	Diabetes mellitus NOS with ketoacidosis
C104z00	Diabetes mellitus with nephropathy NOS
C11y000	Steroid induced diabetes

Read code	Read term
C10D.00	Diabetes mellitus autosomal dominant type 2
C107.11	Diabetes mellitus with gangrene
C106z00	Diabetes mellitus NOS with neurological manifestation
C108700	Insulin dependent diabetes mellitus with retinopathy
C109900	Non-insulin-dependent diabetes mellitus without complication
C109400	Non-insulin dependent diabetes mellitus with ulcer
K01x100	Nephrotic syndrome in diabetes mellitus
C108500	Insulin dependent diabetes mellitus with ulcer
C10E.11	Type I diabetes mellitus
C106100	Diabetes mellitus, adult onset, + neurological manifestation
C10EN00	Type 1 diabetes mellitus with ketoacidotic coma
C10G.00	Secondary pancreatic diabetes mellitus
C10FB00	Type 2 diabetes mellitus with polyneuropathy
C105z00	Diabetes mellitus NOS with ophthalmic manifestation
C10F911	Type II diabetes mellitus without complication
C10F000	Type 2 diabetes mellitus with renal complications
C10FQ00	Type 2 diabetes mellitus with exudative maculopathy
C10C.11	Maturity onset diabetes in youth
C10FH00	Type 2 diabetes mellitus with neuropathic arthropathy
C10F200	Type 2 diabetes mellitus with neurological complications
C10EQ00	Type 1 diabetes mellitus with gastroparesis
C10FE00	Type 2 diabetes mellitus with diabetic cataract
C109600	Non-insulin-dependent diabetes mellitus with retinopathy
C10B000	Steroid induced diabetes mellitus without complication
C10F400	Type 2 diabetes mellitus with ulcer
C107.12	Diabetes with gangrene
Cyu2.00	[X]Diabetes mellitus
C105100	Diabetes mellitus, adult onset, + ophthalmic manifestation
C10FR00	Type 2 diabetes mellitus with gastroparesis
C10zz00	Diabetes mellitus NOS with unspecified complication
C10FJ11	Insulin treated Type II diabetes mellitus
C101000	Diabetes mellitus, juvenile type, with ketoacidosis
C10EE00	Type 1 diabetes mellitus with hypoglycaemic coma
C106000	Diabetes mellitus, juvenile, + neurological manifestation
C107z00	Diabetes mellitus NOS with peripheral circulatory disorder
C10FD00	Type 2 diabetes mellitus with hypoglycaemic coma
C106.13	Diabetes mellitus with polyneuropathy
C108400	Unstable insulin dependent diabetes mellitus
C10z.00	Diabetes mellitus with unspecified complication

Read code	Read term
C10y.00	Diabetes mellitus with other specified manifestation
C10FA00	Type 2 diabetes mellitus with mononeuropathy
C10FL11	Type II diabetes mellitus with persistent proteinuria
C10F100	Type 2 diabetes mellitus with ophthalmic complications
C10EP00	Type 1 diabetes mellitus with exudative maculopathy
C109C00	Non-insulin dependent diabetes mellitus with nephropathy
C10N100	Cystic fibrosis related diabetes mellitus
C10ER00	Latent autoimmune diabetes mellitus in adult
C10z100	Diabetes mellitus, adult onset, + unspecified complication
C108E00	Insulin dependent diabetes mellitus with hypoglycaemic coma
C10EJ00	Type 1 diabetes mellitus with neuropathic arthropathy
C10EA00	Type 1 diabetes mellitus without complication
C104100	Diabetes mellitus, adult onset, with renal manifestation
L180600	Pre-existing diabetes mellitus, non-insulin-dependent
C10F500	Type 2 diabetes mellitus with gangrene
C10E500	Type 1 diabetes mellitus with ulcer
C10E900	Type 1 diabetes mellitus maturity onset
C107200	Diabetes mellitus, adult with gangrene
C10E400	Unstable type 1 diabetes mellitus
C10FF00	Type 2 diabetes mellitus with peripheral angiopathy
C10E000	Type 1 diabetes mellitus with renal complications
C101100	Diabetes mellitus, adult onset, with ketoacidosis
C109J12	Insulin treated Type II diabetes mellitus
C107100	Diabetes mellitus, adult, + peripheral circulatory disorder
C10E300	Type 1 diabetes mellitus with multiple complications
C10F611	Type II diabetes mellitus with retinopathy
C108000	Insulin-dependent diabetes mellitus with renal complications
C10FG00	Type 2 diabetes mellitus with arthropathy
C10F300	Type 2 diabetes mellitus with multiple complications
C102100	Diabetes mellitus, adult onset, with hyperosmolar coma
C10FP00	Type 2 diabetes mellitus with ketoacidotic coma
C10D.11	Maturity onset diabetes in youth type 2
C10EM11	Type I diabetes mellitus with ketoacidosis
C10E200	Type 1 diabetes mellitus with neurological complications
C101y00	Other specified diabetes mellitus with ketoacidosis
C109411	Type II diabetes mellitus with ulcer
C10EC00	Type 1 diabetes mellitus with polyneuropathy
C109J11	Insulin treated non-insulin dependent diabetes mellitus
C10EF00	Type 1 diabetes mellitus with diabetic cataract

Read code	Read term
C108A00	Insulin-dependent diabetes without complication
C106y00	Other specified diabetes mellitus with neurological comps
C109100	Non-insulin-dependent diabetes mellitus with ophthalm comps
C109000	Non-insulin-dependent diabetes mellitus with renal comps
C108512	Type 1 diabetes mellitus with ulcer
C108E11	Type I diabetes mellitus with hypoglycaemic coma
C109612	Type 2 diabetes mellitus with retinopathy
C109200	Non-insulin-dependent diabetes mellitus with neuro comps
C108D00	Insulin dependent diabetes mellitus with nephropathy
C109212	Type 2 diabetes mellitus with neurological complications
C10E100	Type 1 diabetes mellitus with ophthalmic complications
C108100	Insulin-dependent diabetes mellitus with ophthalmic comps
C109412	Type 2 diabetes mellitus with ulcer
C109E00	Non-insulin depend diabetes mellitus with diabetic cataract
C104y00	Other specified diabetes mellitus with renal complications
C108C00	Insulin dependent diabetes mellitus with polyneuropathy
C10E312	Insulin dependent diabetes mellitus with multiple complicat
C109B00	Non-insulin dependent diabetes mellitus with polyneuropathy
C108300	Insulin dependent diabetes mellitus with multiple complicatn
C10yz00	Diabetes mellitus NOS with other specified manifestation
C109C12	Type 2 diabetes mellitus with nephropathy
C108711	Type I diabetes mellitus with retinopathy
C109E11	Type II diabetes mellitus with diabetic cataract
C108511	Type I diabetes mellitus with ulcer
C108600	Insulin dependent diabetes mellitus with gangrene
C10zy00	Other specified diabetes mellitus with unspecified comps
C109H12	Type 2 diabetes mellitus with neuropathic arthropathy
C10FA11	Type II diabetes mellitus with mononeuropathy
C10EH00	Type 1 diabetes mellitus with arthropathy
C109500	Non-insulin dependent diabetes mellitus with gangrene
C108712	Type 1 diabetes mellitus with retinopathy
C10F311	Type II diabetes mellitus with multiple complications
C109D00	Non-insulin dependent diabetes mellitus with hypoglyca coma
C109011	Type II diabetes mellitus with renal complications
C109300	Non-insulin-dependent diabetes mellitus with multiple comps
С10уу00	Other specified diabetes mellitus with other spec comps
C108y00	Other specified diabetes mellitus with multiple comps
C108200	Insulin-dependent diabetes mellitus with neurological comps
C10E600	Type 1 diabetes mellitus with gangrene

Read code	Read term
C10FE11	Type II diabetes mellitus with diabetic cataract
C109012	Type 2 diabetes mellitus with renal complications
C102000	Diabetes mellitus, juvenile type, with hyperosmolar coma
C108F00	Insulin dependent diabetes mellitus with diabetic cataract
C109E12	Type 2 diabetes mellitus with diabetic cataract
C109H11	Type II diabetes mellitus with neuropathic arthropathy
C109511	Type II diabetes mellitus with gangrene
C10y100	Diabetes mellitus, adult, + other specified manifestation
C10z000	Diabetes mellitus, juvenile type, + unspecified complication
C102z00	Diabetes mellitus NOS with hyperosmolar coma
C103000	Diabetes mellitus, juvenile type, with ketoacidotic coma
C109D12	Type 2 diabetes mellitus with hypoglycaemic coma
C103z00	Diabetes mellitus NOS with ketoacidotic coma
C10EB00	Type 1 diabetes mellitus with mononeuropathy
C105000	Diabetes mellitus, juvenile type, + ophthalmic manifestation
C10E511	Type I diabetes mellitus with ulcer
C10E911	Type I diabetes mellitus maturity onset
C10E912	Insulin dependent diabetes maturity onset
C10FD11	Type II diabetes mellitus with hypoglycaemic coma
C10FC11	Type II diabetes mellitus with nephropathy
C108012	Type 1 diabetes mellitus with renal complications
C109G00	Non-insulin dependent diabetes mellitus with arthropathy
C109512	Type 2 diabetes mellitus with gangrene
C105y00	Other specified diabetes mellitus with ophthalmic complicatn
C10E411	Unstable type I diabetes mellitus
C108011	Type I diabetes mellitus with renal complications
C109C11	Type II diabetes mellitus with nephropathy
C10F411	Type II diabetes mellitus with ulcer
C10C.12	Maturity onset diabetes in youth type 1
C10E611	Type I diabetes mellitus with gangrene
C108F11	Type I diabetes mellitus with diabetic cataract
C10FB11	Type II diabetes mellitus with polyneuropathy
C10E412	Unstable insulin dependent diabetes mellitus
C109F11	Type II diabetes mellitus with peripheral angiopathy
C10F011	Type II diabetes mellitus with renal complications
C108212	Type 1 diabetes mellitus with neurological complications
C108D11	Type I diabetes mellitus with nephropathy
C10FM11	Type II diabetes mellitus with persistent microalbuminuria
C10E712	Insulin dependent diabetes mellitus with retinopathy

Read code	Read term
C10E711	Type I diabetes mellitus with retinopathy
C108J12	Type 1 diabetes mellitus with neuropathic arthropathy
C109B11	Type II diabetes mellitus with polyneuropathy
C108411	Unstable type I diabetes mellitus
C108J11	Type I diabetes mellitus with neuropathic arthropathy
C108H00	Insulin dependent diabetes mellitus with arthropathy
C109211	Type II diabetes mellitus with neurological complications
C10E311	Type I diabetes mellitus with multiple complications
C10F111	Type II diabetes mellitus with ophthalmic complications
C108812	Type 1 diabetes mellitus - poor control
C109D11	Type II diabetes mellitus with hypoglycaemic coma
C109111	Type II diabetes mellitus with ophthalmic complications
C109F12	Type 2 diabetes mellitus with peripheral angiopathy
C10EA11	Type I diabetes mellitus without complication
C108z00	Unspecified diabetes mellitus with multiple complications
C103100	Diabetes mellitus, adult onset, with ketoacidotic coma
C107000	Diabetes mellitus, juvenile +peripheral circulatory disorder
C108E12	Type 1 diabetes mellitus with hypoglycaemic coma
C109A00	Non-insulin dependent diabetes mellitus with mononeuropathy
C10EG00	Type 1 diabetes mellitus with peripheral angiopathy
C108912	Type 1 diabetes mellitus maturity onset
C108412	Unstable type 1 diabetes mellitus
C10F211	Type II diabetes mellitus with neurological complications
C10EA12	Insulin-dependent diabetes without complication
Cyu2300	[X]Unspecified diabetes mellitus with renal complications
C10E012	Insulin-dependent diabetes mellitus with renal complications
C108B00	Insulin dependent diabetes mellitus with mononeuropathy
C108211	Type I diabetes mellitus with neurological complications
C109G12	Type 2 diabetes mellitus with arthropathy
C109A11	Type II diabetes mellitus with mononeuropathy
C108H11	Type I diabetes mellitus with arthropathy
C108911	Type I diabetes mellitus maturity onset
C10EN11	Type I diabetes mellitus with ketoacidotic coma
C109112	Type 2 diabetes mellitus with ophthalmic complications
C10EC11	Type I diabetes mellitus with polyneuropathy
C104000	Diabetes mellitus, juvenile type, with renal manifestation
C108A11	Type I diabetes mellitus without complication
C10EP11	Type I diabetes mellitus with exudative maculopathy
C10E112	Insulin-dependent diabetes mellitus with ophthalmic comps

Read code	Read term		
C10E512	Insulin dependent diabetes mellitus with ulcer		
C108B11	Type I diabetes mellitus with mononeuropathy		
C10E111	Type I diabetes mellitus with ophthalmic complications		
Куи0300	[X]Glomerular disorders in diabetes mellitus		
C10EE12	Insulin dependent diabetes mellitus with hypoglycaemic coma		
C10EF12	Insulin dependent diabetes mellitus with diabetic cataract		
C10EC12	Insulin dependent diabetes mellitus with polyneuropathy		
C10E212	Insulin-dependent diabetes mellitus with neurological comps		
C10ED12	Insulin dependent diabetes mellitus with nephropathy		
C10EL11	Type I diabetes mellitus with persistent microalbuminuria		
C108112	Type 1 diabetes mellitus with ophthalmic complications		
C10FF11	Type II diabetes mellitus with peripheral angiopathy		
C10F511	Type II diabetes mellitus with gangrene		
History of immunosuppressive conditions at	any point previous to the study consultation		
43C3.11	HIV positive		
A788.11	Human immunodeficiency virus infection		
A788.00	Acquired immune deficiency syndrome		
7840.00	Total excision of spleen		
PK01.11	Asplenia		
D415700	Splenic infarction		
A788z00	Acquired human immunodeficiency virus infection syndrome NOS		
РК000	Anomalies of spleen		
PK01.00	Absent spleen		
D415.00	Other diseases of spleen		
D415z00	Disease of spleen NOS		
A788000	Acute human immunodeficiency virus infection		
A789000	HIV disease resulting in mycobacterial infection		
8C31.00	Transplant immunosuppression		
7840z00	Total excision of spleen NOS		
A789400	HIV disease resulting in multiple infections		
B905300	Neoplasm of uncertain behaviour of spleen		
A789A00	HIV disease resulting in wasting syndrome		
A789600	HIV disease resulting in Burkitt's lymphoma		
7841.00	Other excision of spleen		
PK0z.00	Anomalies of spleen NOS		
D415400	Splenic atrophy		
A788y00	Human immunodeficiency virus with other clinical findings		
A789700	HIV dis resulting in both types of non-Hodgkin's lymphoma		
A789900	HIV disease resulting in lymphoid interstitial pneumonitis		

Read code	Read term		
A788W00	HIV disease resulting in unspecified malignant neoplasm		
A788200	HIV infection with persistent generalised lymphadenopathy		
A789X00	HIV dis reslt/oth mal neopl/lymph,h'matopoetc+reltd tissu		
A789100	HIV disease resulting in cytomegaloviral disease		
A788500	Human immunodeficiency virus with secondary infection		
A788400	Human immunodeficiency virus with neurological disease		
A788300	Human immunodeficiency virus with constitutional disease		
A788U00	HIV disease result/haematological+immunologic abnorms,NEC		
A788X00	HIV disease resulting/unspcf infectious+parasitic disease		
D415600	Splenic fibrosis		
AyuC600	[X]HIV disease resulting in other non-Hodgkin's lymphoma		
AyuCB00	[X]HIV disease result/haematological+immunologic abnorms,NEC		
AyuC300	[X]HIV disease resulting in multiple infections		
AyuCC00	[X]HIV disease resulting in other specified conditions		
AyuC400	[X]HIV disease resulting/other infectious+parasitic diseases		
A789800	HIV disease resulting in multiple malignant neoplasms		
AyuCD00	[X]Unspecified human immunodeficiency virus [HIV] disease		
A788600	Human immunodeficiency virus with secondary cancers		
B62y700	Malignant lymphoma NOS of spleen		
B1z1.00	Malignant neoplasm of spleen NEC		
History of immunosuppressive therapy in th	e year previous to the study consultation		
8BAD.00	Chemotherapy		
8BA5.00	Oral chemotherapy		
7L16100	Intravenous chemotherapy		
8BAD000	Cancer chemotherapy		
7L18200	Intramuscular chemotherapy		
7L1d.00	Delivery of chemotherapy for neoplasm		
8BAL.00	Combined pre-operative chemotherapy and radiotherapy		
7L1dz00	Delivery of chemotherapy for neoplasm NOS		
7L1e.00	Delivery of oral chemotherapy for neoplasm		
7L1ez00	Delivery of oral chemotherapy for neoplasm NOS		
7L1dy00	Other specified delivery of chemotherapy for neoplasm		

## Appendix 6 FLU-CATs Data Handbook

#### **Data sets**

Data for the Flu-CATs Study are collected and uploaded on a weekly and on a monthly basis on to Dropbox by Emma Boyle from CPRD. Each week, two data sets are saved on to Dropbox: one each for children and adults. The following naming convention is followed for the weekly data sets: adults\_YYYYMMDD and child\_YYYYMMDD, with the date of the Monday for each week, for adult and children data sets, respectively.

Each monthly upload comprises four data sets: one data set each with LEPIS form data for adults and children (named form\_adults\_YYYY\_MM and form\_child\_YYYY\_MM); one 'master file' (named masterfile\_YYYY\_MM) containing data on comorbidities, selected treatments and vaccinations; and one 'patient file' (named patient\_YYYY\_MM) containing data that includes dates of death and transfer-out dates.

The weekly data sets are uploaded as tab-delimited text files on to Dropbox and the monthly data sets are saved as Stata files. Detailed data dictionaries for each of the weekly and monthly data sets are provided in the appendix.

## 'Do files'

*Data management* Some data management is necessary for the weekly data sets before they can be analysed. The weekly data sets are saved as text files. They will first need to be downloaded off Dropbox and then 'insheeted' into Stata so as to convert them into Stata format. Once this is done, the relevant data management 'do file' will need to be run.

Separate data management 'do files' have been prepared for adults and children. Each of the 'do files' is to be opened in Stata after the weekly FLU-CATs file has been 'insheeted' into Stata. Once 'insheeted', the 'do file' may be executed and this should result in a complete run of the 'do file' with no errors. The resulting 'clean' file may then be saved as a Stata file. The 'clean' weekly data files will contain clinical measurements and other data collected through the LEPIS form in addition to each of the seven CATs criteria.

The monthly Flu-CATs data uploads require some minimal data management, which is included in the automation do file. The monthly data uploads do not require any additional data management. The automation and analysis 'do files' may be run directly on the files downloaded off Dropbox.

*PMEWS* and *CATs* A separate 'do file' has been written to calculate PMEWS scores in adults. Although the physiological data (MEWS) component can be carried out, using the weekly data downloads, to score the patient data, merging with the monthly data downloads from CPRD will be required as comorbidity data and patient age data are needed. The PMEWS 'do file' performs the necessary data management and generates cumulative PMEWS and CATs scores for the data set.

## **Data reports**

'Do files' have been written to generate weekly and monthly FLU-CATs data reports. Separate 'do files' have been written for adult data and children data, although they are both identical except for the three variables that are present only in the adult data set (blood pressure, social isolation and performance status).

#### Weekly reports

For weekly reports, the 'clean' weekly Stata file is to be used. The input and output directories will need to be checked and modified if necessary. Once this has been done, the 'do file' may be executed. This should result in a complete run with no errors and a new Excel spreadsheet (titled 'Results.xls') with the weekly report should be created in the specified output folder. It is recommended that the results Excel spreadsheet is copied and re-saved in a different directory before running the next set of analyses, as these the 'do files' are programmed to overwrite the existing results spreadsheet.

At the time of writing this handbook, the latest tranche of weekly data for children (uploaded on 27 April 2015) does not have sufficient observations for outcome #1– 'decision to treat with antivirals' to obtain ORs, unadjusted or adjusted, for association with each of the CATs criteria. Because of this, the automated weekly report 'do file' terminates at this point. Until sufficient numbers for this outcome are obtained, the following is recommended:

- i. Run the 'do file' until the error message is seen (until Outcome #1).
- ii. At this point, select portions of the 'do file' from Outcome #2 onwards and execute.

#### Monthly reports

From the monthly tranche of FLU-CATs data, the 'master file' and the 'patient file' will be used to generate a word document summarising findings for each month. As with the weekly data report 'do files', the directories with have to be checked and modified if necessary. Once this has been done, the 'do file' may be executed. This should result in a complete run with no errors and a new Word document (titled 'mydoc1.rtf') with the monthly report should be created in the specified output folder.

#### Notes

- The monthly report 'do file' is best run in new Stata program window. If any changes are made to the 'do file' midway through executing the 'do file', save the changes (as a separate 'do file', if needed), close Stata and reopen the 'do file' in a new Stata window.
- The monthly report document (opens in Word) will need to have all of the plots (saved as 'myplot1.eps', 'myplot2.eps', and so on) presented within the document to be saved in the same folder as the monthly report document itself. This must be kept in mind while e-mailing or sharing monthly reports– all plot files will have to be shared along with the report itself.

## **Data set descriptions**

## Weekly data set: adult (as provided by Clinical Practice Research Datalink)

Variable name	Туре	Description
patid	long	Unique patient identifier
pracid	int	Unique practice identifier
formid	int	Unique LEPIS form identifier
submit_date	long	Date of submission of FLU-CATs form (assumed to be the date of FLU-CATs consultation)
cat	str5	Category: adults/children (all adults in this data set)
gender	byte	Gender: male or female
birthyear	int	Patient's year of birth
mob	byte	Patient's month of birth (for those aged under 16). 0 indicates no month set
frddate	str10	Date the patient first registered with the practice
regdate	str10	
utsdate	str10	Date at which the practice data is deemed to be of research quality
todate	str10	Date the patient transferred out of the practice, if relevant. Empty for patients who have not transferred out
toreason	byte	Reason the patient transferred out of the practice
deathdate	str10	Date of death of patient
lcdate	str10	Date of the last collection for the practice
accept	byte	Flag to indicate whether the patient has met certain quality standards: $1 = $ acceptable, $0 = $ unacceptable
temperature	str32	Body temperature: measured/not measured
temperaturevalue	str4	Body temperature value in °C
severerespiratorydistress	str3	Severe respiratory distress– yes/no
respiratoryexhaustion	str3	Respiratory exhaustion: yes/no
respiratoryrate	str32	Respiratory rate: measured/not measured
respiratoryratevalue	str2	Respiratory rate value in breaths per minute
patientonoxygen	str3	Is the patient on oxygen? yes/no
patientonoxygenvalue	str2	Is this oxygen need new and related to this episode? yes/no
peripheraloxygensaturation	str30	Peripheral oxygen saturation: measured/not measured
peripheraloxygensaturationvalue	str3	Peripheral oxygen saturation value (%)
heartrate	str32	Heart rate: measured/not measured
heartratevalue	str3	Numerical heart rate value
bloodpressure	str12	Blood pressure: measured/not measured
bloodpressuresystolic	str3	Systolic blood pressure value (mmHg)
bloodpressurediastolic	str3	Diastolic blood pressure value (mmHg)
capillaryrefilltime	str40	Capillary refill time: measured/not measured
severedehydration	str2	Signs of severe dehydration: yes/no
newalteredconsciouslevel	str21	New altered consciousness level: alert/confused or agitated/ response to voice only/response to pain only

Variable name	Туре	Description
socialisolation	str7	Lives alone or no fixed abode: yes/no/unknown
performancestatus	str48	Patient's usual activity and ability to self-care prior to this acute illness
causingotherclinicalconcern	str3	Causing other clinical concern? yes/no
causingotherclinicalconcernvalue	str150	Description of the clinical concern ( $\leq$ 150 characters)
treatwithantivirals	str3	Decision to treat with antivirals: yes/no
treatwithantibiotics	str3	Decision to treat with antibiotics: yes/no
refertohospital	str3	Decision to refer to hospital: yes/no

## Weekly data set: children (as provided by Clinical Practice Research Datalink)

Variable name	Туре	Description
patid	long	Unique patient identifier
pracid	int	Unique practice identifier
formid	int	Unique LEPIS form identifier
submit_date	long	Date of submission of Flu-CATs form (assumed to be the date of Flu-CATs consultation)
cat	str5	Category: adults/children (all children in this data set)
gender	byte	Gender: male of female
birthyear	int	Patient's year of birth
mob	byte	Patient's month of birth (for those aged under 16). 0 indicates no month set
frddate	str10	Date the patient first registered with the practice
regdate	str10	
utsdate	str10	Date at which the practice data is deemed to be of research quality
todate	str10	Date the patient transferred out of the practice, if relevant. Empty for patients who have not transferred out
toreason	byte	Reason the patient transferred out of the practice
deathdate	str10	Date of death of patient
lcdate	str10	Date of the last collection for the practice
accept	byte	Flag to indicate whether the patient has met certain quality standards: 1 = acceptable, 0 = unacceptable
temperature	str32	Body temperature: measured/not measured
temperaturevalue	str4	Body temperature value in °C
severerespiratorydistress	str3	Severe respiratory distress: yes/no
respiratoryexhaustion	str3	Respiratory exhaustion: yes/no
respiratoryrate	str32	Respiratory rate: measured/not measured
respiratoryratevalue	str2	Respiratory rate value in breaths per minute
patientonoxygen	str3	Is the patient on oxygen? yes/no
patientonoxygenvalue	str2	Is this oxygen need new and related to this episode? yes/no

Variable name	Туре	Description
peripheraloxygensaturation	str30	Peripheral oxygen saturation: measured/not measured
peripheraloxygensaturationvalue	str3	Peripheral oxygen saturation value (%)
heartrate	str32	Heart rate: measured/not measured
heartratevalue	str3	Numerical heart rate value
capillaryrefilltime	str40	Capillary refill time: measured/not measured
severedehydration	str2	Signs of severe dehydration: yes/no
newalteredconsciouslevel	str21	New altered consciousness level: alert/confused or agitated/ response to voice only/response to pain only
causingotherclinicalconcern	str3	Causing other clinical concern? yes/no
causingotherclinicalconcernvalue	str150	Description of the clinical concern ( $\leq$ 150 characters)
treatwithantivirals	str3	Decision to treat with antivirals: yes/no
treatwithantibiotics	str3	Decision to treat with antibiotics: yes/no
refertohospital	str3	Decision to refer to hospital: yes/no

## Monthly data sets

Four data sets are uploaded on to Dropbox by CPRD each month: two form data sets (one each for adults and children), one master file and 1 patient file. The two form files contain cumulative data from 4 weeks in one 'monthly' data set each for adults and children. The variables in the form files are identical to the variables in the respective weekly data extracts. Descriptions for the master file and the patient file are given below.

## Master file

Variable name	Туре	Description
patid	long	Unique patient identifier
cat	str5	Category: Adults/Children
cardiovascular	float	Presence of cardiovascular disease: yes/no
liver	float	Presence of liver disease: yes/no
neurological	float	Presence of neurological disease: yes/no
renal	float	Presence of renal disease: yes/no
respiratory	float	Presence of respiratory disease: yes/no
diabetes	float	Presence of diabetes: yes/no
immune_supression	float	Presence of immunosuppression: yes/no
statin	float	Prescription of statins: yes/no
antibiotic	float	Prescription of antibiotics: yes/no
antiviral	float	Prescription of antivirals: yes/no
flu_vaccination	float	Seasonal influenza vaccination: yes/no
hib	float	Haemophilus influenza type B vaccination: yes/no
inhaled_steroids	float	Prescription of steroids (inhaled): yes/no
oral_steroids	float	Prescription of steroids (oral): yes/no
pneumococcal_vaccine	float	Pneumococcal vaccination: yes/no

Comorbidities and therapy variables have been coded as 'Yes' for presence of the relevant medcodes/prodcodes at any point before the FLU-CATs consultation.

## Patient file

Variable name	Туре	Description
patid	long	Unique patient identifier
pracid	int	Unique practice identifier
cat	str5	Category: adults/children
formid	int	Unique LEPIS form identifier
submit_date	float	Date of submission of FLU-CATs form (assumed to be the date of FLU-CATs consultation)
gender	byte	Gender: male of female
yob	int	Patient's year of birth (Stata date format)
mob	byte	Patient's month of birth
toreason	byte	Reason the patient transferred out of the practice
year	float	Patient's year of birth (YYYY format)
regdate	float	
todate	float	Date the patient transferred out of the practice, if relevant. Empty for patients who have not transferred out
death	float	Date of death if the patient died

## Appendix 7 FLU-CATs protocol

## NIHR Second Pandemic Influenza Themed Call: Detailed Project Description

**Long Title:** Real time refinement and validation of criteria and tools used in primary care to aid hospital referral decisions for patients of all ages in the event of surge during an influenza pandemic.

**Short Title:** Evaluation and refinement of pandemic influenza community assessment tools (the FLU-CATs study)

MG Semple, JS Nguyen Van Tam, PR Myles, JJ Kirkham, TJ Williams, TP van Staa

## Summary

**Design:** A prospective analysis, linking criteria in a GP's assessment of patients presenting with influenza like illness, to immediate management decisions and patient outcomes.

**Objective:** Assessment, refinement and validation of triage tools to guide GP referral of patients with influenza like illness during a pandemic in readiness for use should widespread illness exceed health care capacity (surge).

**Method:** GPs participating in the General Practice Research Database (GPRD) will record their assessment and management of patients with influenza like illness in LEPIS (Local Eligibility Patient Identification Service) an application linked to their routine in-practice software (Vision<sup>®</sup>). This is an established information technology based method for conducting large research studies in primary care.

High level hospital discharge data are routinely uploaded from secondary care to Vision<sup>®</sup> including: admission date, discharge date, main disease code, main procedure code and if death in hospital date of that death.

There is automated nightly linkage from Vision<sup>®</sup> and LEPIS to GPRD. This is collated by the GPRD research operations team and made available to external researchers on a weekly basis.

GPRD is linked to detailed Hospital Episode Summary data every three months. Data linked includes multiple disease codes, multiple procedure codes, length of admission, levels of augmented care (0 to 3), mortality, and pharmacoeconomics.

**Analysis:** Weekly cumulative analyses are planned using GPRD data. Three monthly analyses are planned using linked HES data as a gold standard.

Univariate and multivariate analyses using unconditional logistic regression will be used to investigate the association between triage criteria threshold values and primary outcomes (hospital admission, and death) and secondary outcomes (length of stay and augmented levels of care [high dependency/intensive care]). The threshold values of triage criteria will be refined by comparing the receiver operator characteristics at various thresholds of abnormality (e.g. respiratory rate of > 30, > 35, > 40).

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

The discriminatory value of existing and refined triage tools will be compared using logistic regression. Triage tools will be compared for their ability to predict outcomes using Area Under the Receiver Operating Characteristic Curve (AUROC) comparisons. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) will be calculated for triage tools using different score thresholds.

The virus, human behaviour, and models of health care provision in the community may change in time. Analysis will be reset between pandemic waves and appropriate comparisons made between pandemic waves.

#### Protocol amendment

The Award Board asked the investigators to consider add an extra resource to include virological diagnosis in a sub sample of patients.

We will explore linking GPRD to the HPA supra-regional microbiology network database to provide linked-anonymised results on microbiological investigations for respiratory pathogens. This will still require NIGB approval and Caldicott compliance. Preliminary enquiries have discovered that a supra-regional database is used by several of the nine HPA regions. This includes patient linked data on communicable diseases including the HPA/RCGP influenza virus swab results. GPRD is now linked to ten NHS datasets (including Hospital Episode Statistics, death certificates, cancer registry data, data from the Myocardial Infraction National Audit Program [MINAP]). These linkages are done on a regular basis using a Trusted Third Party and are all subject to NIGB approval. The project submitted involves already established links between GPRD, HES and Death Certifications. Establishing linkage to the HPA data-set would be a significant additional task for the study but one that would bring great benefit and avoid need for additional swabs to be taken.

Further details of protocol amendments including revised costs to resource linkage to the HPA are given at the end of this document.

#### Timeline

**Phase one:** (inter-pandemic – development / feasibility testing), duration six months during a summer season: set-up and validation of processes; optimisation of the clinical record entry screen; GP acceptability testing; establish data-return format; check completeness of data returns; develop data clean-up algorithms; development of definitions, evaluation of completeness and validation of study outcomes using historical GPRD and HES data; test of LEPIS study link. This will involve 3 to 5 practices experienced in developing GPRD/LEPIS research protocols.

**Phase two:** (inter-pandemic – pilot), duration six months in the consecutive winter season in 50 practices. Using data from cases of influenza like illness: test data-cleaning algorithms and the automated weekly evaluation of performance of triage criteria and tools. Rehearse report preparation to match expected 'battle rhythm' of key pandemic policy advisory bodies (SAGE and PICO). The project will be mothballed at end of phase two.

**Phase three:** will be activated in the event of a pandemic. The study link to LEPIS will be embedded in the Vision<sup>®</sup> software at all GPRD practices (currently 629) by the routine update process. GPs will be will prompted to complete assessment and outcome fields for cases presenting with influenza like illness. The GPRD research group will provide weekly data returns for these patients and three monthly linked HES data. We will run a weekly cumulative analysis against primary outcomes, allowing frequent refinement of criteria and tools against the novel pandemic strain, three monthly validation against HES data and plan adaptation of tools in readiness of surge.

An outline of the study as it would run in phases two and three is presented on page 20.

#### Has the project changed since the Expression of Interest was submitted? Yes

The title has changed to reflect that the aim of the study is to prospectively refine and validate the triage tools in real-time ready for use in the event of surge.

We have added Dr Jamie Kirkham, Centre for Medical Statistics and Health Evaluation, University of Liverpool, as a co-investigator to provide methodological and statistical support to the study at 3% WTE.

We have added a full time pre-doctoral research assistant based at the University of Nottingham to conduct statistical scripting and run analysis in year one. In lieu of this substantial change and additional salary costs, University of Nottingham have agreed to make a 100% institutional contribution to their estates and indirect costs.

## Introduction

The potential for health care demand to exceed clinical capacity (surge) is recognised in historic reports of influenza pandemics and current government guidance.[1,2] Clinical triage tools capable of identifying the need for higher levels of care and risk of severe outcome have an important role in pandemic situations where secondary care capacity may be insufficient to meet demand; the time available for clinical decision making may be limited by workload pressures; and healthcare workers unfamiliar with clinical assessment and admission decision making may be asked to fulfil 'gatekeeper' roles.[3]

CURB-65 is a validated predictor of mortality from community acquired pneumonia in adults but was never intended for use in children.[4,5] CURB-65 does not perform as well in predicting higher levels of care and was not designed to predict mortality from non-pneumonic presentations.[6,7] Challen et al. proposed the Pandemic Medical Early Warning Score (PMEWS) as a clinical triage tool to aid hospital admission decisions for adults in a pandemic situation.[8] They validated PMEWS in adults presenting to hospital with community acquired pneumonia and found that it was better than CURB-65 for predicting the need for admission and higher levels of care but had limited ability to predict mortality. CURB-65 and PMEWS pose problems for use in primary care, the first being in-part reliant upon a contemporaneous serum urea value and the second is computationally complicated. Other severity scoring tools exist but these are not suitable for use in primary care due to a greater dependence upon laboratory or radiological investigations.

In 2009, the Department of Health England published a package of care that included Paediatric and Adult Community Assessment Tools (CATs) and patient pathways for use by the NHS in a severe pandemic event.[9] CATS were developed to help non-specialist front-line staff identify which sick children and adults are most likely to benefit from interventions and levels of care only available in hospitals when resources are limited. CATs were developed by paediatric and adult expert clinical development groups drawing on evidence that supports the recognition of severe influenza and severe pneumonia in the community in adults and children in resource limited settings; severe chronic obstructive pulmonary disease in adults; potentially serious feverish illness in children; and severe bronchiolitis in infants.[3,10,11,12,13,14,15,16,17,18,19] Clinicians were warned not to use the CATs and the pathways unless the local situation precluded normal admission and discharge processes.

CATs use six objective and one subjective criteria based on simple clinical assessment (figure 1). Meeting any CAT criterion warrants referral and admission to hospital. Criteria are: A) severe respiratory distress, B) increased respiratory rate, C) oxygen saturation > 2% on pulse oximetry breathing air or oxygen, D) respiratory exhaustion, E) severe dehydration or shock, F) altered consciousness level and G) other clinical concern. While criteria fields are common to adult and paediatric CATs, the abnormal physiological thresholds and clinical signs are age appropriate. Like PMEWS, there is no requirement for laboratory investigation to complete the assessment. However CATs were only intended for use 'during severe and exceptional circumstances when surge demand for healthcare services leads to a need for strict triage"; and as such, were not deployed during the 2009/10 pandemic.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

#### Work underpinning this study

Goodacre and colleagues (2010) conducted an evaluation of the discriminatory value of the CURB-65 score, PMEWS and CATs for predicting severe illness or mortality in patients with suspected pandemic influenza, but were unable to draw any conclusions regarding their clinical utility in a pandemic situation due to insufficient case numbers especially of adults, and a low incidence of severe outcome.[20]

Semple, Myles, Van-Tam and other members of the UK Pandemic Influenza Clinical Information Network (FLU-CIN) characterised PCR-confirmed pandemic influenza disease in a much larger cohort of 1520 people (1040 adults, 480 children (age < 16 years)) admitted to hospital.[21] (Thorax submitted) FLU-CIN compared the clinical validity and utility of CATs, PMEWS and CURB-65 as predictors for interventions normally only available in hospital, higher levels of care, and death using area under the Receiver Operating Characteristic (ROC) curve (AUROC) comparisons with 95% confidence intervals (paper submitted).[22] CATs showed the best predictive performance for level 2/3 admissions in both adults [AUROC: CAT 0.77 (0.73, 0.80); CURB-65 0.68 (0.64, 0.72); PMEWS 0.68 (0.64, 0.73), comparison of AUROCs p<0.001] and children [AUROC: CAT 0.74 (0.68, 0.80); CURB-65 0.52 (0.46, 0.59); PMEWS 0.69 (0.62, 0.75), p < 0.001].

While the FLU-CIN cohort is limited to patients admitted to hospital with severe influenza and its complications, the data show that triage tools are capable of predicting higher levels or care and or death in children and adults. However the FLU-CIN analysis does not include assessment of triage tools in primary care.

Appropriate use of such triage tools in the community could expedite referral to hospital and where scores are high, immediate admission to level 2/3 care. Prompt admission and allocation of higher levels of care may be associated with improved patient outcomes. Another study by FLU-CIN found that delayed admission to hospital ( $\geq$  4 days after symptom onset) was significantly associated with increased likelihood of admission to critical care and death.[23]

The validity and utility of using triage tools in the community remains untested. Morbidity and mortality rates were low during the H1N1(2009) event when compared to some previous influenza epidemics such as the one in 1989/90 [24] and the use of anti-viral therapy was generally low in the FLU-CIN cohort despite it being widely available at the time. A more severe pandemic may be associated with a greater acceptance of anti-viral therapy and this may impact upon need for higher levels of care and death. Consequently criteria threshold values may need to be adjusted to optimize the ROC for each criterion and the AUROCs for the various triage tools.

#### Justification of this study

The validity and utility of the various triage tools needs to be assessed in a large community-based prospective study of patients presenting with influenza like illness to General Practitioners (GPs), to give confidence to clinicians who make be asked to use such tools in the event of surge, and policy makers who may need to recommend their use to GPs.

Linking GP assessment and management decisions to hospital episode data enables assessment and comparison of the validity and utility of triage in the community in relation to patient relevant outcomes (hospital admission, length of stay, higher levels of care and death).

It would not be possible to conduct this study during a pandemic without prior development of processes, feasibility and pilot studies.

The Health Protection Agency timeline for the UK 2009 pandemic shows only 12 weeks between identification of person-to-person transmission in the UK (first week May) and peak influenza activity (last week July) in the first pandemic wave. Prospective data collection with near real-time iterative and cumulative analysis is the only method for validating triage criteria and tools against a novel pathogen in such a short time.

Since pandemics are unpredictable and infrequent, limited but potentially useful information will be gained from prospective feasibility and pilot work conducted in primary care during seasonal influenza while H1N1v is still circulating.

Conducting this study in real-time during the early stages of a pandemic, when the characteristics of the novel virus are not fully understood, is important as it allows refinement and validation of triage tools against the novel pathogen in preparation for possible surge. This cannot be done until a novel virus emerges. Dame Diedre Hine has recommended that population based studies be established that, in the early stages of a future pandemic, can measure the severity of the pandemic and support decision making.[25]

The study method adheres to the five principles of Dynamic Risk Assessment and as applied to the management of emergency situations by UK Government agencies (Evaluate, Select, Assess, Refine, Reassess) (Home Office Guide to Operational Risk Assessment - Generic Risk Assessment 3.2. [Version 2 September 2008]).

If, as in the 1918/19 epidemic, the behaviour of the virus is markedly different in terms of severity between the first and subsequent waves or evolves to cause severe disease in a particular organ system; then triage criteria may need to be adapted to reflect the consequent changes in health care demand and clinical presentation.

## **Research objectives**

#### Aim

To establish processes now, that can be used in the early stages of a future pandemic event to provide valid community triage tools capable of assisting hospital referral decisions for people of all ages for use if health care demands exceed health care capacity (surge).

#### **Primary objective**

From the start of a future pandemic event, to describe on a weekly cumulative basis the association between various triage tools and pandemic influenza outcomes. This will be supplemented as appropriate, with receiver operator characteristic (ROC) curves analysis and predictive values (positive and negative) of various community triage tools (Adult and Paediatric CATs, PMEWS) to predict outcomes (hospital admission and or death) in people of all ages presenting with pandemic influenza like illness to a large number of general practices in the UK; and to feed this information back to policy makers via the Pandemic Influenza Clinical and Operational Advisory Group's Clinical Sub-group (PICO) and medical members of the Scientific Advisory Group for Emergencies (SAGE).

#### Secondary objectives

- 1. To provide reassurance that it is safe for people who do meet triage criteria and so would not be referred for hospital admission to continue to be managed in the community with advice.
- 2. To describe the associations between specific triage criteria and outcomes (hospital admission, length of stay, need for higher levels of care and or death).
- 3. Using sensitivity analysis to refine threshold values for specific triage criteria and outcomes (hospital admission, length of stay, need for higher levels of care and or death).
- 4. To describe demographics and clinical features of patients that meet threshold criteria and are referred for admission by GPs but are declined admission on assessment at hospital.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

- 5. To describe demographics and clinical features of patients that present with influenza like illness to GPs and after assessment are not considered to need referral to hospital, yet die in the community within 30 days.
- 6. To describe demographics and clinical features of patients that present with influenza like illness to GPs and after assessment are not considered to need referral to hospital, yet die in hospital within 30 days.

We will analyse:

- 1. separately by age group: adults and children (< 16 years)
- 2. cumulatively for primary objectives.
- 3. weekly for primary objectives from initiation of study.
- 4. three monthly for secondary objectives.

#### Policy related

To provide evidence and reassurance to clinicians, policy makers and Ministers that any triage tools recommend for use in the event of surge are validated against the novel pathogen, are safe to use and clinically justified.

## **Plan of study**

The study will run in three phases:

Phase one (inter-pandemic – development and feasibility). Proposed start date 01.04.2012. Duration six months during a summer season. At the start of this project, the researchers will evaluate in detail the validity and completeness of recording of the outcome measures in GPRD (analysing the data as collected up to the start of the study). Code lists will be developed. The frequency of recording of various data fields will be evaluated. In addition, comparisons will be made with HES in order to assess the completeness of recording of hospital admissions. These analyses will provide important information about the quality of GP recording of the outcomes. Based on the large number of published validation studies with GPRD, it is expected that major clinical outcomes are generally recorded well by GPs but that clinical details (such as length of hospital stay) may be less complete. We will set-up and test the technology processes. This will involve 3 to 5 GP practices experienced in developing GPRD research protocols GPs will be involved in optimising the study record entry screen in LEPIS and do user acceptability testing. We will establish the data-return formats; check completeness of data recording by GPs in LEPIS; develop data clean-up algorithms; development of definitions, evaluation of completeness and validation of study outcomes using historical GPRD and HES data; test LEPIS study link.

There will be meetings with the oversight committee prior to commencement, at mid point and end of phase one.

- Phase two (inter-pandemic pilot), Proposed start date 01.10.2012. Duration six months in the consecutive winter season in 50 practices. Using data from cases of influenza like illness: test data-cleaning algorithms and the automated weekly evaluation of performance of triage criteria and tools. We will rehearse report preparation to match expected "battle rhythm" of key pandemic advisory bodies (SAGE and PICO). There will be meetings with the oversight committee prior to commencement, at mid point and end of phase two. The project will be mothballed at end of phase two.
- Phase three will be activated in the event of a pandemic. The link to the web-based electronic record (LEPIS) will be embedded in the Vision<sup>®</sup> software at all GPRD practices (currently 629) by the routine update process. GPs will be will prompted to complete assessment and management fields for all cases presenting with influenza like illness. The GPRD research group will provide weekly data returns for these patients and three monthly linked hospital episode summary data. We will run a weekly cumulative analysis against outcomes, allowing frequent refinement of criteria and tools against the novel pandemic strain, and plan adaptation for use in readiness of surge.

In the event of imminent surge, and at the direction of policy makers at devolved Departments of Health, it will be possible to embed an algorithm behind the clinical record page in Vision<sup>®</sup>/LEPIS that will indicate that triage criteria have been met and so prompt the GP to consider hospital referral. Regional variations of Vision<sup>®</sup> software are provided to practices in devolved UK administrations, which will allow for variations in regional policy. A decision by one administration not to use triage tools during surge would be respected by not deploying the algorithm in that region. Because the GPRD is conducted in collaboration with the providers of the Vision<sup>®</sup> in-practice software, it would be possible to link all users of Vision<sup>®</sup> software to the algorithm, not just those participating in GPRD. We will explore the capability to provide and apply the algorithm to other providers of GP software. The study will continue during surge. The study will continue.

## **Existing research**

There have been two head to head comparisons of the triage tools proposed by DH guidance, both in cohort of patients already admitted to hospital.[20,22]

The validity and utility of using PMEWs, CATs (both triage tools) and CURB-65 (a validated predictor of mortality from community acquired pneumonia) to predict augmented levels of care and or death has been studied by the FLU-CIN in 1520 patients *admitted to hospital* with confirmed pandemic influenza A (H1N1)2009[22].

The ROC curves and AUROC values comparing the predictive value of the three clinical triage tools are described in figure 2. CATs showed the best predictive performance for augmented higher levels of care (effectively HDU and ITU admissions) in both adults [AUROC: CAT 0.77 (0.73, 0.80); CURB-65 0.68 (0.64, 0.72); PMEWS 0.68 (0.64, 0.73), comparison of AUROCs p < 0.001] and children [AUROC: CAT 0.74 (0.68, 0.80); CURB-65 0.52 (0.46, 0.59); PMEWS 0.69 (0.62, 0.75), p < 0.001]. CURB-65 and CAT had similar performance in predicting mortality in adults [AUROC: CAT 0.70 (0.63, 0.77); CURB-65 0.71 (0.65, 0.77); PME 5WS 0.60 (0.52, 0.67), p = 0.009] but CAT performed best as a predictor of mortality in children [AUROC: CAT 0.76 (0.66, 0.86); CURB-65 0.51 (0.39, 0.63); PMEWS 0.69 (0.55, 0.83), p = 0.002].

The receiver operator characteristic, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for each of the tools using various score thresholds (table 1). In adults, a CAT score  $\geq$  3 was the best predictor of level 2/3 admissions, death and combined severe outcome when compared to various cut-off scores for either CURB-65 or PMEWS. In children, a CAT score  $\geq$  3 was the best predictor of level 2/3 admission and combined severe outcome; performing marginally better than a PMEWS score > 9, both significantly better than CURB-65. In children, a PMEWS score > 9 was the best predictor of mortality in children; performing marginally better than a CAT score > 3, both significantly better than CURB-65.

Anonymised electronic general practice data has been used extensively across a wide spectrum of disease areas including seasonal and pandemic influenza. Watkins et al. used GPRD to determine the burden of seasonal influenza in childhood.[26] Hansell et al. (1999) investigated the epidemiology of respiratory disorders adopting similar methods.[27] Mangtani et al. (2004) investigated the effectiveness of influenza vaccination in the elderly.[28] Time series analysis of a similar nature to this proposed study was undertaken by Hajat et al. (1999) to determine the relationship between pollution and consultations for asthma and lower respiratory disorders.[29][30]

## **Research methods**

#### Study design

Prospective observational maximum capture study using anonymised electronic general practice data linked to extended hospital episode summary data.

It is important to note that there will be no specific interventions made by the study.

None of the clinical features that constitute triage criteria are novel.

All clinical feature of interest are examined albeit with variations of adherence in current community practise.

#### Recruitment population

Any person presenting to a GPRD participating practice for consultation with a General Practitioner or Primary Care Nurse Practitioner regardless of date of onset of disease and prior medical history.

GPs participating in GPRD are committed to improving the health of their communities by providing anonymised data for a number of research and quality of service audit purposes.

Data collection templates with reminder flags are regularly uploaded to LEPIS and linked to Vision<sup>®</sup> in-practice software for such purposes.

#### Inclusion criteria

Any person presenting to a GPRD participating practice with influenza like illness regardless of date of onset of disease and prior medical history.

#### **Exclusion criteria**

People who present with any condition other than influenza like illness.

#### Proposed sample size

A formal sample size calculation is not possible and will depend to a great extent upon the clinical attack rate and hospitalisation rate (severity) of the pandemic strain. The clinical attack rate and hospitalisation rate of a future pandemic strain cannot be guessed, however the recent 'mild' pandemic does provide useful information.

In the first wave of the 2009 pandemic the clinical attack rate varied considerably between regions from 446 cases per 100,000 in the rural South-West to 1344 cases per 100,000 in London.[31] Most people experienced a mild, typical influenza like illness and the overall rate of hospitalisation ranged from 1.3% to 2.5% of those affected.

In the event of a pandemic and activation of phase 3 of the study, the study will recruit from all 629 practices participating in the GPRD currently actively caring for approximately 5.14 million people. Based on the limits of the clinical attack rates during the 2009 event, between 23,000 and 69,000 of these people would be expected to present in the first wave. Approximately 10,000 to 30,000 of these patients will present in the first 3 months before peak activity; forming the study cohort available for assessing, refining and validating triage tools in preparation for surge. Based on the limits of the hospitalisation rates previous described, 130 to 750 of these people would be admitted to hospital forming the group with a positive primary outcome measure in this study. In comparison, the FLU-CIN study was able to validate triage tools using similar method of analyses in a cohort of 1520 patients admitted to hospital where the positive primary outcomes groups comprised 250 (16.5%) people who required higher levels of care (level 2 HDU or 3 ITU) and 80 (5.3%) who died. Thus we are confident that this study will be sufficiently powered to assess, refine and validate the triage tools in the timetable described.

## Data Sources: The General Practise Research Database (GPRD) and linked Hospital Episode data

The GPRD research group are named co-investigators in this application.

**The General Practice Research Database (GPRD)** is the world's largest database of anonymised longitudinal medical records from primary care. The Secretary of State for Heath has owned the database since 1994. The GPRD is managed by Medicines and Healthcare products Regulatory Agency (MHRA). The database comprises near real-time comprehensive observational data from over 1000 GPs working in 629 general practices. It is a valuable tool for academic research in a broad range of areas including clinical epidemiology, disease patterns, disease management, outcomes research, and drug utilisation. The quality and reputation of the GPRD data make it an invaluable resource for researchers. There have been over 890 research papers published in peer-reviewed journals using data from this database. In July 2011 data was being collected on 5.14 million active patients of research standard or 8.3% of the UK population attending. The GPRD closely reflects the age, gender, and geographic distribution of the UK.[32] The quality of GPRD data has recently been reported in a systematic review. [33] While some acute musculoskeletal and metabolic conditions are not well recorded in GPRD, the majority of diagnoses were reliably coded and there is good agreement between more common diseases and other datasets. Importantly fro this study, influenza incidence rates derived from GPRD agree closely with data from national influenza surveillance systems.[30]

Detailed Hospital Episode Summary (HES) data is linked to GPRD every three months. HES data includes: detailed disease codes (ICD-10), procedure codes, levels of augmented care, length of stay and death. The ability of GPRD to conduct research across linked databases using this detailed clinical record data has been proven in a population-based study on incidence, risk factors, clinical complications and drug utilisation associated with seasonal influenza.[34]

GP clinical assessments and immediate management decisions are recorded on GPRD/LEPIS at time of consultation. This data is downloaded nightly and collated for access by researchers on a weekly basis. Data on hospital admission and death is typically entered on GPRD with in 48 hours of receipt of notification. Recently Jick et al. (2011) described the ability of GPRD to provide near real-time analysis of the epidemiology of pandemic influenza 2009.[35]

GPRD research group has gained ethical and National Information Governance Board (NIGB) approval to provide anonymised data and other healthcare data linked via the patient's NHS number, sex, date of birth and post code.

GPs who contribute to the database use Vision<sup>®</sup> (In Practice Systems Ltd); a computer software package designed by an established user-group of experienced GPs, to make contemporaneous records of their routine consultations and enter study specific data in LEPIS; a linked application maintained by the GPRD research team.

General Practitioners participating in the GPRD will be prompted on screen to record their assessment and management of patients presenting with influenza like illness. A flag will appear during consultation requesting the GP to complete their assessment on the LEPIS study website. This is the limit of any variation from routine practise; which is to record assessment and key positive and negative rule-out features in in free text fields in Vision<sup>®</sup>. It is important to note that GP are not expected to diverge from their routine clinical assessment of patients and that GP management decisions are already routinely entered in Vision<sup>®</sup>.

Hospitals are required to transmit discharge summaries to GPs within 48 hours or suffer financial penalties. These contain high-level data: primary diagnosis, date of admission, date of discharge or death. This data is manually input to Vision<sup>®</sup>, usually within 48 hours of receipt.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Linked anonymised Vision<sup>®</sup> and LEPIS data is downloaded nightly in a silent background application to the GPRD research group. Weekly extracts of the data are provided to the wider research community as the GPRD.

Linkage to Hospital Episode Summary (HES) data is done by an external NHS group in a way that the GPRD research team does not see any identifying details. HES data includes: method of admission, disease coding (ICD-10), length of stay, level of augmented care, procedural coding (OPCS classification of interventions and procedures, v4.6), cause of death as certified, prescribing and pharmaco-economics. Levels of augmented care are defined by the Department of Health and Intensive Care Society Standard (2009). These high-level data in HES have been mandated for return from all NHS hospitals in England for all patients admitted to since April 2006 to support payment by results. HES data is linked to GPRD at three monthly intervals and are provided to the wider research community.

The Office for National Statistics (ONS) collects information on causes of deaths from death certificates. ONS data is linked to HES monthly and to GPRD every three months.

Notification of death is made by hospitals to GPs via standard operating procedures that ensure this data is handled as a priority to prevent inappropriate communications and facilitate appropriate support to bereaved relatives. Thus death as a status is entered on Vision<sup>®</sup> with little delay. Notice of 'hospital admission' is normally available within 48 hours of admission. The primary outcome measures of hospital admission and death are therefore available for use by GPRD following a nightly download. It is recognised that there is typically a delay of 48 hours after discharge before high-level hospital admission data is available from faxed hospital discharge letters. At the time of writing this proposal there is a 3-month interval in linkage of GPRD to HES and ONS certified cause of death data.

Part of our work in phases 1 and 2 will be study feasibility, conducting necessary validation and if necessary, initiate improved systems of data collection in the case of a pandemic.

#### Data management

The GPRD research group will undertake data collation and secure data warehousing in line with NIGB requirements. The GPRD research group will provide direct access to the GPRD warehouse for the statistician and epidemiologist. The researchers will have no access to patient identifiable data. All data analysis and will be maintained on secured computer servers within the University of Nottingham and University of Liverpool, only accessible to the research team and appropriately protected in accordance with Caldicott principles.

#### Definition of influenza like illness

Influenza like illness (ILI) will be defined per the World Health Organization criteria: 'any person with sudden onset of fever (> 38 °C) and cough or sore throat in the absence of other diagnoses'. This closely matches the Centres for Disease Control (CDC) USA definition used for community incidence studies: 'fever or recent history of fever ( $\geq$  37.8 °C) plus cough and or sore throat in the absence of a known cause other than influenza'. This definition will include those people meeting the British Infection Society/British Thoracic Society/Health Protection Agency/Department of Health (England) guidance criteria (2007): 'presence or recent history of fever (T > 38 °C) plus new cough in the context of influenza circulating in the community'. We have chosen not to adopt the Royal College of General Practitioners' Syndromic Surveillance System algorithm as it depends on self-reporting of muscle ache and or headache, which are poorly reported by young children.

It is accepted that the definition of ILI may be revised in the event of a future pandemic, either on the basis of on-going surveillance information or in the event of emergence of a novel pneumonic pathogen. This is not a concern. This study's aim is to establish automated processes capable of assessing and validating community triage tools in near-real time, which can be applied regardless of any variations of the case-defined entry criteria.

#### **Predictor variables**

Clinical features of patients presenting with influenza like illness as recorded by GPs on LEPIS during their routine consultation which include the criteria used by various triage tools:

- 1. Respiratory Rate (value)
- 2. Oxygen saturation (value)
- 3. Any sign of Severe Respiratory Distress (yes/no). Prompt 'any of: lower chest wall indrawing, sternal recession, grunting, noisy breathing when calm, use of accessory muscles, supra-clavicular recession, tracheal tug, unable to complete sentences in one breath or feeling of suffocation'.
- 4. Respiratory Exhaustion (yes/no) or Apnoea reported (yes/no), apnoea defined as a ≥ 20-second pause in breathing
- 5. Blood pressure (systolic and diastolic values)
- 6. Sternal Capillary Refill Time (normal/> 2 secs)
- 7. Severe dehydration (yes/no). Prompt: 'any of: reduced skin turgor, sunken eyes or fontanelle'.
- 8. Adults only: New altered conscious level (yes/no). Prompt 'any of: new confusion or disorientation in person, place or time; AVCPU score < A; or 'Mini (abbreviated) mental test score < 8'.
- 9. Children only: New altered conscious level (yes/no). Prompt 'any of: new confusion or disorientation in person, place or time; AVPU score < A; or Mini mental test score < 8/10'.
- 10. Strikingly agitated (yes/no)
- 11. New seizures (yes/no)
- 12. Floppy infant (yes/no)
- 13. Social isolation (yes/no). Prompt: 'any of: lives alone; no fixed abode'.
- 14. Chronic disease (yes/no). Prompt: 'any of respiratory, cardiac, renal, metabolic, immune suppressed or sickle disease'.
- 15. Causing other clinical concern to their GP (yes/no). Prompt with 'For example a rapidly progressive or an unusually prolonged illness' (yes/no).

#### Demographic data to be collected silently by background application

- 1. Practice location.
- 2. Socioeconomic data at lower super output level (index of multiple deprivations).
- 3. Ethnicity.
- 4. Sex.
- 5. Age.
- 6. In cases of death, Office of National Statistics cause of death.

#### Outcome measures

#### Primary outcome measures

- 1. Hospital admission within 24 hours of GP assessment.
- Death within 30 days of GP assessment (all causes). Complications leading to death may occur after some weeks (e.g. if prolonged admission to hospital). This outcome definition may miss cases that die as a direct consequence of their illness after 30 days, but based on 2009/10 experiences these are expected to be few.

#### Secondary outcome measures

- Any need for augmented level of care during hospital admission i.e. level 2 High Dependency and level 3 – Intensive/Critical Care, accepting that there are minor differences between paediatric and adult definitions of levels of care.
- 2. Length of hospital stay (stratified > 48 hours,  $\geq$  6 days and  $\geq$  12 days)
- 3. GP's decision to refer for hospital admission.

## Statistical analysis

Separate analyses will be made for paediatric and adult patients and will use age appropriate triage tools where available.

The datasets will be analysed using STATA statistical software.

Weekly cumulative analysis is planned using real-time data from GPRD followed by 3-monthly validation using HES and ONS linked GPRD data. A rolling analysis is required because the virus, human behaviour, and models of health care provision in the community may change in time. The analyses will be reset in keeping with key policy changes in order to assess the impact of any changes. For example the introduction of that automated National Pandemic Flu Service (NPFS) in July 2009 substantially reduced the numbers and altered the case mix of people presenting to GPs.[31]

Univariate and multivariate analysis (using unconditional logistic regression) will be used to investigate the association between triage criteria threshold values and primary outcomes (hospital admission and or death). The threshold values of triage criteria will be refined by describing the receiver operator characteristics of different thresholds of abnormality (e.g. respiratory rate > 30, > 35, > 40) to predict patient outcomes.

It is likely that in the first couple of months of the pandemic, when there are fewer cases, the analyses will be largely descriptive and focus on percentages and cross tabulations. However, as soon as it is feasible, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) will be calculated for each of the triage tools using different triage tool score thresholds. An example of analysis output is given in table 1. The discriminatory value of existing and refined triage tools will be compared using logistic regression. The performance of different triage tools will be compared on their ability to predict outcome using area under the Receiver Operating Characteristic curve (AUROC) comparisons. An example of analysis output is given in figure 2.

Cumulative analysis will be reset between pandemic waves and appropriate comparisons made between pandemic waves. Analyses can be reset if there is a substantial change to the model of pandemic influenza health care provision such as introduction of an automated National Pandemic Influenza Service which would be likely to alter the case mix presenting to GPs.

## **Risks/benefits to patients**

For the individual patient there are no readily identifiable risks that result from the project. All data is anonymised to allow analysis without compromising patient confidentiality. It is possible that participating GPs will adapt their consultation practise to conduct clinical assessment in a structured format. This may benefit patients.

Once the study processes are developed and piloted, the methods can be activated to determine the appropriate management of other novel non-influenza severe acute respiratory pathogens, e.g. SARS coronavirus.

## **Risks/benefits to study**

We have identified two system specific risks for the proposed study:

- That despite prompts in the clinical software and other processes put in place to encourage data entry by GPs (such as GPRD newsletters and emails), that GPs will not enter their assessment in LEPIS and instead use other free-text fields in Vision<sup>®</sup>. To reduce this possibility, the software will be adapted to flag a reminder if an ILI diagnostic code is entered in Vision<sup>®</sup> and the LEPIS study page has not been completed.
- 2. It is accepted that there may be up to a week's delay in availability of data from hospital discharge faxes that is dependent upon manual input to Vision<sup>®</sup> by GPs clerks (e.g. length of stay). There is potential for failure, reduced quality and increased delay of production of discharge faxes at some hospitals due to local pandemic influenza pressures on staff and financial penalties may be lifted. This will be mitigated by the very large size of the study recruiting from practices spread across the UK. This risk is not expected to affect data return for the primary outcome (hospital admission within 24 hours of GP assessment) as this data is returned automatically or notice of death which is handled as a priority to be communicated directly to GPs by clinical staff. Standard operating procedures are in place ensure rapid disseminating of notice of death in primary care systems to prevent inappropriate contacts and distress to bereaved relatives.

## Consent

Patient consent is not required as all patient data is anonymised and no intervention is taking place. Patients and parents of patients at participating practices have the opportunity to opt out of the GPRD scheme at registration and any point thereafter. However after a patient has been assessed and their data transmitted in an anonymised format there is not capability to redact that data. Anonymised patient data in HES is subject to an NIGB section 251 approval for approved use without consent.

## **Ethics**

GPRD research group has generic ethical approval for studies that only make use of anonymised data and linked anonymised Hospital Episode Statistics. All studies require scientific approval from the GPRD Independent Scientific Advisory Committee (ISAC). This study protocol will be submitted to ISAC for review. In the event that ethical review is required by ISAC, a submission will be made to a Multi-Centre Research Ethics Committee via the Integrated Research Application System.

The National Information Governance Board for Health and Social Care has authorised the Information Centre for Health and Social Care to provide anonymised Hospital Episode Statistics as the official statistical database on NHS hospital activity in England under a section 251 approval.

## **Outputs from the study**

In Phase one and two, progress reports to the oversight group will be made every three months, with a final report being submitted at the end of phase two to NETSCC and Department of Health Pandemic Influenza Planning Team.

Reports will detail:

- In Phase one
  - GP involvement in developing data capture screens.
  - User acceptability (GP) testing of data capture screens.
  - Completeness of data from GPRD based on retrospective analysis using HES-linked GPRD data as a gold standard for data completeness.
- In Phase two
  - Weekly statistical analysis of cases of seasonal influenza to demonstrate capability of processes and retrospective validation against HES data.
  - An accrual graph of patients studied by week number plotted above the HPA Weekly National Influenza Report of GP reported ILI consulting rates in the UK.

During phase three (pandemic), summary results of statistical analysis and recommendations regarding the triage tools will be reported to the oversight committee on a fortnightly basis and shared with the Pandemic Influenza Clinical Operation Clinical Subgroup (PICO) and the Scientific Advisory Group for Emergencies (SAGE). The reporting cycle will be flexible and can be adapted to marry with the battle rhythm of these key sources of advice to policy makers. The research team have a deep understanding of the need to communicate their findings successfully.

Reports will detail:

- An accrual graph of patients studied by week number plotted above the HPA Weekly National Influenza Report of GP reported ILI consulting rates in the UK.
- Results of statistical analysis detailing ROC, Sensitivity, Specificity, PPV, NPV for triage criteria and AUROCs for triage tools against the primary outcomes: hospital admission, higher levels of care (2 – HDU, 3 –ITU) and death.
- Recommendations regarding which criteria and tools to use in the event of surge.

In the post pandemic phase a final report will be produced and manuscripts prepared for publication.

Two of the investigators will present findings at an international conference.

## **Research governance**

The University of Liverpool will act as sponsor for the study.

The proposed study will be undertaken in accordance with the University of Liverpool's research governance procedures.

Dr MG Semple (Liverpool) and Prof Jonathan Van-Tam (Nottingham) will be joint guarantors for analysis and reports.
## **Study oversight committee**

A formal steering committee is impractical. A small independent oversight group has already been convened which includes a research active principal in primary care with a particular interest in identification of severe illness in children and a consultant in infectious diseases who is an expert in translating evidence to policy and policy to practice. Both have already made recommendations to the protocol that have been accepted.

Dr Anthony Harnden, Principle in General Practice and Director of Primary Care Research Network Clinical (PCRN) Clinical Trials Unit Oxford. Dr Harnden is a member of PICO; appointed as an independent expert clinical advisor in Primary Care. He has published on identifying factors that identify children with serious infection in primary care, avoidable factors associated with child deaths and the evidence base for interventions delivered to children in primary care.

Dr Barbara Bannister, Consultant in Infectious Diseases, and Consultant Clinical Advisor to Department of Health. Dr Bannister is a member of PICO; appointed as an expert clinical advisor in infectious diseases and as a representative of the DH Pandemic Influenza Programme. Dr Bannister supported the development and communication of operational guidance for medical professionals, including the mass use of antiviral and antibiotic therapy, clinical management guidelines, NPFS algorithms, triage and hospital pathways.

A NIHR NETSCC monitor or representative will be invited to join the group.

In phase one and two the investigators plan to meet with the overseers at least at commencement and at three monthly intervals.

In phase three, weekly reports will be presented to the overseers for ratification before being presented to SAGE, PICO and policy makers in DH.

## **Timetable and milestones**

01/04/2012 – 30/09/2010 Phase one (inter-pandemic – development / feasibility), duration six months during a summer season: set-up and validation of processes, optimisation of the clinical record entry screen in LEPIS, GP acceptability testing, completeness of data, validation of linkage between Vision<sup>®</sup>, LEPIS, HES and GPRD, data-return format and development of data clean-up algorithms. Progress reports and meeting at 3 and 6 months with overseers.

01/10/2012 – 31/03/2013 Phase two (inter-pandemic – pilot), duration six months in a winter season in 50 practices. Using data from cases of influenza like illness: test data-cleaning algorithms and the automated weekly evaluation of performance of triage criteria and tools. Rehearsal of reporting procedures and reporting rhythm to PICO and SAGE. Progress reports and meeting at 3 and 6 months with overseers. A manuscript for publication will be produced at the completion of phase 2.

*Phase three* will be activated in the event of a pandemic, duration 12 months. We will run a weekly cumulative analysis, allowing refinement of criteria and tools against the novel pandemic strain in readiness for surge. Monthly summary reports to overseers during pandemic phase. When ready, refined and validated tools will be presented to overseers, seeking approval to reporting to policy makers. Meeting at least at 3, 6, and 9 months to overseers. A manuscript for publication will be produced in the post pandemic period and before month 12.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

### Expertise

The co-applicants at University of Liverpool (MGS) and Nottingham (JVT and PM) are experienced in conducting pragmatic research during outbreaks and collaborated during the 2009 pandemic on the FLU-CIN. Both groups have institutional support to reorganise work and time commitments in order to conduct this research project as they did in 2009/10.

Dr MG (Calum) Semple (principal investigator) is a Senior Lecturer in Child Health at the University of Liverpool and Consultant in Paediatric Respiratory Medicine at Alder Hey Children's Hospital. His research interests include investigating the clinical and immunological factors associated with severe respiratory viral infections caused by human respiratory syncytial virus, human metapneumovirus and influenza virus. He was seconded to the Department of Health Pandemic Influenza Programme as a clinical advisor from 2008 to 2010 and supported the development of clinical guidance, community triage tools and hospital pathways in preparation for a future pandemic. At the onset of the 2009 A(H1N1) pandemic he joined the Pandemic Influenza Clinical Operational Group (PICO) as an independent expert advisor and with Professor Jonathan van Tam established the UK Pandemic Influenza Clinical Information Network (FLU-CIN).

Professor Jonathan Van Tam, University of Nottingham has a special interest in influenza: epidemiology; transmission; vaccinology; and pandemic preparedness, which now spans more than 20 years. He is an internationally renowned expert on influenza and senior editor of the textbook: Introduction to Pandemic Influenza. He has been a consultant to the World Health Organization since 2004 and sits on the UK Scientific Pandemic Influenza Committee (SPI), and its Pandemic Influenza Clinical and Operational Group (PICO). He was a core member of the UK Scientific Advisory Group for Emergencies (SAGE) during the 2009-10 pandemic crisis and simultaneously led the national FLU-CIN surveillance project for hospitalised pandemic flu cases; and two further 'emergency' pandemic research projects funded by NIHR. His unit is an official WHO Collaborating Centre for pandemic influenza and research, a Faculty of Public Health "national treasure" training location and an HPA Field Epidemiology training centre. He will provide this specialist expertise to the study, particularly around study development and design and policy-related analyses.

Dr Tjeerd-Pieter van Staa is head of GPRD Research. He is a physician with a MSc in Pharmaco-epidemiology from McGill University and PhD from Utrecht University. He has more than 15 years of significant research and industry experience in pharmaco-vigilance, epidemiology and pharmaco-economics. He has been the European Qualified Person for Pharmacovigilance. His current research activities concern the combination of prospective research methods with healthcare databases (including individual and cluster randomised clinical trials within the database and pharmaco-genetic research). He has implemented collaborative research of multiple health-data linkages, including cancer registries, MINAP, ALSPAC, air pollution and bowel screening. Development of pharmaco-epidemiological methods, including multidatabase analyses and visualisation and evaluation of data quality, is another research interest.

Dr Tim Williams is the GPRD research services manager. Tim Williams obtained a PhD from the University of Leeds in 1995 before working within the Post Graduate Medical School at the University of Surrey as a Research Fellow where he undertook technical and research aspects of UK primary care database pharmacoepidemiology. In 2001 he moved to his current position, as an epidemiologist within the General Practice Research Database division within the Medicines and Healthcare products Regulatory Agency. In 2003 he completed his MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, and he is also an Honorary Research Fellow with Brighton and Sussex Medical School.

Dr Puja Myles is associate professor of health protection at the University of Nottingham. Her PhD thesis used a very large GP dataset to investigate risk factors for severe community acquired pneumonia. She is the analyst on the FLU-CIN. She will provide the data processing, analytical and statistical expertise to the study.

Dr Jamie Kirkham is a lecturer in Medical Statistics within the Department of Biostatistics, University of Liverpool. He has experience in statistical consultancy aimed specifically at improving the design and analysis of research projects. He also has experience in developing and validating clinical assessment tools (NIHR funded, Adverse Drug Reaction in Children project). He will provide methodological support to the project and assist with the statistical analysis.

## Service use input

The NIHR Primary Care Research Network (PCRN) Clinical Study Group have reviewed the study outline.

A principle in primary care (AH member of oversight committee) has reviewed to full protocol.

The GPRD research group and development practices include physicians and principles in General Practice who have an appropriate vested interest in optimising the methods for data entry and developing appropriate triage tools for us in the communities they care for.

## **Research staff requirements/justification of resources**

The use of data derived from a very large data set is a complex undertaking and requires specific skills to produce meaningful results. These include expertise in managing and manipulating large general practice datasets, 'cleaning' the data, extracting the relevant information, statistical processing and interpreting the findings appropriately. These need to be matched with relevant influenza clinical and public health skills, including in primary and acute care, health protection and respiratory epidemiology. The research team has therefore been drawn together to reflect these needs and includes expertise in handling large general practice datasets and the relevant clinical skills.

*Phases 1 and 2*: PM will lead in drafting the application for submission to the GPRD ISAC. These forms require detailed methodological description and would be difficult for someone without prior experience of primary care database studies. She will oversee the development of data cleaning and analysis algorithms and weekly report templates in preparation for Phase 3 as well as the validation of primary outcomes so that definitions can be revised if necessary. She will provide supervision to the research assistant for retrospective validation of real-time GPRD data using HES-linked GPRD data (which will be considered the 'gold standard' in terms of data completeness).

*FT pre-doctoral research assistant*: PM will be supported in this work by a full-time pre-doctoral research assistant. In order to keep costs down, we have opted for a pre-doctoral RA but this will then require the necessary input from PM as outlined previously.

*Phase 3*: PM: Ideally, data processing, analysis and production of weekly reports should be performed by a full-time research assistant under PM's supervision. However, it is our experience that, due to the unpredictability of the timing of the pandemic and the need for an immediate start once the pandemic begins, it will not be possible to go through usual recruitment procedures for employing an RA. Moreover, even a very competent post-doctoral research assistant would need some level of training up in the project specific role. In a pandemic situation there will be no scope for delays which is why PM will take full responsibility of the data processing, analysis and production of weekly reports. This is usually a full-time responsibility but we anticipate that the preparation carried out in Phases 1 and 2 will enable PM to carry out these tasks at 60% whole time equivalent.

There are distinct differences in the time commitments required for the pre-pandemic phases (1 and 2) and the pandemic phase 3 which will require increased activity. Research staff time has been adjusted accordingly and to provide timely results to the overseers and policy makers.

<sup>©</sup> Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton So16 7NS, UK.

	Time commitment (WTE) for FEC	
Staff and role	Year 1 (phases 1 and 2), pre-pandemic	Year 2 (phase 3), pandemic
MGS (PI and developer of triage tools)	10%	20%
PM (Very large database analyst)	20%	20%
Pre-doctoral Research Assistant	100%	nil
JVT (Influenza Epidemiology)	3%	5%
JK (Methodology and statistical support)	3%	3%

Appendix 1 details costs for the technology solution planned by the research group, broken down by phases of study and years of study.

## **Duration of the proposed project**

- 1. **Phase one** (inter-pandemic development and feasibility). Proposed start date 01.04.2012. Duration six months during a summer season: set-up and validation of processes, optimisation of the clinical record entry screen, GP acceptability testing, validation of linkage to hospital episode data, data-return format and development of data clean-up algorithms.
- 2. **Phase two** (inter-pandemic pilot). Proposed start date 01.10.2012. Duration six months in 10 to 20 practices during a winter season. Using data from people presenting with of influenza like illness: test data-cleaning algorithms and the automated weekly evaluation of performance of triage criteria and tools. The project will be mothballed at end of phase two.
- 3. **Phase three** will be activated in the event of a pandemic. The duration of a pandemic is hard to estimate. Based on the 2009 event, time from detection of person-to-person spread in the UK to peak activity was three months in the first wave with return to base line activity in a further one month. The second wave had a broader base and longer tail lasting approximately 5 months. The modified GP electronic record will be disseminated to all 629 GPRD practices by the routine update process. Weekly analysis and outputs as described will require increased commitment from all investigators. Costing phase three of the study for one year would allow checks on validity of tools to made between waves; would allow for variations in health seeking behaviour and GP clinical practise between waves, plus a three month wash up period for final analysis and reporting.

## Ancillary costs

Weekly teleconferencing with all collaborators 1 hour, 5 lines,  $\pm 40$  per week =  $\pm 4160$ .

Eight meetings (three monthly) of all collaborators  $\pm 130 \times 6 \times 8 = \pm 6240$ .

Eight meetings (three monthly) of PI + 1 (travel costs) with oversight committee (2). This will be conducted jointly with a NETSCC Monitor from or nominated by NETSCC £130  $\times$  4  $\times$  8 = £4160.

NETSCC will fund a maximum of two people to attend one international conference or one person to attend two conferences (later is preferred option) =  $\pm 4500$ .

Costs of two open-access publications (based on BMJ group rates at 01.09.2011)  $2 \times £1700 = £3400$ .

## **Appendix 1**

## Detailed cost breakdown for research group data acquisition, processing and reporting

Activity	Phase 1, 6 months	Phase 2, 6 months	Phase 3 , 2 months
Project administration practice liaison <sup>a</sup>			
LEPIS software development / modification work $^{\mbox{\tiny b}}$			
Web based data acquisition <sup>c</sup>			
LEPIS running costs <sup>d</sup>			
GPRD data processing modifications <sup>e</sup>			
Develop data collation and cleaning algorithms <sup>f</sup>			
Development of automatic reporting scripts and embedding analysis code <sup>g</sup>			
Scientific input (TVS and TW) <sup>h</sup>			
System documentation <sup>i</sup>			
GPRD data processing system modification and testing <sup>i</sup>			
GPRD data costs <sup>k</sup>			
Weekly download of data for study patients			
Weekly execution of data extraction routine <sup>m</sup>			
Produce and send weekly report <sup>n</sup>			
Subtotal			

Year one, Pre-pandemic (phases 1 and 2)

Year two, Pandemic (phase 3)

**Total GRPD costs** 

### Notes

- (a) Practice Liaison, User Acceptability Testing and management including roll out of required software
- (b) Changes to LEPIS software
- (c) Development and implementation Costs in P1 / P2
- (d) P1 and P2 Negligible running / P3 Software and IT support and maintenance costs
- (e) Changes and further modifications to existing GPRD data processing systems
- (f) Specific system for collating and cleaning raw collection data from General Practices
- (g) P2 specific second phase action
- (h) P1 and P2 development; P3 There needs to be a provision for resolution of 'data problems' from HER data
- (i) Documentation of system specification, design, testing and validation in line with Good Practise Requirement for Data Handlers in eHealth Care Systems PICS
- (j) P2 specific second phase action
- (k) Waived by GPRD, typical cost f per year
- (I) P1 and P2 Negligible costs; Cost for resources associated with extraction of data from master database.
- (m) P1 and P2 Negligible costs; On large P3 scale some provision should be available
- (n) P1 design and development of report, P2 modifications to report, P3 Specific costs associated with large volume distribution.

© Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

## References

- 1. Chief Medical Officer, Great Britain Ministry of Health (1920) Reports on public health and medical subjects. No 4. Report on the pandemic of influenza, 1918–19. His Majesty's Stationery Office, London.
- 2. Department of Health (2009) Pandemic Flu: Management of Demand and Capacity in Healthcare Organisations. Her Majesty's Stationery Office, London.
- 3. Lim WS (2007) Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health. Thorax 62 Suppl 1: 1–46.
- 4. BTS (2009) BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64.
- 5. Lim W, van der Eerden M, Laing R, Boersma W, Karalus N, et al. (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58: 377–382.
- 6. Challen K, Bentley A, Bright J, Walter D (2007) Clinical review: Mass casualty triage- pandemic influenza and critical care. Critical Care 11.
- Mulrennan S, Tempone SS, Ling IT, Williams SH, Gan GC, et al. (2010) Pandemic influenza (H1N1) 2009 pneumonia: CURB-65 score for predicting severity and nasopharyngeal sampling for diagnosis are unreliable. PLoS ONE 5: e12849.
- Challen K, Bright J, Bentley A, Walter D (2007) Physiological-social score (PMEWS) vs. CURB-65 to triage pandemic influenza: a comparative validation study using community-acquired pneumonia as a proxy. BMC Health Services Research 7.
- Department of Health & NHS (2009) Swine flu clinical package for use when there are exceptional demands on healthcare services. COI for Department of Health Gateway ref 12368 http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\_106495.
- 10. British Thoracic Society (2004) Guidelines for the management of Community Acquired Pneumonia (CAP) in Adults. London: BTS.
- 11. British Thoracic Society (2002) Guidelines for the Management of Community Acquired Pneumonia in Childhood. Thorax 57(S1).
- 12. O'Driscoll BR, Howard LS, Davison AG (2008) BTS guideline for emergency oxygen use in adult patients. Thorax 63 Suppl 6: vi1–68.
- 13. World Health Organization (1991) Technical bases for the management of pneumonia in children at first-level health facilities. WHO/ARI/91.20.
- 14. World Health Organization (1994) Management of the child with cough or difficult breathing. WHO/ARI/94.31.
- 15. World Health Organization (2001) Child and adolescent health and development: IMCI technical seminars. WHO/FCH/CAH/01.10.

- 16. World Health Organization (2002) Evidence base for the community management of pneumonia. WHO/FCH/CAH/02.23.
- 17. National Collaborating Centre for Chronic Conditions (2004) Chronic obstructive pulmonary disease Management of chronic obstructive pulmonary disease in adults in primary and secondary care. NICE Clinical Guideline 12. London: Royal College of Physicians of London.
- 18. Scottish Intercollegiate Guidelines Network (2006) Bronchiolitis in children. SIGN Guideline 91. Edinburgh: SIGN.
- 19. National Collaborating Centre for Women's and Children's Health (2007) Feverish illness in children. NICE Clinical Guideline 47. Welsh A, editor. London: RCOG Press.
- 20. Goodacre S, Challen K, Wilson R, Campbell M (2010) Evaluation of triage methods used to select patients with suspected pandemic influenza for hospital admission: a cohort study. Health Technology Assessment 14: 173–236.
- Nguyen-Van-Tam J, Openshaw P, Hashim A (2010) Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 65: 645–651.
- 22. P Myles, J Nguyen-Van-Tam, W-S Lim, K Nicholson, S Brett, et al. (September 2011) A comparison of three triage tools for 2009 pandemic influenza a(H1N1). European Scientific Working group on Influenza (ESWI) Fourth Conference. Malta. pp. A123P.
- 23. Myles P, Semple M, Lim W, Openshaw P, Gadd E, et al. (submitted) Predictors of clinical outcome in a national UK hospitalised cohort across both waves of the Influenza A/H1N1 pandemic 2009–2010.
- 24. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L (2010) Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. PLoS currents: RRN1153.
- 25. Hine D (2010) The 2009 Influenza Pandemic: An independent review of the UK response to the 2009 influenza pandemic. London: Cabinet Office HMG.
- 26. Watkins J (2004) Influenza: burden of disease in childhood. International Congress Series 1263: 263–266.
- 27. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D (1999) Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 54: 413–419.
- 28. Mangtani P, Cumberland P, Hodgson CR, Roberts JA, Cutts FT, et al. (2004) A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. The Journal of Infectious Diseases 190: 1–10.
- 29. Hajat S, Haines A, Goubet SA, Atkinson RW, Anderson HR (1999) Association of air pollution with daily GP consultations for asthma and other lower respiratory conditions in London. Thorax 54: 597–605.
- 30. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302: 766–768.
- 31. Health Protection Agency (2009) Pandemic (H1N1) 2009 in England: an overview of initial epidemiological findings and implications for the second wave.

© Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton So16 7NS, UK.

- 32. Hollowell J (1994) General practice research database (GPRD): scope and quality of data. Office of Population Censuses and Statistics (OPCS): 1–20.
- 33. Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. The British Journal of General Practice: the journal of the Royal College of General Practitioners 60: e128–136.
- 34. Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H (2000) Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19: 834–842.
- 35. Jick H, MacLaughlin D, Egger P, Wiggins P (2011) The United Kingdom 2009 Swine Flu Outbreak As Recorded in Real Time by General Practitioners. Epidemiology Research International 2011.



# Swine flu paediatric community assessment tool

## For use in all children under 16 years old in the community.

This assessment tool should be used during a pandemic situation to assist with the decision as to whether a sick febrile child with flu-like illness needs referral to the nearest general hospital Emergency Department. The majority of children are expected to be managed in the community. Respiratory failure, overwheiming gastroentertits, shock, heart failure and encephalitis are the most likely modes of critical illness in children suffering from swine flu. Complications such as sepsis and meningitis may co-exist.

Criteria Iabel	REFER CHILDREN TO THE NEAREST GENERAL HOSPITAL EMERGENCY DEPARTMENT IF THEY PRESENT WITH ANY OF THE FOLLOWING:
А	Severe respiratory distress Lower chest wall indrawing, sternal recession, grunting, or noisy breathing when calm.
B	Increased respiratory rate measured over at least 30 seconds. 250 breaths per minute if under 1 year, or 240 breaths per minute if 21 year.
C	Oxygen saturation <92% on pulse oximetry, breathing air or on oxygen Absence of cyanosis is a poor discriminator for severe illness.
D	Respiratory exhaustion or apnoek episode Apnoea defined as a >20 second pause in breathing.
Ш	Evidence of severe clinical dehydration or clinical shock Sternal capillary refill time >2 seconds, reduced skin turgor, sunken eves or fontanelle.
H	Altered conscious level Strikingly agliated or irritable, seizures, or floppy infant.
U	Causing other clinical concern to their own GP or clinical team e.g. a rapidly progressive or an unusually prolonged illness.

## Further information

© Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

- This tool is designed to support and empower all healthcare professionals working in difficult circumstances with limited resources, but does not supersede a decision by an experienced clinician about whether, when or where to refer a child.
- The assessment applies to all children under 16 years old and is independent of any prior or existing medical condition.
- Infants less than 2 months old with increased respiratory rate and sternal recession should be referred promptly to the nearest hospital because they are at high risk of suffering severe illness or death.
- Fever alone is not used as a criterion for referral to hospital in children over 3 months of age, as it is a poor discriminator for sever allness.
- Difficulty in feeding indicates a need for assessment but is not by itself a good measure of severe illness
  - When referral is not indicated, a copy of the home care advice leaflet should be provided, with
    encouragement to call again should the child's condition deteriorate.
- Every assessment should include a record of the time of assessment and time of onset of illness. Referrals must include the criteria label(s) to assist with the treatment of children on arrival at hospital.

The Swine Flu Paediatric Community Assessment Tool is endorsed by: The Royal College of General Practitioners, The Royal College of Paediatrics and Child Health, The Royal College of Nursing, The Royal College of Midwives, The College of Emergency Medicine, The Directors of Clinical Care of UK Ambulance Trusts, The British Medical Association and UniterThe Community Practitioners' and Health Visitors' Association.

## ADULT



DOI: 10.3310/hta19890

# Swine flu adult community assessment tool

# For use in all adults aged 16 years or older in the community.

This assessment tool should be used during a pandemic situation to assist with the decision as to whether a sick febrile adult with flu-like illness needs referral to the nearest general hospital Emergency Department. The majority of adults are expected to be managed in the community.

## Respiratory failure, shock, heart failure and encephalopathy are the most likely modes of presentation in adults suffering from severe infection.

Criteria Iabel	REFER ADULTS TO THE NEAREST GENERAL HOSPITAL EMERGENCY DEPARTMENT IF THEY PRESENT WITH ANY OF THE FOLLOWING:
A	Severe respiratory distress Severe breathlessness, e.g. unable to complete sentences in one breath. Use of accessory muscles, supra-davicular recession, tracheal tug or feeling of suffocation.
8	Increased respiratory rate measured over at least 30 seconds. Over 30 breaths per minute.
U	Oxygen saturation <92% on pulse oximetry, breathing air or on oxygen Absence of cyanosis is a poor discriminator for severe iilness.
D	Respiratory exhaustion New abnormal breathing pattern, e.g. alternating fast and slow rate or long pauses between breaths.
Э	Evidence of severe clinical dehydration or clinical shock Systolic blood pressure <90mmHg and/or diastolic blood pressure <60mmHg. Sternal capillary refill time >2 seconds, reduced skin turgor.
F	Altered conscious level New confusion, striking agitation or seizures.
g	Causing other clinical concern to their own GP or clinical team e.g. a rapidly progressive or an unusually prolonged illness.

## Further information

- The tool is designed to support and empower all healthcare professionals working in difficult circumstances with limited resources but does not supersede a decision by an experienced clinician about whether, when or where to refer an adult.
- The assessment applies to all adults aged 16 years or over and is independent of any prior or existing medical condition.
- Fever alone is not used as a criterion for referral as it is a poor discriminator for severe illness.
- Difficulty in self care indicates a need for assessment but is not by itself a good measure of severe illness
  or need for hospital admission. Referral to a community-based support facility may be suitable.
  - When referral is not indicated, a copy of the home care advice leaflet should be provided, with
    encouragement to seek medical advice again should the adult's condition deteriorate.
- Every assessment should include a record of the time of assessment and time of onset of illness. Referrals must include the criteria label(s) to assist with the treatment of adults on arrival at hospital

The Swine Flu Adult Community Assessment Tool is endorsed by: The Royal College of General Practitioners, The Royal College of Physicians, The Royal College of Nursing, The College of Emergency Medicine, The Directors of Clinical Care of UK Ambulance Trusts and The British Medical Association.







2
ì
<u></u>
5
ିର
E
ĕ
$\sim$
9
<u>.</u>
⊴
Ś
÷
7
ğ
2
.⊑
ŝ
Ĕ
5
ğ
5
õ
Ð
Ū
ž
se
5
Ĕ
÷
. <u>u</u>
<u>o</u>
Ψ
Q
۲
¥
ŝ
Ψ
8
š
S
3
ĹШ
Σ
₫.
ō
Ц
5
Ť.
R
5
Ū
Š
Ĕ.
<
0
of
e la
ž
a
>
é
<u>:</u>
U
ē
ē
_
Δ.
-
1 P
LE 1 P
<b>\BLE1 P</b>
TABLE 1 P

40

Outcome	Score		ROC area (95% CI)	Sensitivity, % (95% Cl)	Specificity, % (95% CI)	PPV, % (95% CI)	NPV, % (95% CI)
Level 2/3	CURB-65	≥2	0.62 (0.58, 0.66)	42.4 (35.0, 50.0)	81.2 (78.5, 83.8)	31.6 (25.8, 38.0)	87.3 (84.8, 89.5)
admission		M ∧I	0.56 (0.53, 0.58)	14.1 (9.4, 20.1)	97.2 (95.9, 98.2)	51.0 (36.3, 65.6)	84.7 (82.3, 86.9)
	PMEWS	<u>~</u>	0.52 (0.51, 0.53)	97.7 (94.3, 99.4)	6.3 (4.7, 8.1)	17.6 (15.3, 20.1)	93.1 (83.3, 98.1)
		>2	0.54 (0.51, 0.56)	90.4 (85.1, 94.3)	17.4 (14.9, 20.1)	18.3 (15.8, 21.1)	89.8 (84.2, 94.0)
		m A	0.54 (0.51, 0.56)	90.4 (85.1, 94.3)	17.4 (14.9, 20.1)	18.3 (15.8, 21.1)	89.8 (84.2, 94.0)
		< 4	0.59 (0.56, 0.62)	84.7 (78.6, 89.7)	32.6 (29.4, 35.8)	20.5 (17.6, 23.6)	91.2 (87.5, 94.1)
		√ 5	0.62 (0.58, 0.65)	76.3 (69.3, 82.3)	47.0 (43.7, 50.4)	22.8 (19.5, 26.4)	90.6 (87.5, 93.2)
		>7	0.65 (0.61, 0.69)	55.4 (47.7, 62.8)	74.9 (71.8, 77.7)	31.1 (26.0, 36.5)	89.1 (86.6, 91.3)
		6 <	0.57 (0.54, 0.61)	24.9 (18.7, 31.9)	89.7 (87.5, 91.6)	33.1 (25.2, 41.8)	85.3 (82.9, 87.6)
		< 11	0.52 (0.50, 0.54)	5.1 (2.4, 9.4)	98.7 (97.7, 99.4)	45.0 (23.1, 68.5)	83.5 (81.1, 85.8)
	CATs	∩ ∧I	0.68 (0.64, 0.72)	48.6 (41.0, 56.2)	87.3 (84.8, 89.4)	43.9 (36.8, 51.1)	89.2 (86.9, 91.2)
		≥4	0.60 (0.57, 0.63)	22.0 (16.2, 28.9)	98.4 (97.3, 99.1)	73.6 (59.7, 84.7)	86.0 (83.7, 88.1)
		l> S	0.52 (0.51, 0.54)	4.5 (2.0, 8.7)	100.0 (99.6, 100.0)	100.0 (63.1, 100.0)	83.6 (81.2, 85.8)
Death	CURB-65	≥2	0.64 (0.57, 0.70)	48.4 (35.5, 61.4)	78.8 (76.1, 81.4)	12.7 (8.7, 17.6)	96.0 (94.4, 97.3)
		m ∧I	0.54 (0.50, 0.59)	12.9 (5.7, 23.9)	95.8 (94.4, 97.0)	16.3 (7.3, 29.7)	94.6 (92.9, 95.9)
	PMEWS	<u>~</u>	0.52 (0.50, 0.54)	98.4 (91.3, 100.0)	5.8 (4.4, 7.5)	6.2 (4.8, 7.9)	98.3 (90.8, 100.0)
		>2	0.52 (0.47, 0.56)	87.1 (76.1, 94.3)	16.3 (14.0, 18.7)	6.2 (4.7, 8.0)	95.2 (90.8, 97.9)
		m A	0.52 (0.47, 0.56)	87.1 (76.1, 94.3)	16.3 (14.0, 18.7)	6.2 (4.7, 8.0)	95.2 (90.8, 97.9)
		>4	0.54 (0.48, 0.59)	77.4 (65.0, 87.1)	30.1 (27.2, 33.0)	6.6 (4.9, 8.6)	95.5 (92.5, 97.5)
		√5	0.55 (0.49, 0.61)	66.1 (53.0, 77.7)	43.7 (40.5, 46.8)	6.9 (5.0, 9.3)	95.3 (92.9, 97.1)
		>7	0.59 (0.52, 0.65)	46.8 (34.0, 59.9)	70.8 (67.8, 73.6)	9.2 (6.3, 13.0)	95.4 (93.7, 96.8)
		6 <	0.54 (0.49, 0.60)	21.0 (11.7, 33.2)	87.7 (85.5, 89.7)	9.8 (5.3, 16.1)	94.6 (92.9, 96.0)
		> 11	0.51 (0.48, 0.53)	3.2 (0.4, 11.2)	98.2 (97.1, 98.9)	10.0 (1.2, 31.7)	94.1 (92.5, 95.5)
							continued

© Queen's Printer and Controller of HMSO 2015. This work was produced by Venkatesan *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Outcome	Score		ROC area (95% Cl)	Sensitivity, % (95% Cl)	Specificity, % (95% Cl)	PPV, % (95% CI)	NPV, % (95% CI)
	CATs	N	0.65 (0.58, 0.71)	46.8 (34.0, 59.9)	82.9 (80.4, 85.2)	14.8 (10.1, 20.6)	96.1 (94.6, 97.3)
		≥4	0.58 (0.53, 0.63)	19.4 (10.4, 31.4)	95.8 (94.4, 97.0)	22.6 (12.3, 36.2)	94.9 (93.4, 96.2)
		l> 5	0.51 (0.49, 0.54)	3.2 (0.4, 11.2)	99.4 (98.7, 99.8)	25.0 (3.2, 65.1)	94.2 (92.6, 95.5)
Combined severe	CURB	≥2	0.63 (0.59, 0.66)	43.5 (36.3, 50.8)	81.9 (79.1, 84.4)	35.0 (29.0, 41.5)	86.6 (84.0, 88.8)
outcome (level 2/3 admission or death)		N ∧I	0.56 (0.53, 0.58)	14.1 (9.5, 19.9)	97.4 (96.1, 98.4)	55.1 (40.2, 69.3)	83.5 (81.0, 85.7)
	PMEWS	~	0.52 (0.51, 0.53)	97.9 (94.7, 99.4)	6.4 (4.8, 8.2)	19.0 (16.6, 21.6)	93.1 (83.3, 98.1)
		>2	0.53 (0.51, 0.56)	89.5 (84.3, 93.5)	17.3 (14.8, 20.0)	19.6 (17.0, 22.4)	88.0 (82.1, 92.5)
		× م	0.53 (0.51, 0.56)	89.5 (84.3, 93.5)	17.3 (14.8, 20.0)	19.6 (17.0, 22.4)	88.0 (82.1, 92.5)
		>4	0.58 (0.55, 0.61)	83.2 (77.2, 88.2)	32.5 (29.4, 35.8)	21.7 (18.8, 24.9)	89.6 (85.7, 92.8)
		> 5	0.61 (0.57, 0.65)	74.9 (68.1, 80.9)	47.1 (43.7, 50.5)	24.2 (20.8, 27.8)	89.3 (86.0, 92.0)
		> 7	0.64 (0.60, 0.68)	53.4 (46.1, 60.6)	74.9 (71.9, 77.8)	32.4 (27.2, 37.9)	87.7 (85.1, 90.0)
		6 <	0.57 (0.53, 0.60)	23.6 (17.7, 30.2)	89.6 (87.4, 91.6)	33.8 (25.9, 42.5)	83.9 (81.3, 86.2)
		< 11 <	0.52 (0.50, 0.54)	5.2 (2.5, 9.4)	98.8 (97.8, 99.4)	50.0 (27.2, 72.8)	82.3 (79.8, 84.6)
	CATs	N ∧I	0.68 (0.64, 0.72)	48.2 (40.9, 55.5)	87.8 (85.4, 89.9)	46.9 (39.8, 54.2)	88.3 (85.9, 90.4)
		54	0.60 (0.57, 0.63)	21.5 (15.9, 28.0)	98.6 (97.5, 99.3)	77.4 (63.8, 87.7)	84.8 (82.4, 87.0)
		>5	0.52 (0.51, 0.54)	4.2 (1.8, 8.1)	100.0 (99.6, 100.0)	100.0 (63.1, 100.0)	82.3 (79.8, 84.6)

TABLE 1 Predictive value of CATs, CURB-65 and PMEWS scores for predicting severe outcomes in adults ( $\geq$  16 years), n = 1040 (continued)

## EME HS&DR HTA PGfAR PHR

Part of the NIHR Journals Library www.journalslibrary.nihr.ac.uk

This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health

## Published by the NIHR Journals Library